Mathematical Model for IL-6-Mediated Tumor Growth, and Targeted Treatment by Nazari, Fereshteh (Author) et al.
Mathematical Model for IL-6-Mediated Tumor Growth, and Targeted Treatment
by
Fereshteh Nazari
A Dissertation Presented in Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy
Approved July 2017 by the
Graduate Supervisory Committee:
Trachette L. Jackson, Co-Chair
Carlos Castillo-Chavez, Co-Chair
Sherry Towers
Yun Kang
ARIZONA STATE UNIVERSITY
August 2017
ABSTRACT
Head and neck squamous cell carcinoma (HNSCC), the sixth most common can-
cer type worldwide, accounts for more than 630,000 new cases and 350,000 deaths
annually. Drug-resistance and tumor recurrence are the most challenging prob-
lems in head and neck cancer treatment. It is hypothesized that a very small frac-
tion of stem-like cells within HNSCC tumor, called cancer stem cells (CSCs), is
responsible for tumor initiation, progression, resistance and recurrence. It has also
been shown that IL-6 secreted by head and neck tumor-associated endothelial cells
(ECs) enhances the survival, self-renewal and tumorigenic potential of head and
neck CSCs. In this study we will use a mathematical multi-scale model which op-
erates at the intracellular, molecular, and tissue level to investigate the impacts of
EC-secreted IL-6 signaling on the crosstalk between tumor cells and ECs during
tumor growth. This model will be calibrated by using the experimental in vivo
data.
Eventually the model will be modified to explore the responses of head and neck
cancer cells to combination therapy involving Tocilizumab (an anti-IL-6R anti-
body) and Cisplatin (the most frequently used chemotherapy for head and neck
cancer). The model will be able to predict the final proportion of CSCs in response
to endothelial cell-secreted IL-6 and drug therapies. The model will be validated
by directly comparing the experimental treatment data and the model predictions.
This could potentially provide a condition under which we could control enlarge-
ment of the head and neck CSC pool and tumor recurrence. It may also suggest
the best bounds for Cisplatin and/or Tocilizumab dose and frequency to be tested
in the clinical trial.
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Chapter 1
INTRODUCTION
Cancer is one of the major public health challenges globally, and is the second lead-
ing cause of death in the United States Siegel et al. (2017). The American Cancer
Society recently estimated that approximately 1,700,000 new cancer cases are ex-
pected to be diagnosed in 2017, which is equivalent to more than 4,600 new cases
each day Siegel et al. (2017). Figure 1.1 shows the average annual incidence rate of
all cancer types combined for the years 2009 to 2013 per 100,000 individuals in the
US population by state. Despite all the treatment improvements and medical ad-
vances, cancer-related death rates are still extremely high. More than half a million
Americans die from cancer each year. It is estimated that cancer will cause 600,920
deaths in the US in 2017, corresponding to about 1,650 deaths per day Siegel et al.
(2017). Collectively, the cancer incidence and mortality rates make it a deadly dis-
ease that affects the vast majority of the population globally, and not just in the US.
Therefore, it is crucially important that more research is aimed at investigating the
causes of cancer and developing new therapeutic treatment strategies.
Cancer can be defined as a genetic disease caused by the accumulation of mu-
tations in somatic cells Altrock et al. (2015). During the multiple steps of evolution
from normal to cancerous, altered somatic cells acquire the capabilities of sustain-
ing proliferative signaling, evading growth suppressors, resisting cell apoptosis,
enabling replicative immortality, inducing angiogenesis, and activating invasion
and metastasis Altrock et al. (2015); Hanahan and Weinberg (2011b). In partic-
ular, these mutated cells do not obey the highly regulated processes of normal
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Figure 1.1: Incidence Rates of all Cancer Types Combined for the Years 2009-2013.
Average annual rate per 100,000, age adjusted to the 2000 US standard population.
Data sources: North American Association of Central Cancer Registries (NAACCR), 2016
cell division and death, which can result in tumor initiation Jackson et al. (2014).
Fortunately, not all the tumors can survive the early stages of tumor growth. To
progress towards malignancy and further invasion, tumor cells rely on interactions
with stromal cells for a continuous supply of nutrients. There are also multiple ad-
ditional factors that aid the persistence of newly formed tumors within a tissue.
Namely, stochastic DNA replication errors in cells, crosstalk between tumor cells
and the tissue microenvironment, radiation exposures and diet are some of the fac-
tors contributing to carcinogenesis of tumors.
There are two well-known theories explaining the malignancy potential of mu-
tated tumor cells. According to the stochastic hypothesis, tumor cells display ho-
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mogeneity in sense that each cell has an equal potential to initiate and propagate
tumors, as well as metastasize. Therefore, this implies that there is no selectivity
between the cancer cells in a tissue Dick (2009). The stochastic model explains het-
erogeneity in tumors by spontaneous shifts in cell phenotypes Albers et al. (2012).
However, there is an abundance of emerging evidence that supports an alternative
hypothesis that tumors are initiated and maintained by a population of tumor cells
that have many of the biological characteristics of normal adult stem cells. This
model, the cancer stem cell (CSC) hypothesis, is based on the notion that tumors, like
those found in adult tissues, arise from multipotent cells that exhibit the ability to
self-renew and give rise to differentiated tissue cells Krishnamurthy et al. (2014);
No¨r et al. (2014); Zhu et al. (2014). Additionally, it states that the bulk of the tumor
tissue is composed of rapidly proliferating cells called transit-amplifying cells and
post-mitotic differentiated cells. These cells do not contribute to tumor initiation.
They are derived from the cancer stem cells by differentiation, but are not capable
of tumor initiation by themselves Prince and Ailles (2008); Reya et al. (2001).
An extensive number of studies have utilized these two theories to describe
tumor initiation, its heterogeneous structure, and tumor progression in different
types of cancer Albers et al. (2012); Civenni et al. (2011); Girouard and Murphy
(2011); Gupta et al. (2011); Quintana et al. (2008); Taghizadeh et al. (2010). For in-
stance, one study demonstrated that in melanomas about 25% of unsorted cells
were able to initiate tumors in immunocompromised mice, supporting the stochas-
tic model Quintana et al. (2008). In other recent works, evidence contrary to the
stochastic model has been presented. For instance, cells with high levels of CD44HIGH
ALDHHIGH expression (cancer stem cells) taken from a primary human head and
neck tumor were able to create tumors in mice much more often than cells with
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low expression of these markers, which supports the cancer stem cell hypothesis
Krishnamurthy et al. (2014). Furthermore, it was shown that CD44HIGHALDHHIGH
cells were more tumorigenic and created more aggressive tumors than their coun-
terparts with low levels of CD44 and ALDH, providing more evidence in favor of
the cancer stem cell (CSC) hypothesis. It is hypothesized that CSCs are responsible
for tumor initiation, progression resistance and recurrence Hermann et al. (2010);
Krishnamurthy et al. (2014); Prince et al. (2007). Markers for cancer stem cells have
now been identified in a variety of malignancies, including tumors of the blood,
breast, colon, brain, and head and neck Krishnamurthy et al. (2014).
Head and Neck Squamous Cell Carcinomas
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common
cancer in the world, diagnosed in approximately 400,000-600,000 people globally
each year Neiva et al. (2009); Parfenov et al. (2014); Pearson et al. (2016). High risk
strains of human papilloma virus (HPV), alcohol consumption and tobacco use are
the most common risk factors for HNSCC Pearson et al. (2016). Survival rates in
patients with head and neck cancer are poor and have not improved during the
last three decades, despite extensive basic and clinical research Neiva et al. (2009);
Pulte and Brenner (2010).
Conventional treatment for head and neck cancer has consisted of surgery and
radiation combined with and/or followed by chemotherapy. Cisplatin is the most
common chemotherapeutic agent prescribed for the treatment of HNSCC No¨r et al.
(2014). Although Cisplatin is able to help to raise the quality of life of patients with
HNSCC, it does not considerably improve the 5-year survival rete due to drug-
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resistance and metastasis.
Attempts to understand the mechanisms behind the tumorigenic process and
drug-resistance of tumors led to the discovery of HNSCC cancer stem cells Krish-
namurthy et al. (2014). HNSCC cancer stem cells are a small population of HNSCC
tumors which are uniquely tumorigenic, multipotent cancer cells endowed with
the ability to self-renew Krishnamurthy et al. (2014); Pearson et al. (2016). Further-
more, it was shown that HNSCC tumor cells have a heterogeneous hierarchical
structure and are capable of distant metastasis. All together, these facts support the
idea of cancer stem cell hypothesis for HNSCC tumors. Unlike most cells within a
tumor, cancer stem cells (CSC) are often resistant to conventional chemo- and/or
radiation therapy, making it necessary to design new therapeutic approaches that
target these cancer stem cells Finkel et al. (2016). However, direct targeting and
ablation of CSCs might cause toxicities related to the unintended elimination of
normal stem cells Krishnamurthy et al. (2014). It has also been demonstrated that
growth and survival of CSCs are highly influenced by tumor micro-environmental
factors and molecular signaling, including cytokines like interleukin-6 (IL-6) Kr-
ishnamurthy et al. (2014). IL-6 is a protein (signaling molecule) secreted by T-cells,
macrophages and osteoblasts, and which acts as both a pro-inflammatory cytokine
and an anti-inflammatory myokine. More interestingly, it has been revealed that
HNSCC CSCs reside in perivascular niches and that IL-6 secreted by endothelial
cells (ECs) in the tumor niche enhances the survival, self-renewal and tumor ini-
tiation potentials of CSCs in primary head and neck tumor Krishnamurthy et al.
(2014). In fact, IL-6 phosphorylates Signaling Transducer and Activator of Tran-
scription 3 (STAT3) via binding to its natural receptor, IL-6R, and the transmem-
brane cytokine receptor, gp130 (and signaling through the Janus kinases). Phos-
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phorylation of STAT3 is an indicative of stemness Krishnamurthy et al. (2014).
Therefore, targeting the IL-6-induced signaling pathways may inhibit the survival
and self-renewal potential of CSCs. Thus, drugs that block the cross-talk between
endothelial cells and CSCs within the perivascular niche may inhibit and/or con-
trol tumor growth. This is a potential alternative treatment that could be used in
combination with conventional therapies.
One of the main challenges in studying CSCs and developing anti-IL-6 ther-
apies has been development of efficient in vitro and/or in vivo methods to un-
derstand the impacts of CSCs on the pathobiology of HNSCC. One of the rea-
sons for this is the need to perform most studies with primary HNSCC specimens,
which are difficult to obtain. In addition, in vivo experimentation is expensive
and time consuming, and in vitro methods have limited capacity for expansion of
head and neck cancer stem cells. Along with experimental methods, mathemati-
cal and computational modeling approaches provide a useful framework to study
cancer progression since they can integrate biological parameters and make pre-
dictions across different time and/or spatial scales. Moreover, mathematical mod-
els provide a powerful tool to facilitate drug development and pre-clinical eval-
uation of efficacy, which cannot be easily understood by using conventional wet-
lab experiments alone Olsen and Siegelmann (2013); Tang et al. (2014); Wang et al.
(2015). Among the recent mathematical techniques commonly used today, mul-
tiscale models have been widely applied to model tumor growth, tumor-induced
angiogenesis and treatment Altrock et al. (2015); Deisboeck et al. (2011); Jackson
et al. (2014); Jain et al. (2008); Olsen and Siegelmann (2013); Perfahl et al. (2011);
Plank et al. (2004); Sanga et al. (2006); Shirinifard et al. (2009); Tang et al. (2014); Tee
and Distefano Iii (2004); Wang et al. (2013). Most existing models, however, suf-
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fer from the lack of (1) sufficient resolution to evaluate drug effects at the cellular
level; (2) validation of the model predictions using the actual experimental data;
and (3) inclusion of tumor cell heterogeneity and tumor cell plasticity.
Statement of Purpose
The fact that HNSCC CSCs form only a small portion of the total tumor burden,
but may play a disproportionately important role in determining tumor growth
and treatment outcomes shapes the goals of this study. The overarching objec-
tive is to develop a predictive computational framework that will: (1) advance our
current understanding of the differential impact of IL-6 on CSC self-renewal and
HNSCC growth; and (2) optimize the clinical use of combination therapy involv-
ing targeted treatment with Tocilizumab (an anti-IL-6R antibody) and Cisplatin.
This project has two main parts. Part I is to build and calibrate an integrated
cellular and molecular model for the IL-6 dependent growth HNSCC tumors from
a small population of cancer stem-like cells and use it, and its extensions, to: (1)
derive functional relationships among self-renewal and cell death and IL-6 con-
centration, 2) predict the response of HNSCC to Tocilizumab, an anti-IL6 antibody
and 3) incorporate the mechanism of action of Cisplatin and quantify its influence
on the tumor growth and stem cell proportion post-treatment.
Part II is to extend this model to a fully multi-scale framework designed to in-
vestigate the role of IL-6 and CSCs in the bidirectional communication (i.e. crosstalk)
between endothelial cells and tumor cells that contributes to and enhances key as-
pects of tumorigenesis and can lead to evasive therapeutic resistance.
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In Chapter 1, we build and analyze a preliminary mathematical model for the
growth of tumors from a small population of cancer stem-like cells and use it to
predict tumor growth dynamics and cellular composition. In chapter 2, we extend
the model introduced in Chapter 1 to include the molecular level details of tumor
cell-secreted IL-6 signaling and its impacts on tumor growth and CSC self-renewal.
We also run preliminary simulations of the response of cancer cells to Tocilizumab.
Finally, in Chapter 3, we expend the model introduced in Chapter 2 to describe en-
dothelial cell-tumor cell crosstalk. The model in Chapter 3 includes tumor angio-
genesis, vascular tumor growth, and response to treatment. This model operates
at three levels: (1) intracellular, (2) cellular and (3) tissue levels are integrated to
describe IL-6 signaling and silencing, cancer stem cell driven tumor growth, and
combination therapy with Tocilizumab and Cisplatin.
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Chapter 2
DEVELOPMENT AND ANALYSIS OF A MATHEMATICAL MODEL BASED
ON THE CANCER STEM CELL HYPOTHESIS
The main goal of this chapter is to build and analyze a preliminary mathemat-
ical model for the growth of tumors from a small population of cancer stem-like
cells and use it to predict tumor growth dynamics and cellular composition. Ac-
cording to the CSC hypothesis, tumors have a hierarchical structure and originate
from a small number of tumor initiating cells. These cancer stem cells (CSCs) are
capable of both self-renewal and differentiation, thereby producing all the distinct
cell types found within a tumor and contributing to heterogeneity Michor (2008).
During the process of CSC differentiation, one of the two daughter cells retains it’s
”stemness”, whereas the other differentiates into other cell types with little or no
ability to self-renewal Al-Hajj et al. (2003); Cabrera et al. (2015); Michor (2008); Zhu
et al. (2014). Therefore, following the CSC hypothesis, we develop a mathemati-
cal model that assumes CSCs initiate and sustain tumor growth and that the bulk
of the tumor tissue is derived through the differentiation of CSCs. We perform a
rigorous mathematical analysis of the system of equations and use the model to
predict the asymptotic behavior of CSCs at equilibrium and over the tumor’s ex-
ponential growth phase. We also carry out a local sensitivity analysis in oder to
suggest the most influential parameters on the final percentage of the CSCs at dif-
ferent stages of tumor growth. Eventually, this model will be extended in order to
study the impact of tumor microenvironmental factors and molecular signaling on
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the tumor growth dynamics as well as tumor response to combination therapy.
2.1 Modeling Cancer Stem Cell Driven Tumor Growth
In this section we develop a mathematical model for cancer stem cell-driven
tumor growth in order to investigate the dynamics of cancer initiation and pro-
gression, as well as to determine the ultimate proportion of CSCs within a grow-
ing tumor. Since tumors that arise from CSCs include both tumorigenic and non-
tumorigenic cells Michor (2008), our model tracks the temporal evolution of cancer
stem cells and non-CSCs, including both progenitor and terminally differentiated
cells (Figure 3.1).
Symmetric
division
Asymmetric
division
Differentiation
and	death
Rounds	of	transient	amplification	
Stem	cells Progenitor cells Differentiated	cells
S(t) E(t) D(t)
Figure 2.1: Schematic Diagram of the Stem Cell Division Processes Considered in
the Amplifying Factor Mathematical Model
Table 3.1 tabulates each model variable along with the units.
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Table 2.1: List of Model Variables
Variable Description Units
S HNSCC stem cells # of cells
E HNSCC progenitor tumor cells # of cells
D HNSCC differentiated tumor cells # of cells
Cancer cell equations
The total cellular composition of a tumor at time t is divided into cancer stem
cells S(t), transient amplifying/progenitor tumor cells E(t) and terminally differ-
entiated tumor cells D(t). Equation (2.1.1), below, describes temporal changes in
the cancer stem cell (S) population:
dS
dt︸︷︷︸
Stem cell
= αSPS(S) S︸ ︷︷ ︸
Stem cell self-renewal
− δS S︸︷︷︸
Stem cell death
(2.1.1)
CSCs divide at rate, S. The first term in (2.1.1) assumes that stem cells can either
symmetrically renew with the probability of PS(S), creating two identical daugh-
ter cells that retain ”stemness”, or, with the probability of (1 − PS(S)), they can
asymmetrically differentiate into one stem and one progenitor cell. It is assumed
that the self-renewal probability, PS(S), varies depending on the total cancer stem
cell population size. The second term of (2.1.1) assumes that CSCs die at a death
rate, δS.
Equations (2.1.2) and (2.1.3) describe temporal changes in the progenitor and
terminally differentiated cell populations.
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dE
dt
= Ain αS(1− PS(S)S︸ ︷︷ ︸
Amplified
stem cell differentiation
− αE E︸︷︷︸
Progenitor cell
differentiation
− δE E︸︷︷︸
progenitor cell death
(2.1.2)
dD
dt
= Aout αEE︸ ︷︷ ︸
progenitor ce ll
differentiation
− δD D︸ ︷︷ ︸
differentiated cell death
(2.1.3)
As depicted Figure 3.1, progenitor cells (2.1.2) undergo a limited number (w)
of mitotic cycles, so called transit-amplifying (TA) cell divisions, before entering a
post-mitotic terminally differentiated state Al-Hajj and Clarke (2004); Clarke and
Fuller (2006). In this model, instead of adding w sub-compartments of progenitor
cells, it is assumed that each differentiated stem cell is amplified on upon entry
into the progenitor. This is a simplified version of the model developed in Gan-
guly and Puri (2006) and this approach has also been used in Gentry and Jackson
(2013). The assumptions about amplification imply that the efflux from the stem
compartment is augmented by a factor Ain as soon as the cells enter the progenitor
pool as shown in the first term in (2.1.2).
The second term in (2.1.2) assumes that progenitor cells transition to fully dif-
ferentiated cells via TA cell division at rate αE. Finally, the second term in (2.1.2)
assumes that progenitor cells die at rate δE.
Immediately before leaving the progenitor compartment, cells are further am-
plified by a factor Aout = 2 because the transition from progenitor to terminally
differentiated cells results in the loss of one progenitor cell and the gain of two
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terminally differentially cells as shown in the first term in (2.1.3). These two am-
plification factors are selected such that Ain × Aout = 2w, where w = the number
of successive stages of TA cell divisions before transforming into mature cell Gan-
guly and Puri (2006). Terminally differentiated cells live for a specified amount of
time and then die at rate δD.
The probability of cancer stem cell self-renewal
The probability of CSC self-renewal, PS, can be regulated by extrinsic and in-
trinsic chemical signaling as well as environmental (niche) constraints. Certain
environmental cues can promote self-renewal, while others promote differentia-
tion. Similarly, proteins produced by stem cells themselves can affect self-renewal
in an autocrine manner. Many published mathematical models use a Hill func-
tion Anderson and Mackey (2001); Bernard et al. (2003); Gentry and Jackson (2013);
Wang et al. (2010), which can be derived from receptor-ligand binding kinetics, to
describe the effect of chemical signals on the probability of symmetric self-renewal.
For these reasons, our model assumes the following functional form for the prob-
ability of stem cell-self renewal:
PS(S) =
(PSmax − PSmin)PnNs
PnNs + S
n + PSmin · (2.1.4)
As the number of cancer stem cells approaches zero, the probability of symmet-
ric self-renewal approaches the maximum value, PSmax . Conversely, as the number
of CSCs approaches infinity, the probability of symmetric self-renewal approaches
a minimum value, PSmin . The parameter PNs may be interpreted as the number of
stem cells for which the probability of symmetric self-renewal is halfway between
the maximum and minimum values. Higher values of the exponent n > 1 increase
13
the sensitivity of stem cells to signals that promote symmetric self-renewal. Figure
2.2 plots the probability of CSC self-renewal as a function of cell number for the
baseline parameters of the model and for two different choices of the parameter
PNs .
Figure 2.2: The Probability of Stem Cell Self-renewal, PS, as a Function of Stem Cell
Number.
Thus, the model system that we study, referred to as the Amplification Factor
Model hereafter, is given by:
Amplification Factor Model
dS
dt
= αSPS(S)S− δSS
dE
dt
= Ain αS(1− PS(S))S− αEE− δEE (2.1.5)
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dD
dt
= 2 αEE− δDD
2.2 Basic Mathematical Analysis of the Amplification Factor Model
In the subsections below, we present some of the general results of our basic
mathematical analysis of model 2.1.5. This type of analysis allows us to better un-
derstand the dynamic behavior that this model can exhibit.
2.2.1 Positiveness of the solutions
Proposition 2.2.1 Let the initial condition for model 2.1.5 be S(0) > 0 and E(0) > 0
and D(0) > 0. Then, the solutions (S(t), E(t), D(t)) of model 2.1.5, with positive initial
data, will remain positive for all time t > 0.
Let assume that S(0) > 0, E(0) > 0, D(0) > 0 and t1 is the smallest upper bound
of all times that one of the three solutions, S(t), E(t) and D(t) becomes zero. That
is,
t1 = Sup {t > 0 : S(t) > 0, C(t) > 0, D(t) > 0} > 0
Now, by contradiction, assume the case that S(t1) = 0. Then, from the first equa-
tion in model 2.1.5 for all t ∈ [0, t1] we have:
dS
dt
= αSPS(S)S− δSS
=
{
αS
[
(PSmax − PSmin)PnNs
PnNs + S
n + PSmin
]
− δS
}
S.
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Now, let
L = Min
{
αS
[
(PSmax − PSmin)PnNs
PnNs + S
n + PSmin
]
− δS : t ∈ [0, t1]
}
.
Then,
dS(t)
dt
≥ LS(t),
which implies that
dS
dt
S
=
dS
S
dt
=
d(ln(S)
dt
≥ L, for t ∈ [0, t1].
That is,
ln(S(t1))− ln(S(0)) ≥ Lt1.
Thus,
S(t1) ≥ S(0)eLt1 > 0, for t ∈ [0, t1].
This a contradiction to the assumption that S(t1) = 0. Thus, S(t) > 0 for all
positive times whenever S(0) > 0. Similarly, it can be shown that C(t) and D(t)
are positive for all time t > 0 if the initial values C(0) > 0 and D(t) > 0.
2.2.2 Boundedness of solutions
Proposition 2.2.2 Solutions of model 2.1.5 are bounded provided αS < δS.
Assume that αS < δS. Then we show that S(t) is bounded under the given condi-
tion. Since by definition PS(S) is less than or equal to one, from the first equation
in model 2.1.5 we have:
dS
dt
= αSPS(S)S− δSS
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≤ αSS− δSS
= (αS − δS)S.
Therefore,
S(t) ≤ C1e(αS−δS)t,
where, C1 is an arbitrary constant. Hence, S(t) is bounded whenever αS < δS.
Similarly, for the second equation in model 2.1.5, we have:
dE
dt
= Ain αS(1− PS(S))S− αEE− δEE
≤ Ain αSS− αEE− δEE
= AinαSS− (αE + δE)E
We showed that S(t) is bounded whenever αS < δS, which means that under
the given assumption, there exists an upper-bound, US, for S(t) for all time t such
that
S(t) ≤ US, for all t > 0,
which implies that
E(t) ≤ e−(αE+δE)t
(
AinαSUS
∫
e(αE+δE)tdt + C2
)
=
AinαSUS
(αE + δE)
+ C2e−(αE+δE)t
Hence, E(t) is bounded whenever S(t) is bounded. That is, E(t) is bounded when-
ever αS < δS. Similarly, it can be easily shown that D(t) is bounded whenever E(t)
is bounded. Thus, D(t) is bounded whenever αS < δS. This completes the proof of
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the proposition.
2.2.3 Existence of non-negative equilibria
In this section, the possible equilibrium point(s) of model 2.1.5 will be explored.
Setting the right hand side of model 2.1.5 equal to zero and solving for S, E and D,
we will obtain E0 = (0, 0, 0) as a trivial equilibrium of model 2.1.5. Before finding
the non-trivial equilibrium of model 2.1.5, we assess the condition under which E0
becomes unstable, thereby removing the possibility of eliminating the tumor. To
study the local stability of E0 = (0, 0, 0), we just need to look at the signs of all the
eigenvalues of the Jacobian of the system evaluated at (0, 0, 0) given by:
J(0,0,0) =

αSPSmax − δS 0 0
AinαS(1− PSmax) −(αE + δE) 0
0 2αE −δD
 .
The eigenvalues of matrix J(0,0,0) are given by:
λ1 = αSPSmax − δS,
λ2 = −(αE + δE) < 0,
λ3 = −δD < 0.
This implies that model 2.1.5 has a trivial equilibrium E0 = (0, 0, 0) that is un-
stable if αSPSmax − δS > 0 and is stable if αSPSmax − δS < 0.
Now, assume
Condition(i) : αSPSmin < δS < αSPSmax
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then the zero equilibrium E0 becomes unstable and a new equilibrium point ”may”
emerge.
Continuing to assume that condition (i) satisfied, now let
E1 = (S∗, E∗, D∗), (2.2.1)
be an arbitrary equilibrium of model 2.1.5, where S∗, E∗ and D∗ are obtained from
setting the right-hand-sides of the equations in model 2.1.5 to zero. The nontrivial
steady states are given by:
S∗ = PNs
(
αSPSmax − δS
δS − αSPSmin
)1/n
(2.2.2)
E∗ = (αS − δS)Ain
(αE + δE)
S∗ (2.2.3)
D∗ = 2αE
δD
E∗. (2.2.4)
Condition (i) guarantees positiveness of S∗. Therefore, S∗ and consequently E∗
and D∗ exist and are positive whenever condition (i) holds and:
Condition (ii) : αS > δS
To find a relation between the existence of the trivial and non-trivial equilibria
let us first define the effective reproduction rate (Re) as the ratio of the “effective
stem cell self-renewal” (αSPSmax − αSPSmin) over the “effective stem cell death” (i.e.,
δS − PSminαS).
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Re = effective stem cell self-renewaleffective stem cell death =
αSPSmax − αSPSmin
δS − PSminαS
=
αS(PSmax − PSmin)
δS − PSminαS
Remark 1: According to Condition (i),Re > 0.
Remark 2: It is assumed that the effective stem cell death happens whenever
PS(S) = PSmin .
Now, expanding and simplifying factors in the equation ofRe, we obtain:
Re = αSPSmax − δS
δS − αSPSmin
+ 1
Thus, equilibrium point E1 = (S∗, E∗, D∗) given by Eqns. (2.2.2), (2.2.3) and
(2.2.4) can be re-written as
S∗ = PNs(Re − 1)1/n (2.2.5)
E∗ = (αS − δS)Ain
(αE + δE)
S∗ (2.2.6)
D∗ = 2αE
δD
E∗ (2.2.7)
It is worth mentioning that second inequality in Condition (i) results in δS < αS
since PSmax ≤ 1. Furthermore, Condition (i) is equivalent to Re > 1. Thus, Con-
dition (i) along with the definitions of S∗, E∗, D∗ and Re lead us to the following
proposition.
Proposition 2.2.3 Model 2.1.5 has a non-negative non-trivial equilibrium whenever con-
dition (i) holds. In other words, model 2.1.5 has a non-trivial equilibrium whenever Re
exceeds unity,Re > 1.
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From the biological point of view, Proposition 2.2.3 says that the model 2.1.5
has a non-negative equilibrium point exists whenever the ”effective self-renewal
rate of stem cells” is greater than ”effective death rate of stem cells” and this is just
as would be expected.
2.2.4 Local stability of equilibria
Proposition 2.2.4 The trivial equilibrium point E0 = (0, 0, 0) is stable whenever αSPSmax <
δS. Otherwise, it is unstable.
Remark: Instability condition of E0 = (0, 0, 0) is in agreement with the neces-
sary condition for existence of non-zero equilibrium of model 2.1.5.
At the trivial equilibrium point (0, 0, 0), substituting S = 0 into the definition
of PS(S) gives PS(0) = PSmax . As a result αSPSmax is the maximum rate of stem cell
self-renewal. Thus, Proposition 2.2.4 says that once the maximum rate of CSC self-
renewal becomes greater than their death rate, then the trivial equilibrium point
(0, 0, 0) loses stability and completely eradicating the tumor is no longer possi-
ble. Therefore, when (0, 0, 0) is unstable, small perturbations in the reproduction
or death rates can lead to the persistence of a tumor. This result is biologically
reasonable since as the reproduction rate is greater than the death rate, the tumor
tends to grow rather than die out.
Now assume that conditions (i) and (ii) are satisfied, which makes (0, 0, 0)
unstable and (as we showed above) a new equilibrium, E1, emerges. To study
the stability of this nontrivial equilibrium, we will look at the eigenvalues of the
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Jacobian of model 2.1.5 evaluated at E1, which is given by:
JE1(S
∗, E∗, D∗) =

B1 0 0
B2 −(αE + δE) 0
0 2αE −δD
 .
B1 =
αS(PSmax − PSmin)PnNs
PnNs + (S
∗)n
(
1− n(S
∗)n
PnNs + (S
∗)n
)
+ αSPSmin − δS
B2 =
Ain αS(PSmax − PSmin)PnNs
PnNs + (S
∗)n
(
n(S∗)n
PnNs + (S
∗)n
− 1
)
+ AinαS(1− PSmin)
Using the fact that at non-trivial equilibrium PS(S∗) = δSαS , B1 can be reduced such
that:
JE1(S
∗, E∗, D∗) =

αS(PSmax−PSmin )PnNs
PnNs+(S
∗)n
[
− n(S∗)nPnNs+(S∗)n
]
0 0
B2 −(αE + δE) 0
0 2αE −δD
 ,
with the following eigenvalues:
γ1 =
αS
positive︷ ︸︸ ︷
(PSmax − PSmin) PnNs
PnNs + (S
∗)n
negative︷ ︸︸ ︷(
− n(S
∗)n
PnNs + (S
∗)n
)
+
negative by Condition(i)︷ ︸︸ ︷
αSPSmin − δS
γ2 = −(αE + δE) < 0
γ3 = −δD < 0
Therefore, since all the eigenvalues are negative, we can conclude that the positive
non-trivial equilibrium, E1 is always locally stable which leads to the following
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proposition.
Proposition 2.2.5 The positive non-trivial equilibrium of model 2.1.5 is always locally
asymptotically stable.
From the biological point of view, Proposition 2.2.5 suggests that as long as the
death rate of CSCs is bounded by Condition (i) (αSPSmin < δS < αSPSmax), the tumor
persists to grow and reaches to an equilibrium level, E1. Interestingly, violating
Condition (i) leads to exponential growth of tumor. Assume that
δS < αSPSmin (2.2.8)
then we have
dS
dt
= αS
(PSmax − PSmin)PnNS
PnNS + S
n S +
Positive︷ ︸︸ ︷
(αSPSmin − δS) S > 0·
Therefore, S grows exponentially whenever δS < αSPSmin . Furthermore, for a
chosen set of parameter values (explained in Section 2.4), Figure 2.3 numerically
illustrates that various death rates of CSCs can results in different tumor growth
dynamics. The blue line shows the tumor volume over days when Condition (i)
satisfies. We keep all the parameter values fixed except δS. Decreasing δS to a value
less than αSPSmin leads to an unbounded (exponential) growth of tumor (orange
line).
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Figure 2.3: Bounded vs Exponential Growth of Tumor Volume. The blue line nu-
merically illustrates the bounded growth of tumor volume when δS < αSPSmin . The
orange line numerically shows that when δS > αSPSmin , the tumor volume growth
exponentially.
2.3 Characterizing Tumor Composition
Most tumors are a heterogenous mixture of cells with some degree of differ-
entiation. One of the conjectures of the cancer stem cell hypothesis is that a small
population of CSC gives rise to the bulk of the tumor cells with more differentiated
phenotypes. However is not at completely clear that CSCs are necessarily a small
minority within a tumor Johnston et al. (2010). In fact, recent studies have raised
the possibility that various types of tumors may contain widely different propor-
tions of CSCs Johnston et al. (2010). In this section we explore tumor composition,
in terms of CSC proportion, at steady state and during the tumor’s exponential
growth phase. We further provide an explanation for the variation in the observed
CSC percentage.
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2.3.1 Cancer stem cell fraction at the steady state
In order to find the proportion of cancer stem cells at the steady state, we use
Eqns. 2.2.5-2.2.7 and define:
T =
S∗
S∗ + E∗ + D∗
=
1
1+ (αS−δS)AinαE+δE +
2αE(αS−δS)Ain
δD(αE+δE)
. (2.3.1)
Recall that at steady state, according to Condition (ii), αS > δS. That is, T is
always a positive value. Now let
M =
(αS − δS)Ain
αE + δE
+
2αE(αS − δS)Ain
δD(αE + δE)
,
then T can be re-written as:
T =
1
1+ M
.
Depending on the parameter values, T, the fraction of CSCs at the steady state,
can be either very small and close to zero or this fraction could also be close to
one. For example, the values of αS being nearly the same as δS (but larger) leads
to high CSC fraction, while large values of Ain or small values of δD leads to low
CSC fraction. That is, when the CSC division rate is very close to the CSC death
rate, then there is a high probability that tumor dies out because PCs do not have
a chance to populate (Eq. 2.2.3). Furthermore, high values of Ain implies that
each progenitor or transient amplifying cell undergoes a large number of rounds
of amplification before differentiating into a terminally differentiated cell which
results in a fast (slow) growth rate of PCs (CSCs).
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Partial derivatives of M with respect to the parameters (αS− δS) and Ain reveal
that any increase in αS and Ain decreases the fraction of CSCs at steady state:
∂M
∂(αS − δS) = Ain
[
δD + 2αE
δD(αE + δE)
]
∂M
∂Ain
= (αS − δS)
[
δD + 2αE
δD(αE + δE)
]
Moreover, partial derivatives of M with respect to αE (not shown) shows that
depending on the value of ∆ = δD − 2αE, T can be either negatively or positively
correlated to αE. That is, the balance between the number of TA cell divisions
and the rate of division of CSCs influences the percentage of CSCs at the steady
state. Moreover, the balance between the rate of differentiation of progenitor cells
and the death rate of differentiated cells not only can impact the proportion of
progenitor cells but also can influence the proportion of CSCs at the steady state.
In the next section we will numerically illustrate the correlation between CSCs
proportion and the aforementioned parameter values.
2.3.2 Asymptotic behavior of CSCs
As discussed earlier, moving from bounded to exponential growth requires in-
creases in the division rate of CSCs, αS, and/or decreases in the death rate of CSCs,
δS, such that:
δS < αSPSmin . (2.3.2)
Note that the inequality (2.3.2) contradicts Condition (i) and consequently there is
no longer a steady state and solutions of model 2.1.5 will grow exponentially.
Exploring the long-term asymptotic behavior of components of model 2.1.5 en-
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ables us to obtain an estimate of the proportion of the cancer stem cells in the
tumor as time approaches infinity. In this case, we have:
lim
t→∞ PS(S(t)) ≈ PSmin ·
Thus for long times, the model 2.1.5 can be approximated by following system
of linear ordinary differential equations:
dS
dt
≈ (αSPSmin − δS)S
dE
dt
≈ Ain αS(1− PSmin)S− αEE− δEE
dD
dt
≈ 2 αEE− δDD
These equations can be explicitly solved and the solutions are given by:
Sa(t) = C0 eβt
Ea(t) =
AinαS(1− PSmin)
β+ αE + δE
C0 eβt + C1 e−(αE+δE)t
Da(t) =
2 αE Ain αS(1− PSmin)
(β+ δD)(β+ αE + δE)
C0 eβt +
2αE
δD − (αE + δE)C1e
−(αE+δE)t + C2 e−δDt
where, β = αSPSmin − δS is the net growth rate of cancer stem cells and C0, C1
and C2 are arbitrary constants which satisfy in the initial condition of the system.
However, since we assumed that t→ ∞, the above solutions can be reduced to:
Sa(t) = C0 eβt
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Ea(t) =
AinαS(1− PSmin)
β+ αE + δE
C0 eβt
Da(t) =
2 αE Ain αS(1− PSmin)
(β+ δD)(β+ αE + δE)
C0 eβt
Now we can use the approximations above to estimate the proportion of cancer
stem cells in the tumor during the long-term, exponential growth phase.
T∞ = lim
t→∞
S(t)
S(t) + E(t) + D(t)
≈ Sa(t)
Sa(t) + Ea(t) + Da(t)
=
C0 eβt
C0 eβt +
AinαS(1−PSmin )
β+αE+δE
C0 eβt +
2 αE Ain αS(1−PSmin )
(β+δD)(β+αE+δE)
C0 eβt
=
1
1+
AinαS(1−PSmin )
β+αE+δE
+
2 αE Ain αS(1−PSmin )
(β+δD)(β+αE+δE)
Now, let
F =
AinαS(1− PSmin)
β+ αE + δE
+
2 αE Ain αS(1− PSmin)
(β+ δD)(β+ αE + δE)
· (2.3.3)
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Then, T∞ can be rewritten as
Sa(t)
Sa(t) + Ea(t) + Da(t)
=
1
1+ F
. (2.3.4)
Partial derivatives of F suggest that, the proportion of CSCs during the expo-
nential growth phase, T∞, is highly correlated to the values of αS and Ain. This
result suggests that decreasing the proliferation rate of CSCs and/or reducing the
number of TA divisions for progenitor cells can effectively decrease the final pro-
portion of the CSCs within a tumor.
2.4 Numerical Simulations
In this section, we first introduce a representative set of parameter values and
numerically simulate tumor growth over time for various growth scenarios. In ad-
dition, we illustrate how the proposed parameters relationships derived in Section
2.3 influence the proportion of the CSCs in the tumor.
2.4.1 Parameter values
Input parameters necessary to characterize the dynamics of the CSC, progenitor
and differentiated cell pools include the cell division and death rates as well as
the probability of stem and progenitor cell self-renewal. The proportion of cancer
stem cells (CSCs) within a tumor varies widely among cancer types and cell lines
Liu et al. (2013). CSCs make up only a fraction of 1% of the proliferating cells in
the bone marrow and approximately 1− 10% of the proliferating cells in epithelial
cancers. Parameter values for cancer stem cells (including symmetric/asymmetric
division rates) also vary widely across tumor types. In Gao et al. (2013) the cell-
cycle length is approximated around Tc = 25 hours which is in agreement with
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the result given in Driessens et al. (2012) in which Tc is estimated to be varying
between one and two days. Therefore, for our numerical simulations we use αE =
ln2/1.04 and αS ∈ [ln2/1.04/2 , ln2/1.04]. The death rate of differentiated cancer
cells, δD, has varied widely in a window between 0.01 per day to 15-18 per week
in previous studies Gentry and Jackson (2013); Molina-Pen˜a and A´lvarez (2012);
Rodriguez-Brenes et al. (2015); Weekes et al. (2014). Finally, under this assumed
hierarchical structure, CSCs live longer than both progenitor and differentiated
caner cells Clarke and Fuller (2006), so the maximum death rate of progenitor and
differentiated cells (δE, δD) is chosen to be larger than the death rate of CSCs, δS. A
representative set of baseline parameter values is provided in Table 2.2.
Table 2.2: Baseline Parameter Values For the Amplification Model
Parameters Baseline Values Units Reference
Aout 2 dimensionless Ganguly and Puri (2006)
αS 0.6 1day Driessens et al. (2012)
Gao et al. (2013)
αE
log(2)
1.04
1
day Driessens et al. (2012)
Gao et al. (2013)
P∗Smin 0.014 dimensionless Weekes et al. (2014)
PSmax 0.90 dimensionless Weekes et al. (2014)
Ain 2–20 dimensionless
δS 1.5 αSP∗Smin
1
day
δD 0.0612 1day Molina-Pen˜a and A´lvarez (2012)
δE 0.2 1day
PNs 800000 dimensionless
n 3 dimensionless
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2.4.2 Simulations
The model 2.1.5 is simulated using the parameter values given in Table 2.2
(unless otherwise stated). To initiate tumor growth, we begin with one thousand
CSCs, which corresponds to (S(0)=1000, E(0)=0, D(0)=0) being used as the initial
condition for our simulations. Figure 2.4 depicts tumor volume over time for vari-
ous values of the number of TA divisions, Ain, and the division rate of CSCs, αS. It
is evident from Figure 2.4 that both Ain and αS can considerably impact the rate of
tumor growth and the percentage of CSCs.
Numerical simulations suggest that higher values of both of the number of TA
division, Ain, and the division rate of CSCs increase the rate of tumor growth. Fig-
ures 2.4-A and 2.4-C show the tumor volume dynamic over time for various values
of Ain and αS. In contrast, as depicted in Figures 2.4-B and 2.4-D (dashed lines), the
higher values of Ain and αS result in the smaller percentage of CSCs at the equi-
librium level. For instance, increasing Ain from 2 to 20 causes approximately 88%
reduction in the percentage of CSCs at day 100. Interestingly, the changes in the
percentage of CSCs also change the percentage of PCs (Figures 2.4-B and 2.4-D)
All together, these results suggest that depending on the parameter values tumor
composition, specifically the percentage of CSC%, can be different in various tu-
mors. This is fairly reasonable, since the probability of CSC self-renewal and death
can be influenced by microenvironmental factors, which can vary among different
tumor types.
To emphasize the above results further, Figure 2.5 depicts the dependence of the
fraction of CSCs at steady state on some of the key parameters of the model. The
percentage of CSCs is negatively correlated to the increasing values of the division
rates of CSCs, αS, and also Ain, whereas it is positively correlated to the death rate
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Figure 2.4: Simulations of the model 2.1.5, showing (A) the tumor volume for
Ain = 2, 10 and 20, (B) the percentage of CSCs (dashed lines) and PCs (solid lines)
for Ain = 2 and 20, (C) the tumor volume for α = 0.2, 0.6 and 1, (D) the percentage
of CSCs (dashed lines) and PCs (solid lines) for αS = 0.2 and 0.6.
of CSCs. That is, any increase in αS or Ain (δS) results in a decrease (an increase)
in the final percentage of CSCs (Figures 2.5-A, B and C). Moreover, Figure 2.5-A
suggests that a 10-fold increase in the division rate of CSCS, αS leads to a 15 percent
difference in CSC percentage. However, Figure 2.5-B suggests that perturbations
in the baseline value of the death rate of CSCs, δS, have only moderate impact
on the CSC percentage when compared to changes in the CSC division rate. It
shows that a 5-fold change in the death rate of CSCs leads to a 0.02 difference
in the percentage of CSCs. In addition, Figure 2.5-D numerically illustrates that
32
depending on the value of ∆ = δD − 2αE, the percentage of CSCs can be either
negatively or positively correlated to the division rate of PCS, αE.
Figure 2.5: Fraction of Stem Cells Within the Tumor; it is shown that at the steady
state how the fraction of cancer stem cells depends on the parameter values of the
model.
2.5 Summary and Discussion
The discovery of the tumor-initiating cells, so called cancer stem cells (CSCs),
that share many features of normal stem cells led to the new hypotheses explaining
the origins and progression of cancerous tumors. Among those, CSC hypothesis
suggests that malignant growth is driven by a small subpopulation of CSCs Wicha
et al. (2006) and that those cells are responsible for tumor growth, resistance, and re-
currence. In addition, the bulk tumor consists of cells lacking stemness (non-CSC)
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which are not able to not capable of initiating and sustaining, and re-initiating
tumor growth, regardless of their differentiation status or proliferative capacity
Enderling et al. (2013). These cells are generated from CSCs through their differ-
entiation. While numerous studies support that CSCs are a rare population within
a tumor, there are newly emerging evidence suggesting a large variation in CSC
fractions within and among tumors Enderling et al. (2013); Reya et al. (2001). Can-
cer stem cells have now been identified in tumors of the breast, brain, head and
neck, and blood, among others Al-Hajj et al. (2003); Gentry and Jackson (2013);
Krishnamurthy et al. (2014); Singh et al. (2003). Emerging evidence suggests that
CSCs exhibit resistance to chemotherapy and radiotherapy and are involved in the
establishment of metastasis Krishnamurthy et al. (2014); Molina-Pen˜a and A´lvarez
(2012). Taken together, all these findings suggest that curative therapy will require
the complete ablation of CSCs.
Due to the difficulty of isolating and studying stem cells experimentally, math-
ematical modeling can provide further insight into the fundamental issues under-
lying CSC biology and can shed light on the potential of stem cell targeted treat-
ments. Several mathematical and computational models has been developed to
investigate the growth dynamics involved during tumorigenesis in hierarchical
tissue and have increasingly been applied to the biological system that arises from
CSC/non-CSC dynamics Kapitanov (2012); Michor et al. (2005); Sottoriva et al.
(2010); Tomasetti and Levy (2010); Turner et al. (2009); Youssefpour et al. (2012)
(also see Weekes et al. (2014) for a review). Ganguly et al. (2006) developed a math-
ematical based on a cell compartments method to pose and validate nonintuitive
scenarios arising from the cancer stem cell hypothesis. This model describes for-
mation of CSCs/PCs from normal stem/progenitor cells. They showed that CSC
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and PC populations reach a steady population and maintain a constant mature
cell population. The model is compartmentalized into norma/abnorma stem cells,
early and late progenitor and differentiated cells and it assumed that the onco-
genic mutations in normal stem and/or progenitor cells produces the cancerous
stem/progenitor cells. It is also assumed that each late progenitor cells under-
goes a limited number of cell division stages (ω) and once divides enters to a new
progeny compartment with a less capacity of cell division. They showed that mu-
tations in stem cells lead to faster growth of the abnormal progeny when compared
to mutations in progenitor cells. Following the modeling technique in Ganguly
and Puri (2006) and also Gentry and Jackson (2013), we designed a simple mathe-
matical model based on the CSC hypothesis to study cancer stem cell-driven tumor
growth and to evaluate its ability to estimate the stem cell proportion in a tumor at
steady state and during exponential growth. However, in our model we just track
the tumor cell population and instead of adding ω number of sub-compartment of
progenitor cells, it is assumed that each stem cell is amplified on upon entry into
the progenitor cell pool, whereas there is no amplification upon exit to the termi-
nally differentiated cell pool. A thorough mathematical analysis of the model 2.1.5
was carried out and the condition required for tumor initiation, bounded progres-
sion and/or exponential growth was introduced. Numerical simulations further
illustrated the impact of the various parameters on the tumor growth dynamics
and the fraction of CSCs in the tumor.
Depending of the balance between the division rate of CSCs, αS, and the death
rate of CSCs, δS, the qualitative behavior of the model (tumor) changes. For the
values of αS and δS which satisfy in αSPSmin < δS < αSPSmax , tumor growth is
bounded and reaches to a steady population whereas δS < αSPSmin causes an ex-
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ponential growth of CSCs which can results in unbounded exponential growth of
tumor. In addition, numerical simulations suggested that the tumor growth rate is
extremely sensitive to the small changes in the parameter values involved in the
CSC self-renewal probability (n and PNS) and also the amplifying factor Ain. Both
n and PNS can be regulated by the tumor microenvironmental factors suggesting
that the tumor mircoenvironment can induce pathways that provide better con-
ditions for cell division and survival such as recruiting additional microvessels
into stem cell niche, which provides additional sources of nutrition and oxygen for
tumor cells to grow and survive. Furthermore, there are other studies that empha-
sizes the potential influences of the Ain. Sottoriva et al. (2010) and Enderling et al.
(2013) used an agent-based model and cellular automaton approaches and shown
that in addition to cancer stem cell self-renewal the number of amplifications of
progenitor cells is one of the most pivotal modulators of overall tumor dynamics.
Considering the important role of CSCs in tumor initiation, progression and
in developing targeted therapies, one of the central objectives of this chapter is
to predict the fraction of CSCs in various stages of tumor growth. Interestingly,
a growing line of biological evidence suggests that depending on the tissue of
origin, cancer type, individual physiology, the fraction of CSCs can vary from a
very small proportion (close to zero) to almost the whole proportion of the tumor
(close to one). Therefore, we used our model 2.1.5 to not only estimate the fraction
of cancer stem cells, but also to find possible explanations for the wide variation
in percentages of CSCs that has been reported Enderling et al. (2013); Reya et al.
(2001). Our results suggest that the fraction of CSCs depends on the balance be-
tween the influx rate of stem cells into the progenitor compartment, (αS − δS)Ain,
and the efflux rate of progenitor cells into the terminally differentiated caner cells
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compartment, αE + δE. It further depends on the balance between the division
rate of the progenitor cells, αE and the death rate of differentiated cancer cells, δD.
Moreover, the model predictions suggested that the fraction of cancer stem cells
is significantly influenced by relatively small changes in the value of amplification
factor Ain. Recall that Ain × 2 = 2w, where w is ”the number of successive stages
of cell division before transforming into differentiated mature cell”. So, higher
value of Ain could result in a higher fraction of non-CSCs and a lower fraction of
CSCs. In fact, amplification factor may vary in response to tumor niche signaling.
To support our claim, for instance, in Foley and Mackey (2009) it is assumed that
the amplification factor, A(G), depends on Granulocyte-colony stimulating factor
(G-CSF), which they modeled as A(G) = (Amax − Amin) G(t)G(t)+bA + Amin. G(t) is
the concentration of G-CSF at time, Amax, Amin are the maximum and minimum
of amplification factors, respectively, and bA controls the steepness of the function.
The functional form of A(G) suggests that the amplification factor is low whenever
there is no G-CSF-induced signal, but when there is plentiful signal. the amplifica-
tion factor is high. So, in line with these assumptions in Foley and Mackey (2009),
our numerical simulations suggest that under the influences of the tumor micro-
environmental factors, CSC fraction can almost get any value between 0 and 1.
This is well documented that CSCs reside in perivascular niches and depend
on crosstalk with tumor-associated endothelial cells for their survival and main-
tenance of an undifferentiated state Krishnamurthy et al. (2014). These discover-
ies suggest the essence of developing the new therapeutic methods that targets
that blocks signaling pathways initiated by endothelial cells and that contribute to
CSC survival and self-renewal. However, the mechanisms involving the crosstalk
between endothelial cells and CSC are unknown. However, mathematical mod-
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els along with experimental methods are providing strong tools to explore those
mechanisms. In the next chapters we extend our model to include the impacts of
some of the tumor microenvironmental factors, endothelial cells and investigate
the significant role of the cross-talk between endothelial and tumor cells. The ex-
tended models also are used to study the responses of tumor cells to both targeted-
therapy alone or in combination with chemotherapy.
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Chapter 3
A MATHEMATICAL MODEL FOR IL-6-MEDIATED, STEM CELL DRIVEN
TUMOR GROWTH AND TARGETED TREATMENT
In this chapter, we develop a preliminary mathematical model for cancer stem
cell-driven tumor growth that includes the molecular level details of tumor cell-
secreted IL-6 signaling. Our immediate goal is to gain insight into the impact of
IL-6 on tumor growth and CSC self-renewal. The platform we model is the in vivo
growth of human tumor xengrafts that originate from a small population of CSCs
in a mouse model system. Krishnamurthy et al. Krishnamurthy et al. (2014) trans-
planted primary human CSCs into IL-6+/+ immunodeficient/athymic mice and
recorded the volume of generated tumors at 24 time-points over 121 days after im-
plantation. Using IL6 +/+ mice data as our experimental baseline, we preform rig-
orous parameter estimation and sensitivity analysis in order to fully calibrate our
model. Furthermore, in order to quantify the influence of host (murine) stromal IL-
6 on tumor growth and the survival of CSCs, they transplanted the same number
of CSCs in IL-6-/- immunodeficient mice and showed that tumor xenografts gen-
erated in the IL-6+/+ mice produced a greater number of tumors that were larger
in size than in the IL-6 -/- mice. In addition, they reported that the fraction of
CSCs in the IL-6+/+ mice tumor xenografts was approximately 10-fold larger than
in the IL-6-/- mice. Therefore, to further validate and test the predictive power
of our modeling framework we use it, and the IL-6-/- mice data, to explore the
effects of murine stromal IL-6 secretion on human cancer cell growth. This is the
first step in our larger goal of quantifying the impact of human stromal IL-6 secre-
tion on cancer stem cell percentage and tumor growth dynamics and assessing its
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potential as a therapeutic target.
3.1 Modeling Cancer Stem Cell Driven Tumor Growth Pre-treatment
In this section we develop a mathematical model for cancer stem cell-driven tu-
mor growth that is designed to quantify the influence of tumor cell-secreted IL-6 sig-
naling on tumor growth and cellular composition. The model is then extended to
include therapeutic intervention with the anti-IL-6R antibody, Tocilizumab (TCZ).
This model formulation only considers IL-6 produced by the human cancer stem
and non-stem (bulk) cells. It is important to note that host (murine) stromal cells
are also capable of producing a form of IL-6, however, murine IL-6 does not di-
rectly bind to human IL-6R and therefore, murine IL-6 cannot directly (only indi-
rectly) impact tumor growth. The pre-treatment model tracks the temporal evolu-
tion of three cancer cell types (stem, progenitor, and terminally differentiated) as
well as IL-6 and membrane bound IL-6 receptors (IL-6R) in their free and bound
forms as depicted in Figure 3.1. Although a soluble form of IL-6R (sIL-6R) exists
and can bind IL-6 with a similar affinity as membrane bound IL-6R, we choose to
simplify our modeling approach by not including sIl-6R because there is evidence
that its role is most important during trans signaling when cells lack IL-6R.
Table 1 lists each model variable along with its units.
Cancer Cell Equations
The proposed model is an extension of the model developed in Chapter 1. That
is, the total cellular composition of an HNSCC tumor at time t is divided into HN-
SCC cancer stem cells S(t), HNSCC transient amplifying/progenitor tumor cells
40
Figure 3.1: Schematic Diagram of the Molecular Processes Considered in the Math-
ematical Model: IL-6 Binding Dynamics.
E(t) and HNSCC terminally differentiated tumor cells D(t). Tumor cell secreted-
IL-6, denoted by L(t), binds to unoccupied (free) IL-6 receptors (IL-6R) on the
surface of stem, progenitor and differentiated cells denoted by RS, RE, and RD;
respectively. Association of IL-6 to IL-6R results in the formation of IL-6/IL-6R
complexes, which are represented by CS(t), CE(t) and CD(t), respectively, for each
cell type.
The probability of cancer stem cell self-renewal
In the absence of tumor cell-secreted IL-6, the probability of CSC self-renewal,
PS, is given by
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Table 3.1: List of Model Variables
Variable Description Units
S HNSCC stem cells # of cells
E HNSCC progenitor tumor cells # of cells
D HNSCC differentiated tumor cells # of cells
L IL-6 fmol
RS IL-6R on stem cells fmol
CS IL-6, cell bound IL-6R complex on stem cells fmol
RE IL-6R on progenitor cells fmol
CE IL-6, cell bound IL-6R complex on progenitor
cells
fmol
RD IL-6R on differentiated cells fmol
CD IL-6, cell bound IL-6R complex on differentiated
cells
fmol
PS(S) =
(PSmax − PSmin)PnNs
PnNs + S
n + PSmin · (3.1.1)
There is experimental evidence supporting the fact IL-6 impacts cancer stem cell
self-renewal and that the proportion of CSCs increases due to the presence of IL-6
Krishnamurthy et al. (2014). Therefore, in the presence of tumor cell-secreted IL-6,
we modify the functional form of PS given by (3.1.1) so that it still decreases as S
increases, but also increase as the fraction of bound receptors per cell φS =
CS
RTS S
in-
creases. There are many assumptions we could make for these modifications. For
now we assume that PSmax remains unchanged (and constant), but PSmin increases
as the amount of bound IL-6 receptors increases. This helps to ensure that IL-6 will
impact stem cell fate when the tumor is large. Together, these assumptions yield:
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PS(S, φS) =
(PSmax − PSmin(φS))PnNs
PnNs + S
n + PSmin(φS),
PSmin(φS) = µS
(
PSmax − P∗Smin
)
φS + P∗Smin
(3.1.2)
Remark 1: The first equation in 3.1.2 ensures that even if there is no IL-6 present,
the probability of self-renewal will decrease with population size. When IL-6 is
present, the minimum probability for self-renewal, PSmin , will increase to a frac-
tion, µS, of its maximum value as the fractional occupancy of bound receptors per
cell, φS, increases.
IL-6-Related Equations
Equation 3.1.3 describes the association at rate k f and dissociation at rate kr
of IL-6 (L) to its cell-bound receptors (RS, RE and RD) on stem, progenitor and
differentiated cells, respectively (Figure 3.1). An underlying assumption in this
equation is that the binding rates are the same, independent of cell type. IL-6 is
removed via natural decay at rate λL and is produced by tumor cells at rate ρ.
dL
dt
=− k f LRS︸ ︷︷ ︸
IL6 binding to
stem cells
+ krCS︸︷︷︸
IL6 dissociation
from stem cells
− k f LRE︸ ︷︷ ︸
IL6 binding to
progenitor cells
+ krCE︸︷︷︸
IL6 dissociation
from progenitor cells
− k f LRD︸ ︷︷ ︸
IL6 binding to
differentiated cells
+ krCD︸ ︷︷ ︸
IL6 dissociation
from differentiated cells
− λLL︸︷︷︸
IL6 natural decay
+ ρ(S + E + D)︸ ︷︷ ︸
IL-6 Production
by tumor cells
(3.1.3)
Equations 3.1.4, 3.1.5 and 3.1.6 describe the temporal changes in free IL-6 recep-
tors on each of the cell types that we are considering. The first two terms in each
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equation are the association and dissociation of IL-6 to IL-6R. The recycling terms
describe the reactions by which IL-6 is used up in the processes of mediating its
cellular response, and the free receptors are recycled back to the cell surface. Fol-
lowing the formulation in, the last two terms in each equation describe the produc-
tion of new free receptors as new cells are generated and the loss of these receptors
as cells die. Definitions of P(·) and D(·) are provided in the following section.
We note that when IL-6 binds to IL-6R, it subsequently recruits a GP130 molecule
to form a ternary complex (IL- 6/IL-6R/GP130) Hirabayashi and Lemmey (2012).
However, we do not model GP130 explicitly here, instead, we indirectly account
for its role in the binding parameters and recycling parameters.
dRS
dt
=− k f LRS︸ ︷︷ ︸
IL6 binding to
stem cells
+ krCS︸︷︷︸
IL6 dissociation
from stem cells
+ kpCS︸︷︷︸
Recycling
+ RTSPS (S, φS)︸ ︷︷ ︸
Generation of new RS
via cell proliferation
− RS
RS + CS
RTSDS (S, φS)︸ ︷︷ ︸
Loss of RS
via cell death
(3.1.4)
dRE
dt
=− k f LRE︸ ︷︷ ︸
IL6 binding to
progenitor cells
+ krCE︸︷︷︸
IL6 dissociation
from progenitor cells
+ kpCE︸ ︷︷ ︸
Recycling
+ RTEPE (E, φE)︸ ︷︷ ︸
Generation of new RE
via cell proliferation
− RE
RE + CE
RTEDE (E, φE)︸ ︷︷ ︸
Loss of RE
via cell death
(3.1.5)
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dRD
dt
=− k f LRD︸ ︷︷ ︸
IL6 binding to
differentiated cells
+ krCD︸ ︷︷ ︸
IL6 dissociation
from differentiated cells
+ kpCD︸ ︷︷ ︸
Recycling
+ RTDPD (D, φD)︸ ︷︷ ︸
Generation of new RD
via cell proliferation
− RD
RD + CD
RTDDD (D, φD)︸ ︷︷ ︸
Loss of RD
via cell death
(3.1.6)
Equations 3.1.7, 3.1.8 and 3.1.9, are analogous to the ones above as they de-
scribe changes in receptor-ligand complexes on each cell type. Similarly in these
equations, the internalization term describes the reactions by which the complex
is internalized and the free receptors are recycled to the cell surface. The last term
in each equation describes the loss of these receptor complexes due to cell death.
dCS
dt
= k f LRS︸ ︷︷ ︸
IL6 binding to RS
− krCS︸︷︷︸
IL6 dissociation
from RS
− kpCS︸︷︷︸
Internalization
− CS
RS + CS
RTSDS (S, φS)︸ ︷︷ ︸
Loss of CS
via cell death
(3.1.7)
dCE
dt
= k f LRE︸ ︷︷ ︸
IL6 binding to RE
− krCE︸︷︷︸
IL6 dissociation
from RE
− kpCE︸ ︷︷ ︸
Internalization
− CE
RE + CE
RTEDE (E, φE)︸ ︷︷ ︸
Loss of CE
via cell death
(3.1.8)
dCD
dt
= k f LRD︸ ︷︷ ︸
IL6 binding to RD
− krCD︸ ︷︷ ︸
IL6 dissociation
from RD
− kpCD︸ ︷︷ ︸
Internalization
− CD
RD + CD
RTDDD (D, φD)︸ ︷︷ ︸
Loss of CD
via cell death
(3.1.9)
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Proliferation and Death Function Definitions
The functions PS (S, φS), PE (E, φE) and PD (D, φD) are the rates at which
new stem cells, progenitor and differentiated cells are generated, respectively. These
relationships are taken directly from equations 2.1.1, 2.1.2 and 2.1.3 and are there-
fore given by:
PS (S, φS) = αSPS(S, φS)S (3.1.10)
PE (E, φE) = AinαS(1− PS(S))S− αEE (3.1.11)
PD (D, φD) = 2αEE (3.1.12)
The second to last terms in equations 3.1.4, 3.1.5 and 3.1.6 assume that a total
of RTS , RTE , and RTD , new free receptors are generated at the proliferation rates
defined in equations (2.1.13) - (2.1.15); respectively.
The functions DS (S, φS), DE (E, φE) and DD (D, φD) are the death rates of stem
cells, progenitor and differentiated cells; respectively. These relationships are taken
directly from equations 2.1.1, 2.1.2 and 2.1.3 and are therefore given by:
DS (S, φS) =
δS
1+ γ1φS
S (3.1.13)
DE (E, φE) =
δE
1+ γEφE
E (3.1.14)
DD (D, φD) =
δD
1+ γDφD
D (3.1.15)
The last terms in equations 3.1.4 - 3.1.6 and in equations 3.1.7 - 3.1.9 assume that
the fraction of the total number of receptors that are either free or bound, respec-
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tively, are removed at the death rates defined in equations (2.1.16) - (2.1.18).
Notes on the Model Formulation
This formulation assumes that the total number (converted to fmol using molecu-
lar weight) of receptors per cell (RTS , RTE and RTD) remains constant. This means
that the total amount of IL-6R in the system should be conserved. In other words:
Total IL-6R in the system that is associated with stem cells = IL-6R/cell× the num-
ber of stem cells. In terms of our variables, for stem cells this equations reduces
to RS(unoccupied IL-6R) +CS(occupied IL-6R) = RTS × S. We can ensure that the
model equations do in fact conserve IL-6R by considering the sum
dRS
dt
+
dCS
dt
= RTS (PS (S, φS)−DS (S, φS)) = RTS
dS
dt
Therefore, upon integration, we have
RS + CS = RTS S. (3.1.16)
Similarly, for progenitor and differentiated cells we have
RE + CE = RTE E, (3.1.17)
RD + CD = RTD D. (3.1.18)
Using Eqs. (3.1.16-3.1.18) we have, RS = RTS S − CS, RE = RTE E − CE and
RD = RTD D − CD, so we can remove three equations dRSdt , dREdt and dRDdt from the
model and replace RS, RE and RD by RTS S− CS, RTE E− CE and RTD D − CD, re-
spectively. These changes result in following model system with a reduced number
of equations:
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Model (1): IL-6 Model with Amplification Factor
dS
dt
= αSPS(S, φS)S− δS1+ γSφS S
dE
dt
= AinαS(1− PS(S, φS))S− αEE− δE1+ γEφE E
dD
dt
= 2αEE− δD1+ γDφD D
dL
dt
= −k f L(RTS S− CS) + krCS − k f L(RTE E− CE) + krCE
− k f L(RTD D− CD) + krCD − λLL + ρT(S + E + D) (3.1.19)
dCS
dt
= k f L(RTS S− CS)− krCS − kpCS −
δS
1+ γSφS
CS
dCE
dt
= k f L(RTE E− CE)− krCE − kpCE −
δE
1+ γEφE
CE
dCD
dt
= k f L(RTD D− CD)− krCD − kpCD −
δD
1+ γDφD
CD
dS
dt ,
dE
dt and
dD
dt in Model (1) describe the tumor growth at the tissue level whereas
dL
dt ,
dCS
dt ,
dCE
dt and
dCD
dt represent the cell surface dynamics of receptor-ligand bind-
ings. Binding IL-6 to IL-6R activates the receptors on the cell membrane which
leads to intracellular signal transduction cascade which by itself enhances the self-
renewal probability of CSCs and survival of tumor cells. Tracking the temporal
changes of the number of IL-6-IL-6R complex molecules (φS, φE and φD) at the in-
tracellular level allows us to quantify the impacts of IL-6 mediated pathways on
CSC self-renewal potentials and tumor cell death. A schematic representation of
the incorporated scales in Model (1) is given in Figure 3.2.
It is worth mentioning that in addition to the aforementioned levels, this model
is running in two different time scales. While the changes at molecular level hap-
48
Figure 3.2: Schematic Illustration of the Interaction Between IL-6 and Tumor Cells;
The left panel represents a closer look to the IL-6-IL-6R complex molecules on the
tumor cell membrane. Tumor secreted IL-6 binds to unoccupied IL-6 receptors on
tumor cells (CSCs, PCs and DCs) and initiate signaling pathways which promote
the self-renewal probability of CSCs and enhance survival of tumor cells. Tracking
the temporal changes of the fractional occupancies of IL-6R (φS, φE and φD) allows
us to quantify the impacts of IL-6 on tumor growth dynamics.
pens in seconds, the events related to tumor cell division, differentiation and death
occur at the scale of days and even weeks.
We will use this model as a foundation for extensions designed to study the
effects of human stromal cell-secreted IL-6 on the tumor growth dynamics and further
to investigate the response of CSCs to combination therapy using a Cisplatin and
Tocilizumab (TCZ).
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3.2 Numerical Analysis
In this section, we first introduce the parameter values that we can find from
the literature. For parameters which there is no information, we estimate them by
performing a best-fit to experimental data, particularly, to IL-6+/+ mice data with
initial condition (S0, E0, D0, L0, CS0 , CE0 , CD0) = (1000, 0, 0, 0, 0, 0, 0). Furthermore,
we will perform uncertainty and sensitivity analysis to find the most influential
parameters on the tumor growth, percentage of CSCs and the fractional occupan-
cies of bound IL-6 receptors on CSCs.
3.2.1 Parameter values
The parameter values obtained from the literature are tabulated in Table 3.2.
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Table 3.2: Parameter Values Taken from the Literature and Their Sources
Parameters Baseline Units Reference
Values
Aout 2 dimensionless Ganguly and Puri (2006)
αS 0.6 day
−1 Driessens et al. (2012)
Gao et al. (2013)
αE
log(2)
1.04 day
−1 Driessens et al. (2012)
Gao et al. (2013)
P∗Smin 0.014 dimensionless Weekes et al. (2014)
PSmax 0.90 dimensionless Weekes et al. (2014)
k f 2.35 fmol
−1day−1 O¨zbek et al. (1998)
kr 2.24 day−1 Hirabayashi and Lemmey (2012)
O¨zbek et al. (1998)
λ 0.4152 day−1 Lindmark et al. (2001)
ρ 7× 10−7 fmol−1per cellday−1 Bran et al. (2011)
Nilsson et al. (2005)
PRIES et al. (2006)
RTS 1.66× 10−6 fmol−1per cell Boayue et al. (1998)
Shkeir et al. (2013)
Snyers and De Wit (1990)
Takizawa et al. (1993)
RTE
1
8 RTS fmol
−1per cell Krishnamurthy et al. (2014)
RTD
1
8 RTS fmol
−1per cell Krishnamurthy et al. (2014)
For those parameters which there was little or no published information, we
compute a best fit to experimental data to obtain reasonable estimates. In sec-
tion 2.2.4, we also perform uncertainty and sensitivity analysis to find the most
influential parameters on the tumor growth, percentage of CSCs and the fractional
occupancies of bound IL-6 receptors on CSCs.
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3.2.2 Experimental data
To begin to understand the impact of stromal IL-6 on the survival of CSCs,
Krishnamurthy et al. Krishnamurthy et al. (2014) generated tumor xenografts by
transplanting primary human cancer stem-like cells in severe combined immun-
odeficient mice. Specically, immediately after surgical removal of the primary tu-
mor from patients with HNSCC, ALDHHIGHCD44HIGH cells were sorted and trans-
planted into IL-6 +/+ or IL-6 -/- immunodeficient mice. This approach differs from
scaffold experiments where xenograft tumors vascularized with functional human
microvessels are generated in SCID mice. In that experimental setup, human tu-
mor cells are seeded along with human dermal microvascular endothelial cells
(HDMECs) in poly(L-lactic) acid biodegradable scaffolds, resulting in the growth
of human tumors with human vasculature and an additional source of human IL-
6 (the HDMECs). In the experimental setup modeled here, no human endothelial
cells are implanted and the only source of human IL-6 are the tumor cells them-
selves. Another difference between the experimental approach modeled here and
others in the literature, is the use of primary tumor cells and not immortalized tu-
mor cell lines. Figure 3.3 shows the relevant data taken from Krishnamurthy et al.
(2014) . When 1,000 ALDHHIGHCD44HIGH were cells transplanted into the IL-6
+/+ mice, the result was more and larger tumors as compared to the transplanta-
tion of 1000 (ALDHHIGHCD44HIGH) into IL-6 -/- deficient litter mates.
3.2.3 Estimating baseline parameter values using IL6+/+ mice data
We fit the mathematical model to the IL-6+/+ mice data in Krishnamurthy et al.
(2014) in oder to estimate the baseline parameter values for those that we could
not obtain in the current literature (Ain, PNs , kp,γi and µ). Data for tumor volume
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Figure 3.3: Data for Tumor Growth (A) and Stem Cell Percentage (B) Taken Directly
from Krishnamurthy et al. (2014).
over time (day 50 through day 121) is given in Figure 3.3. We use GraphClick
software to extract the data for the tumor volume at each time point in Figure
3.3. The data fitting process uses R lsoda solver with a time-step of one day to
predict the volume of the tumor over time. The Monte Carlo parameter sweep method
Cowan (1998) is used to minimize the Pearson χ2 statistic by comparing extracted
tumor volume from data in Figure 3.3 and the tumor volume predicted by the
mathematical model, over 24 data time-points. Remark: In order to normalize the
percentage of cancer stem cells by the primary human tumor stem cell percentage,
it is assumed that the primary human HNSCC tumor is contained 2.1% tumor
stem cells, which is normalized to 1%. The parameter values obtained via this
fitting process are tabulated in Table 3.3.
As we mentioned earlier, the long-term goal of this study is to evaluate the im-
pact of human endothelial cell-secreted IL-6 (EC-IL-6) on the tumorigenic potential
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Table 3.3: List of Estimated Parameter Values for Model (1) Using IL-6+/+ Mice
Data.
Parameters Baseline Values Units Reference
Ain 2 dimensionless Fitted to data
δS 1.5αSP∗Smin
1
day Assumed
δE 0.0612 1day Assumed
δD 0.0612 1day Assumed
PNs 728455 dimensionless Fitted to data
n 2.6 dimensionless Assumed
kp 24.95 1day Fitted to data
µ 0.04 dimensionless Fitted to data
γi 2.38 dimensionless Fitted to data
of CSCs. The rationale is that the IL-6 expression is higher in the endothelial cells
than in the HNSCC tumor cells Krishnamurthy et al. (2014). To do so, we will use
an extended version of Model (1) developed in Chapter 3 along with data from
an experiment in which human tumor cells and human endothelial cells are trans-
planted into immunodeficient mice Krishnamurthy et al. (2014). Therefore, we will
use the model developed here, Model (1), to estimate baseline parameter values
that we will later use in the extended model presented in Chapter 3.
3.2.4 Characterizing IL-6 dependent tumor growth
We fit Model (1) to the IL-6+/+ mice data (given in Figure 3.3) to estimate the
baseline parameter values for those that we could not find any information in the
literature (Ain, PNs , kp,γi and µ). The best-fit parameter values are tabulated in Ta-
ble 3.3 and results of the numerical simulations are depicted in Figure 3.4-A. There
is a strong correlation between the model output (red) and the experimental data
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in Krishnamurthy et al. (2014) (blue). The green line in Figure 3.4-A represents the
tumor volume over time when no IL-6 is produced by tumor cells, thereby show-
ing how much even low secretion rates of IL-6 (ρ = 7−7 fmolcell×day) influence tumor
growth. In addition, we use the best-fit parameter values to predict the percent-
age of CSCs on the last day of the experiment. Figure 3-B shows the experimentally
measured percentage of CSCs in primary tumors (brown), the experimentally mea-
sured percentage of CSCs on day 121 for tumors grown in IL-6 +/+ mice (blue),
along with our mathematical model prediction (red). The model is able to accu-
rately capture the correct proportion of stem cells and Figure 3-D shows how the
stem cell percentage evolves over time.
Figure 3.4: (A) Best Fit of the Model Prediction of Tumor Volume Over Time to
the IL-6+/+ Data in Krishnamurthy et al. (2014). The green line in (A) shows the
special case in which the tumor cells are not producing IL-6, ρ = 0. (B) Comparison
of the experimentally measured percentage of CSCs in primary tumors (brown),
the experimentally measured percentage of CSCs on day 121 for tumors grown in
IL-6 +/+ mice (blue), and the mathematical model prediction percentage of CSCs
on day 121 (red). (C) Model prediction of the temporal changes in the factional
occupancy of IL-6 receptors on CSCs, φS. (D) Model prediction of the stem cell
percentage over time.
Recall that the first step in the IL-6 signal transduction pathway is to binding
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to IL-6R. The IL-6-IL-6R complex then recruits GP130. The triple complex of IL-
6-IL-6R-GP130 activates signaling pathways (such as STAT3) Garbers et al. (2015);
Zhang et al. (2006) that play a critical role in the self-renewal and survival of CSCs.
Therefore, the fractional occupancies of bound receptors can provide a useful tool
for quantifying the influence of tumor cell-secreted IL-6 on the tumorigenic poten-
tial of CSCs and subsequently on tumor growth dynamics. Figure 3.4-C plots the
fractional occupancy of IL-6R on CSCs over time for our baseline level of tumor
secretion of IL6. The model suggests that a fractional occupancy of 12% on CSCs
is sufficient to result in the experimentally observed tumor growth rate. In fact,
because endothelial cells can secrete higher levels of IL-6 than tumor cells Krish-
namurthy et al. (2014), if we were to add endothelial cells to our model then we
would expect even greater interdependencies among IL-6, tumor growth dynam-
ics and the tumorigenic potential of CSCs.
Figure 3.5 shows that if we fix all the other parameters while varying the se-
cretion rate of tumor IL-6, ρ, then relatively small changes in this value (from
ρ = 7e − 7 to 5.35e − 6 fmol/cell/day) lead to 90% fractional occupancy. This
supports the idea that an IL-6 agonist could temper the effects of IL-6-induced
pathways, thereby impeding tumor growth.
Sensitivity analysis
We use sensitivity analysis to determine which parameters are the most influen-
tial on the tumor volume, TV = S(t)+E(t)+D(t)106 , percentage of cancer stem cells,
Ω = S(t)S(t)+E(t)+D(t) × 1002.1 and the fraction of occupied bound receptors on the CSCs,
φS =
CS
RTS S
, at days = 15, 50, 90 and 120. The uncertainty quantification method
we use is a global sensitivity analysis that uses Latin Hypercube Sampling (LHS)
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Figure 3.5: The Fractional Occupancies of IL-6R on CSCs, φS, Highly Depends on
Secretion of IL-6 by Human Tumor Cells, ρ
along with Partial Rank Correlation Coefficient (PRCC) 1 to assess the sensitivity
of the output of interest (tumor volume, percentage of cancer stem cells, and the
fraction of occupied bound receptors) to each of the parameters at the given time-
pointsBlower and Dowlatabadi (1994); Marino et al. (2008); Sanchez and Blower
(1997). The LHS method involves defining baseline values and ranges for each of
the parameters, assuming they obey a uniform distribution, and carrying out mul-
tiple runs (number of runs = 1000) of the sampled values for the response output
(TV, Ω, and φS in this case) Blower and Dowlatabadi (1994); Marino et al. (2008);
Sanchez and Blower (1997). We use the best-fit parameter values as the baseline
parameter values to calculate LHS PRCC values and ±10% of the best-fit parame-
ter values as the range.
1More information about LHS & PRCC can be found in Appenidx
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As depicted in Figures (3.6-3.8), sensitivity analysis reveals that in some cases,
parameter sensitivity varies as the tumor grows. For example, since |PRCC(TV, Ain)| ≈
1 and |PRCC(TV, αS)| ≈ 1 (Figure 3.6), tumor volume is highly sensitive to the
relatively small changes in both the amplification factor, Ain, and the stem cell pro-
liferation rate, αS, at all the times. However, the tumor volume becomes less and
less sensitive to the parameter PSmax as tumor volume increases. Other parameters
with a large influence on the tumor volume are the death rate of the terminally
differentiated cancer cells, δD; the minimum probability of CSC self-renewal, P∗Smin ;
the production rate of IL-6 by tumor cells, ρ; and the total number of IL-6 receptors
on CSCS, RTS . These results highlight how critically important CSC dynamics are
for driving tumor growth. Interestingly, the only influential parameter not related
to CSCs and IL-6 is the maximum death rate of the terminally differentiated cancer
cells.
Ain S E S E D PNs n PS
min
PS
max
-1
-0.5
0
0.5
1
PR
CC
 (T
um
or 
vo
lum
e)
at day= 15
at day= 50
at day= 90
at day= 120
kf kr kp RTS
RT
E
RT
D
-1
-0.5
0
0.5
1
PR
CC
 (T
um
or 
vo
lum
e)
at day= 15
at day= 50
at day= 90
at day= 120
Figure 3.6: PRCC Values for the Parameters of Model (1) Using the Tumor Volume
as the Output of Interest
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PRCC values given in Figure 3.7 shows that percentage of CSCs within the tu-
mor is also highly influenced by the amplification factor, Ain, at all times. The
death rate of the terminally differentiated cancer cells, δD and the minimum prob-
ability of CSC self-renewal, P∗Smin , are most influential at later times, while the stem
cell proliferation rate, αS becomes less influential as the tumor grows larger.
Figure 3.7: PRCC Values for the Parameters of Model (1) Using the Percentage of
Caner Stem Cells as the Output of Interest
Finally, PRCC values for parameters using the fractional occupancy, φS, as the
output of interest (Figure 3.8) reveals that Ain, ρ, and RTS are consistently the most
influential parameters. Again, αS is influential early in tumor growth, but loses its
impact for later times.
We used IL-6+/+ mice data to estimate the baseline parameter values (Tables
3.2 and 3.3 ) that will be used in the extended version of Model (1) to study the
impacts of EC-IL-6 and treatment on tumor growth. We further used these base-
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Figure 3.8: PRCC Values for the Parameters of Model (1) Using Fraction of Occu-
pied Bound Receptors as the Output of Interest
line parameter values to run a global sensitivity analysis on Model (1) in order to
determine the most influential parameters on the tumor growth dynamics includ-
ing changes in the tumor volume, percentage of CSCs and fractional occupancies
of IL-6 bound receptors over time. We observed that some of the parameters are
influential at all the time-points; whereas, some of the others are more influential
at the early stages of tumor growth but their significance is reduced as the tumor
grows larger. This might be due to the tendency of the system to reach to a sta-
ble state relatively quickly. Numerical simulations suggests that soon after tumor
starts to grow, both the fractional occupancies of bound receptors and CSC per-
centage rapidly reach equilibrium and remain fixed for all the future time points
(Figures 3.4-C and 3.4-D).
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3.2.5 Impacts of Murine stromal cell-secreted IL-6 on tumor growth
In addition to IL-6+/+ mice, Krishnamurthy et al. (2014) used the same ap-
proach to generate tumor genografts in IL-6-/- mice, which are unable to produce
murine stromal IL-6 (gray data points in Figure 3.3-B). Despite the fact that murine
IL-6 can not directly impact human tumor cell proliferation (since it can not bind
to IL-6 receptors on the tumor cells Coulie et al. (1989)), they reported that tumor
xenografts generated in the presence of murine IL-6 (in IL-6+/+ mice) produced a
greater number of tumors that were larger in size than in the IL-6 -/- mice Krishna-
murthy et al. (2014). On the other hand, it is known that both human and murine
IL-6 do react with the murine stromal IL-6-receptor Coulie et al. (1989). Thus, one
potential interpretation of this data is that murine IL-6 secreted by stromal cells of
the host in IL-6+/+ mice is affecting the mouse endothelial cells leading to in-
creased angiogenesis and survival potential for the tumor cells Krishnamurthy
et al. (2014). So we would like to test the ability of Model (1) to fit and explain
this idea as further validation. Also, insights gained may be viewed as a useful
first step in our overarching goal of understanding the role of human endothelial
(stromal) cell secreted IL-6, which directly impacts cancer growth.
Method description
Knowing the most influential parameters from the previous section, in order to
explore the effects of murine IL-6 on the dynamics of tumor growth, we need to
address the following question:
”which of the influential parameters should be altered in response to the ab-
sence of Murine stromal IL-6?”. In fact, the interaction between CSCs and their
surrounding microenvironment is poorly understood Lu et al. (2014); Noll et al.
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(2014); O’Brien et al. (2010); Plaks et al. (2015). However, what is well-understood
is that tumor microenvironment plays a crucial role in regulating proliferation and
survival of tumor cells as well as mediating a potential protective environment
for stem cells to grow and divide without interruption Lu et al. (2014); Noll et al.
(2014); O’Brien et al. (2010); Plaks et al. (2015); Sujata and Chaudhuri (2008). In
particular, IL-6 secreted by endothelial cells within tumor niche directly regulates
CSC growth and behavior through binding to their receptors on the CSCs Noll et al.
(2014). Despite the fact that murine IL-6 can not bind to IL-6 receptors on the hu-
man tumor cells, it still has indirect impacts on the tumor niche. In fact, it has been
shown that IL-6 function is not just limited to modulating the CSC self-renewal,
rather IL-6 has an indirect impact on CSC growth through recruiting mesenchymal
stem cells (MSCs), which results in angiogenesis as well as providing nutrition and
oxygen for the tumor cells Noll et al. (2014). Therefore, among the most influen-
tial parameters obtained via sensitivity analysis, we need to choose those that can
be altered in response to the absence of murine IL-6 in tumor microenvironment.
Thus, the potential parameter candidates are Ain, n and PNS since the rest can only
be changed through IL-6-IL-6R binding signals. To support our claim, we provide
some biological evidence below.
The balance between self-renewal and differentiation, as well as, the number of
TA divisions of progenitor cells is regulated by the tumor niche in order to main-
tain the cancer stem cell function and protection against chemotherapeutic agents
Clarke and Fuller (2006); Noll et al. (2014). As a result, the number of stem cells
within a particular tissue can be regulated by controlling the number of compo-
sition of existing niches Clarke and Fuller (2006). The number of TA divisions is
flexible in various tissues and can respond to extracellular signals Insco et al. (2009);
Monk et al. (2010). However, little is currently known about the mechanism that
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regulates and/or determines the number of TA division Clarke and Fuller (2006);
Insco et al. (2009); Monk et al. (2010). In addition, mutations may allow transit
amplifying progenitor cells to escape the controls that normally regulate the num-
ber of TA divisions leading to continued proliferation rather than terminal dif-
ferentiation Clarke and Fuller (2006). Alternatively, oncogenic mutations arising
in transit-amplifying progenitor cells may imbue them with stem cell properties
of self-renewal resulting in a pool of cancer stem cells in a fully neoplastic state
Clarke and Fuller (2006).
In Model (1), parameter Ain reflects the controlling effects of the ”regulatory
feedback signaling” of transit-amplifying progenitor cell division Ganguly and
Puri (2006). Therefore, it is reasonable to assume that the number of TA divisions
(which corresponds to the value of Ain) might vary in response to the absence
and/or presence of murine IL-6. Along with that, PRCC values show Ain has the
largest impact on both tumor growth and CSC percentage. However, tumor vol-
ume is positively correlated to Ain while CSC percentage is negatively correlated
to it. So, our challenge is to numerically find a balanced value of Ain which favors
both of the changes in IL-6-/-mice data.
Both PNS and n are parameters that represent effects of micro-environmental
influences on tumor growth (including murine IL-6) in Model (1). For larger val-
ues of n, tumor microenvironmental factors have more regulatory control on tu-
mor growth and CSC self-renewal. So in the absence of IL-6 we would expect a
larger value of n since comparing IL-6-/-mice and IL-6+/+mice data suggests that
murine IL-6 enhances CSCs growth and survival Krishnamurthy et al. (2014). PNS
measures the time it takes to reduce the probability of CSC self-renewal to halfway
between PSmax and P
∗
Smin
. Numerical simulations reveal that it takes almost 14 days
for a 50% decrease in the probability of CSC’s self-renewal. So in the absence of
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IL-6 we would expect a decrease in the amount of time that it takes to reduce the
probability of CSC self-renewal corresponding to a decrease in the IL-6+/+ best-fit
parameter value for PNS .
Now, in order to fit Model (1) to the IL-6-/-mice data, we keep all of the IL-6+/+
best-fit parameter values unchanged except those candidate parameters indicated
above. Increasing Ain = 2 and n = 2.6 to Ain = 18.8 and n = 4.2, and also
decreasing PNS = 728400 to PNS = 77600, we find the best-fit parameter values for
IL-6-/-mice data as depicted in Figure 3.9-A. With these set of parameter values
our model also can capture the experimentally observed percentage of CSCs at
day 120 (Figure 3.9-B). Furthermore, Figure 3.9-C shows despite the slower tumor
growth dynamics in IL-6-/- mice, the fractional occupancies of IL-6R on CSCs does
not change when compared to IL-6+/+ mice data. The IL-6-/- best-fit parameter
values are tabulated in Table 3.4.
Table 3.4: List of Estimated Parameter Values for Model (1) Using IL-6-/- Mice
Data.
IL-6-/- mice data IL-6+/+ mice data Parameter Description
Ain ≈ 18←−←− Ain ≈ 2 Amplification factor
PNs = 77600←−←− PNs = 728400 Half-max stem cell self-renewal
concentration
n = 4.2←−←− n = 2.6 Steepness parameter for PS
To summarize, we re-fit Model (1) to the IL-6-/- mice data as further validation
of the model and as a way of testing its ability to capture tumor growth dynamics
even in the absence of murine IL-6. To do so, among the most influential param-
eter values we chose the ones that could be altered in response to the absence of
Murine IL-6. Then we fixed all the other best-fit IL-6+/+ mice parameter values
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Figure 3.9: Fitting Model (1) to the IL-6-/- Data by Using Parameter Values Given
in Tables 3.2, 3.3 and 3.4.
and varied the values of those candidate parameters to find the best-fit of Model
1 to the IL-6-/- mice data. Additionally, we saw that murine IL-6 mostly affects
parameters that represent the influence of the tumor micro-environment including
Ain, PNS and n. This led us to conclude that the murine IL-6 secreted by host cells
can affect the system by impacting the associated tumor microenvironment.
3.3 Treatment of HNSCC Tumors with Anti-IL-6R Antibody, Tocilizumab
We have already shown, in the previous sections, that tumor cell-secreted IL-
6 can significantly impact tumor growth. Recall that Figure 3.5 shows how the
secretion rate of IL-6 by human tumor cells impacts the fraction of occupied IL-6
receptors. Specifically, we studied the (extreme) case in which there is no secretion
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of IL-6 by human tumor cells and saw significant tumor reduction. This motivated
us to add treatment with an anti-IL-6R, Tocilizumab (TCZ), to our current model
and explore its effects on the growth rate of tumors generated in IL-6+/+ mice.
Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody against the
IL-6 receptor that has FDA approval for the treatment of moderate to severe RA,
however given its efficacy against IL-6R it also has potential as a targeted cancer
therapy.
3.3.1 Two-compartment pharmacokinetic model
Experimental evidence suggests a biphasic plasma concentration-time curve
for TCZ Igawa et al. (2010). Consequently, we proposed the following 2-compartment
model to describe TCZ pharmacokinetics. The general two-compartment pharma-
cokinetic modeling framework consists of a central compartment, denoted by Is,
and peripheral compartment, denoted by Ip. The central compartment is com-
posed of the blood and highly vascularized organs, such as the liver and kidney.
The peripheral compartment is made up of slowly perfused tissues and organs.
Table 3.5: Variables Related to TCZ-Therapy Model
Variable Description Units
Is Free anti-IL-6R antibody in systemic circulation fmol
Ip Free anti-IL-6R antibody in peripheral compartment fmol
Pharmacokinetic models can be further specified by the type of drug admin-
istration. Intravenous injection or i.v. injection is the injection of a substance as
a bolus or infusion directly into a blood vessel (intravenous) Turner et al. (2011).
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Figure 3.10: General Two-Compartment Pharmacokinetic Model for (A) Intra-
venous Bolus (i.p.) and (B) Intraperitoneal (i.p.) Injection.
Intraperitoneal injection or i.p. injection is the injection of a substance into the
peritoneal cavity. It is more often used in small animals than large mammals and
humans. In general, it is preferred when intravenous access is challenging or when
large volume of fluids are needed to be injected or when low blood pressure pre-
vents the use of intravenous injection Turner et al. (2011). A general schematic
representation of the PK-model for both types of injection, i.v. injection and i.p.
injection, is given in Figure 3.10.
The corresponding equations for single dose i.v. injection (Figure 3.10-A) are
given by:
dIs
dt
= − k12 Is + k21 Ip︸ ︷︷ ︸
Pharmacokinetcs
−kel Is (3.3.1)
67
dIp
dt
= + k12 Is− k21 Ip︸ ︷︷ ︸
Pharmacokinetcs
where k12 and k21 are the transfer rate constants between the two compartments
and kel is the elimination rate from central compartment.
In prior works several PK-models have been designed differing in generalized
assumptions about the number of compartments and/or the path of connectivities.
For instance, Charusanti et al. assumed an i.p. injection 3-compartment PK model
involving: (1) intraperitoneal cavity, (2) blood and (3) tumor cells. In this model
the drug is assumed to be injected to intraperitoneal cavity and then the blood
delivers the drug to the tumor cells Charusanti et al. (2004). Dedrick and Fless-
ner also designed a PK model for i.p. injection involving two compartments, the
peritoneal cavity and a body compartment. They assumed that the drug transfers
from the peritoneal cavity into surrounding area via three parallel paths governed
by tissue-specific (liver, hollow viscera and parietal tissue) permeabilities Dedrick
and Flessner (1997). In other work, Elishmereni et al. designed a PK model un-
der i.p. injection based on data in mice. In this model the drug is injected into
the administration site and transported through three tissue compartments to the
plasma. Then the drug is transported to the target tissue and/or degraded via
three additional compartments Elishmereni et al. (2011). The model that we are
using is a combination, but simplified version of these models. Instead of multiple
number of intraperitoneal cavity compartments, we have one peripheral compart-
ment, which includes the intraperitoneal cavity.
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Single dosing via intravenous injection
We assume that at time t0, a single dose of drug, d0, is administered by intravenous
bolus. Then the pharmacokinetic model with the initial condition Is(t0) = d0 and
Ip(t0) = 0 can be analytically solved and is given by:
Is(t) = Is(t0)
(
Ae−α(t−t0) + Be−β(t−t0)
)
, t ≥ t0 (3.3.2)
where,
α =
(k12 + k21 + kel) +
√
(k12 + k21 + kel)2 − 4k21kel
2
β =
(k12 + k21 + kel)−
√
(k12 + k21 + kel)2 − 4k21kel
2
A =
k21 − α
β− α
B =
k21 − β
α− β
A proof of this result is given in Section B of Appendix.
Single dosing via intraperitoneal injection
Using the same approach for intraperitoneal injection we can show that the phar-
macokinetic model with the initial condition Is(t0) = 0 and Ip(t0) = d0 can be
analytically solved and is given by:
Is(t) = Ip(t0)
(
Ape−α(t−t0) + Bpe−β(t−t0)
)
, t ≥ t0 (3.3.3)
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where, α and β are defined above and
Ap =
k21
β− α
Bp =
k21
α− β
From this point on, we will use the PK-model with i.v. injection given given
by Eq. 3.3.2. The pharmacokinetic rate constants (k12, k21 and kel) are estimated by
fitting the analytical solution of Is(t) to the experimental data described in Igawa
et al. (2010). Briefly, in this experiment TCZ and a pH-dependent binding vari-
ant of TCZ, PH2, were intravenously injected at single doses of 1 mg/kg in order
to calculate and compare the pharmacokinetics of TCZ and PH2 in normal mice.
Plasma concentration of TCZ over time and the best fit of Is(t) to the pharmacoki-
netic data are shown in Figure 3.11 and the best-fit pharmacokinetic parameter
values are tabulated in Table 3.6.
Table 3.6: Pharmacokinetic Parameter Values
Parameters Values Units Reference
k12 14.30 day−1 Estimated
k21 5.55 day−1 Estimated
kel 0.004 day
−1 Estimated
Multiple-dosing
We assume that the drug is administered by intravenous bolus injections several
times to the body. Now, we need to account for the remaining drug in the body
from the previous injections. Firstly, assume that the drug is administered at arbi-
70
Figure 3.11: Time Profiles of TCZ in Plasma. The best fit of Is(t) (solid line) defined
by Eq. 3.3.1 is plotted together with experimental data (dots) from an in vivo study
Igawa et al. (2010) of TCZ (and a PH-dependent binding variant of TCZ) in normal
mice.
trary dosing time-points denoted by τ = (τ1, τ2, · · · , τm) ∈ Rm such that τj ≥ 0 for
j = 1, · · · , m and τj−1 < τj. That is, τj denotes the timing of each dose. τj− τj−1 de-
notes the length of the time between the jth and (j + 1)th injection and m, accounts
for the the total number of injections. Therefore, the concentration of drug in the
central compartment right after the jth administration, I js(t), can be given by:
I js(t) =

0, t < τ1
∑
j
i=1 di
[
Ae−α(t−τi) + Be−β(t−τi)
]
, τj ≤ t < τj+1&1 ≤ j ≤ m− 1
∑mi=1 di
[
Ae−α(t−τi) + Be−β(t−τi)
]
, t ≥ τm
(3.3.4)
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where di is the dosing concentration at the ith injection.
Special case: equidistance dosing time-points and equal dose of d
Now assume that a fixed concentration of drug, d, is administered to the body at
equidistance time-points every pi-units of time. Then the concentration of drug in
the systemic circulation at time t can be given by:
I js(t) =

0, t < τ1
d
[
A 1−e−jpiα1−e−piα e
−α(t−τj) + B 1−e−jpiβ
1−e−piβ e
−β(t−τj)
]
, τj ≤ t < τj+1&1 ≤ j ≤ m− 1
d
[
A 1−e−mpiα1−e−piα e
−α(t−τm) + B 1−e−mpiβ
1−e−piβ e
−β(t−τm)
]
, t ≥ τm
(3.3.5)
A proof is given in Section B of Appendix. Similarly, for i.p. injection we have
I js(t) =

0, t < τ1
d
[
Ap 1−e
−jpiα
1−e−piα e
−α(t−τj) + Bp 1−e
−jpiβ
1−e−piβ e
−β(t−τj)
]
, τj ≤ t < τj+1&1 ≤ j ≤ m− 1
d
[
Ap 1−e
−mpiα
1−e−piα e
−α(t−τm) + Bp 1−e
−mpiβ
1−e−piβ e
−β(t−τm)
]
, t ≥ τm
(3.3.6)
In the next section we will add targeted treatment to Model (1) and will use Is(t)
given by Eq. 3.3.5 to add TCZ to the system. We define our dosing schedule based
on the experiments described in Mochizuki et al. (2015). Briefly, two biodegrad-
able scaffolds seeded with human tumor and endothelial cells were transplanted
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in mice. When the xenograft tumors reached 200 mm3, mice were treated with
5mg/kg tocilizumab weekly. In the experiment that generated the data for our
model (shown in Figure 3.3), scaffolds are not used for transplantation of human
HNSCC in mice. Therefore, we will administer TCZ when the xenograft tumors
reach to 125 mm3 (the volume without scaffolds). In the experiments described in
Mochizuki et al. (2015), TCZ is administered as a series of intraperitoneal injections.
Here we assume that once injected, the drug rapidly extravasates into the systemic
circulation, which approximates injection into the central compartment. Moreover,
since we do not have human endothelial cells in our model, there is much less IL-6
present in the tumor environment. Therefore, we will consider TCZ administra-
tion for both a high dose of 5mg/kg and a lower dose of drug, 1mg/kg, weekly
for 7 weeks.
3.3.2 Model equations related to treatment with anti-IL-6R antibody,
Tocilizumab
In this section we modify Model (1) with the equations necessary to describe
treatment with TCZ. TCZ is an anti-IL-6R antibody that binds to IL-6R on tumor
cells and inhibits formation of IL-6–IL-6R complex molecules. Soon after drug
administration, TCZ reaches the tumor environment and binds to IL-6R on tumor
cells at a rate kIf , and dissociates at a rate k
I
r. The complex of TCZ and IL-6R on
stem, progenitor and differentiated cells, denoted by CIS, C
I
E and C
I
D, respectively.
Equation 3.3.7 describes the association and dissociation of TCZ in the tumor, I(t),
to IL-6 cell-bound receptors on tumor cells.
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dI
dt
= − kIf IRS︸ ︷︷ ︸
Anti-IL6R binding to
stem cells
+ kIrC
I
S︸︷︷︸
Ani-IL6R dissociation
from stem cells
− kIf IRE︸ ︷︷ ︸
Anti-IL6R binding to
progenitor cells
+ kIrC
I
E︸︷︷︸
Anti-IL6R dissociation
from progenitor cells
− kIf IRD︸ ︷︷ ︸
Anti-IL6R binding to
differentiated cells
+ kIrC
I
D︸ ︷︷ ︸
IL6 dissociation
from differentiated cells
+ k12 Is − k21 I︸ ︷︷ ︸
Pharmacokinetics
(3.3.7)
Underlying assumptions for this equations are: (i) the tumor resides in a phar-
macokinetic compartment of its own, (ii) the binding rates are the same, indepen-
dent of cell type; (iii) TCZ is transferred into the tumor from the systemic circu-
lation at the same rate as the peripheral tissue, k12; and (iv) the tumor volume is
negligible compared to the volume of mouse; therefore the amount of the drug
leaking into blood stream (at the rate k21) will not affect the concentration of free
TCZ in the systemic circulation. Thus, the full model after adding treatment with
TCZ can be given by:
TCZ-Therapy Model
dS
dt
= αSPS(S, φS)S︸ ︷︷ ︸
Stem cell self-renewal
− δS
1+ γSφS
S︸ ︷︷ ︸
Stem cell death
dE
dt
= AinαS(1− PS(S, φS))S︸ ︷︷ ︸
Amplified
stem cell differentiation
− αEE︸︷︷︸
Progenitor cell
differentiation
− δE
1+ γEφE
E︸ ︷︷ ︸
progenitor cell death
dD
dt
= 2αEE︸ ︷︷ ︸
progenitor cell
differentiation
− δD
1+ γDφD
D︸ ︷︷ ︸
differentiated cell death
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dL
dt
= − k f LRS︸ ︷︷ ︸
IL6 binding to
stem cells
+ krCS︸︷︷︸
IL6 dissociation
from stem cells
− k f LRE︸ ︷︷ ︸
IL6 binding to
progenitor cells
+ krCE︸︷︷︸
IL6 dissociation
from progenitor cells
− k f LRD︸ ︷︷ ︸
IL6 binding to
differentiated cells
+ krCD︸ ︷︷ ︸
IL6 dissociation
from differentiated cells
− λLL︸︷︷︸
IL6 natural decay
+ ρT(S + E + D)︸ ︷︷ ︸
IL-6 Production
by tumor cells
dI
dt
= − kIf IRS︸ ︷︷ ︸
Anti-IL6R binding to
stem cells
+ kIrC
I
S︸︷︷︸
Ani-IL6R dissociation
from stem cells
− kIf IRE︸ ︷︷ ︸
Anti-IL6R binding to
progenitor cells
+ kIrC
I
E︸︷︷︸
Anti-IL6R dissociation
from progenitor cells
− kIf IRD︸ ︷︷ ︸
Anti-IL6R binding to
differentiated cells
+ kIrC
I
D︸ ︷︷ ︸
IL6 dissociation
from differentiated cells
+ k12 Is − k21 I︸ ︷︷ ︸
Pharmacokinetics
dRS
dt
= − k f LRS︸ ︷︷ ︸
IL-6 binding to
stem cells
+ krCS︸︷︷︸
IL-6 dissociation
from stem cells
+ kpCS︸︷︷︸
Recycling
− kIf IRS︸ ︷︷ ︸
Anti-IL6R binding to
IL-6R
+ kIrC
I
S︸︷︷︸
Anti-IL-6R dissociation
from stem cells
+ RTSPS (S, φS)︸ ︷︷ ︸
Generation of new RS
via cell proliferation
− RS
RS + CS + CIS
RTSDS (S, φS)︸ ︷︷ ︸
Loss of RS
via cell death
dCIS
dt
= + kIf IRS︸ ︷︷ ︸
Anti-IL6R binding to
IL-6R
− kIrCIS︸︷︷︸
Ani-IL6R dissociation
from stem cells
− C
I
S
RS + CS + CIS
RTSDS (S, φS)︸ ︷︷ ︸
Loss of CIS
via cell death
dCS
dt
= + k f LRS︸ ︷︷ ︸
IL6 binding to RS
− krCS︸︷︷︸
IL6 dissociation
from RS
− kpCS︸︷︷︸
Internalization
− CS
RS + CS + CIS
RTSDS (S, φS)︸ ︷︷ ︸
Loss of CS
via cell death
dRE
dt
= − k f LRE︸ ︷︷ ︸
IL-6 binding to
progenitor cells
+ krCE︸︷︷︸
IL-6 dissociation
from progenitor cells
+ kpCE︸ ︷︷ ︸
Recycling
− kIf IRE︸ ︷︷ ︸
Anti-IL6R binding to
IL-6R
+ kIrC
I
E︸︷︷︸
Anti-IL-6R dissociation
from progenitor cells
+ RTEPE (E, φE)︸ ︷︷ ︸
Generation of new RE
via cell proliferation
− RE
RE + CE + CIE
RTEDE (E, φE)︸ ︷︷ ︸
Loss of RE
via cell death
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dCIE
dt
= + kIf IRE︸ ︷︷ ︸
Anti-IL6R binding to
IL-6R
− kIrCIE︸︷︷︸
Ani-IL6R dissociation
from progenitor cells
− C
I
E
RE + CE + CIE
RTEDE (E, φE)︸ ︷︷ ︸
Loss of CIE
via cell death
dCE
dt
= + k f LRE︸ ︷︷ ︸
IL6 binding to RE
− krCE︸︷︷︸
IL6 dissociation
from RE
− kpCE︸ ︷︷ ︸
Internalization
− CE
RE + CE + CIE
RTEDE (E, φE)︸ ︷︷ ︸
Loss of CE
via cell death
dRD
dt
= − k f LRD︸ ︷︷ ︸
IL-6 binding to
differentiated cells
+ krCD︸ ︷︷ ︸
IL-6 dissociation
from differentiated cells
+ kpCD︸ ︷︷ ︸
Recycling
− kIf IRD︸ ︷︷ ︸
Anti-IL6R binding to
IL-6R
+ kIrC
I
D︸ ︷︷ ︸
Anti-IL-6R dissociation
from differentiated cells
+ RTDPD (E, φD)︸ ︷︷ ︸
Generation of new RD
via cell proliferation
− RD
RD + CD + CID
RTDDD (E, φD)︸ ︷︷ ︸
Loss of RD
via cell death
dCID
dt
= + kIf IRD︸ ︷︷ ︸
Anti-IL6R binding to
IL-6R
− kIrCID︸ ︷︷ ︸
Ani-IL6R dissociation
from differentiated cells
− C
I
D
RD + CD + CID
RTDDD (D, φD)︸ ︷︷ ︸
Loss of CID
via cell death
dCD
dt
= + k f LRD︸ ︷︷ ︸
IL6 binding to RD
− krCD︸ ︷︷ ︸
IL6 dissociation
from RD
− kpCD︸ ︷︷ ︸
Internalization
− CD
RD + CD + CID
RTDDD (D, φD)︸ ︷︷ ︸
Loss of CD
via cell death
It is worth mentioning that similar to our calculations for Model (1), it can be
shown that the equations for treatment model satisfy:
RS = RTS S− CS − CIS
RE = RTE E− CE − CIE
RD = RTD D− CD − CID
Variables and parameter values related to anti-IL-6R treatment are tabulated in
Tables 3.7 and 3.8, respectively.
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Table 3.7: Variables Related to TCZ-Therapy Model.
Variable Description Units
I Free anti-IL-6R antibody in the tumor fmol
CIS Anti-IL-6R–cell bound IL-6R complex on stem cells fmol
CIE Anti-IL-6R–cell bound IL-6R complex on progenitor cells fmol
CID Anti-IL-6R–cell bound IL-6R complex on differentiated cells fmol
Table 3.8: Parameter Values Related to Anti-IL-6R Treatment. (∗) VolT is the vol-
ume of the tumor in µl and is equal to (volume of 1 million tumor cells)× (S+E+D),
where, the volume of 1 tumor cell is 1× 10−6µl Cunningham et al. (1999).
Parameters Values Units Reference
kIf 8.5/VolT* fmol
−1day−1 Mihara et al. (2005)
kIr 21.6 day
−1 lens.org/092-218-642-694-833
3.3.3 Predicting the effect of TCZ therapy
We used the treatment model to investigate (predict) tumor response to ad-
ministration of TCZ for 7 weeks. Once the tumor reached 125mm3, at each time
point Is(t) (given by Eq. 3.3.5) was calculated assuming that 1mg/kg or 5mg/kg
of TCZ was added to the system via i.v. injection, weekly. Is(t) determined the
amount of drug entering the tumor. Figure 3.12-A shows the model predictions
for the amount of TCZ within the tumor for the two different doses. Our model
predicts a 25% and 28% reduction in the tumor volume as compared with tumor
volume without treatment for the two different dosing strategies (Figure 3.12-B).
This result is very similar to the experimentally observed tumor reduction shown
in Mochizuki et al. (2015) for UM-HMC-3B tumor xenografts.
77
Figure 3.12: (A) The Amount of TCZ Within the Tumor During 7 Weeks of Treat-
ment. (B) Model predictions of tumor volume vs. time after treatment with TCZ.
1mg/kg or 5 mg/kg of TCZ is administered weekly when tumor reaches 125 mm3.
Small Doses of TCZ Are Sufficient to Outcompete IL-6
The reduction in tumor growth described above is due to the fact that TCZ com-
petes with IL-6 for IL-6R, which results in a sudden decrease in the number of the
IL-6–IL-6R signaling complexes. Our modeling framework allows us to quantify
these molecular changes caused by administration of TCZ. As shown in Figure
3.13, after treatment there is an 80-90% decrease in the fraction of IL-6R occupied
by IL-6 on tumor cells (φS, φE and φD). Figure 3.13 also shows that administration
of doses as small as 1mg/kg of TCZ is sufficient for saturating IL-6R with TCZ
molecules.
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Figure 3.13: Model (1) Predictions after tTCZ-Therapy: (A) Model prediction of the
temporal changes in the factional of IL-6 receptors on CSCs that are occupied by
IL-6, φS, for the control case (no treatment, blue), 1 mg/kg TCZ (red), and 5 mg/kg
TCZ (yellow). (B) Model prediction of the temporal changes in the factional of IL-6
receptors on CSCs that are occupied by TCZ, φI , for doses of 1 mg/kg TCZ (blue),
and 5 mg/kg TCZ (red).
The Effect TCZ On Tumor Cell Death is More Pronounced Than Its Effect on
CSC Self-renewal
Administration of TCZ interferes with the IL-6-mediated pathways that enhance
the survival and self-renewal properties of CSCs. Specifically, the TCZ mediated
reduction in IL-6-IL-6R signaling complexes decreases the pro-survival effects of
IL-6, which results in an increase in the death rates of tumor cells. Our model
predicts an increase of approximately 24-27% in the death rates of CSCs (Figure
3.14-A), progenitor cells and terminally differentiated cells. The same mechanism
also results in a decrease in the probability of CSC self-renewal. Figure 3.14-B
shows that TCZ causes an early reduction of 12-13% in the probability of CSC
self-renewal. However, in the later weeks of treatment this difference decreases to
2-4%. This marginal impact of TCZ on the self-renewal probability is likely due to
the tendency of CSCs to quickly reach to their equilibrium level (see Figure 3.4-D).
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Figure 3.14: Model Predictions of the Temporal Impact of Administering 1mg/kg
or 5mg/kg of TCZ on the (A) Death Rate of CSCs, (B) Probability of CSC Self-
Renewal and (C) Percentage of CSCs Within the Tumor.
Changes in self-renewal and death rates of CSCs alter the fraction of CSCs post-
treatment. Our model predicts that there is a small increase in the percentage of
CSCs after treatment with TCZ (Figure 3.14-C). That is, the effect of TCZ on tumor
volume is characterized by overall tumor reduction, but a final tumor composition
that has a slightly larger proportion of CSCs. This could be due to the fact that stem
cell self-renewal is tightly regulated in our model; see equation (5). Because cancer
cells can become self-sufficient in growth signals, it is likely that CSCs could es-
cape control from some of cellular regulatory mechanisms that are usually in place
Hanahan and Weinberg (2000, 2011a). It has also been suggested that cancer stem
cells are not as dependent on the stem cell niche as normal stem cells Li and Neaves
(2006); Li and Li (2006). Should either of these situations occur, CSCs self-renewal
would be less dependent on regulatory mechanisms and on niche signaling. This
would significantly loosen the tightly regulated feedback interactions that dictate
80
the modes of stem-cell division in our model, resulting in a greater impact on the
final stem cell percentage after therapy.
Interestingly, the minor increase in the percentage of CSCs predicted by our
model is somewhat comparable to the results reported in Mochizuki et al. (2015)
where they showed that TCZ has mixed effects on the fraction of CSCs post ther-
apy. Given these varied results for the influence of TCZ on CSC percentage, we re-
peated the sensitivity analysis described above and considered PRCC values both
before and after the first dose of TCZ. The results are shown in Figure 3.15. Com-
paring the most influential parameters (Figure 3.15) before and after treatment,
suggests that administration of the drug does not change the set of parameters to
which the percentage of CSCs is most sensitive. The most influential parameters
remain Ain, δD and PSmin .
Therefore, relaxing the assumptions associated with stem cell self-renewal is
not the only possibility for reducing stem cell percentage post therapy. Figure 3.16
shows that even slightly increasing the amplification factor, Ain, after treatment be-
gins also reduces the percentage of CSCs post therapy. Decreasing the maximum
death rate for the terminally differentiated cancer cells has the same effect on the
final percentage of CSCs.
The Frequency of Dosing Does Not Significantly Impact Tumor Response to
TCZ
In the simulations above, TCZ was administered in doses of 1 or 5 mg/kg weekly
for 7 weeks. Eventually, we will use modified and extended versions of this model
to optimize the timing of combination therapies that deliver TCZ along with cy-
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Figure 3.15: PRCC Values for the Parameters of TCZ-Therapy Model Using the
Percentage of Caner Stem Cells as the Output of Interest.
totoxic chemotherapeutic agents like cisplatin. However, even for delivery as a
single agent, the effect dose frequency has on tumor response is an open question.
Furthermore, anti-cancer therapies may be selected based on the convenience of
administration to patients, so understanding the differential effect of various dos-
ing schedules is imperative. We therefore used the model to predict the effect of
administering TCZ every 14, 21 and 28 days.
Figure 3.17 shows that increasing the time between doses does not lead to large
increases in tumor volume. In fact, there little difference in tumor response among
all of the dosing schedules tested. Together these results suggest that administer-
ing TCZ every 3 o 4 weeks might be preferable to weekly administration as this is
clinically more desirable and it leads to only minor changes in tumor volume.
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Figure 3.16: Model Predictions of the Tumor Volume Vs. Time for the Control
Cases as Well as for Treatment With 1 or 5 mg/kg TCZ When the Amplification
factor, Ain, is slightly increased from its baseline value (A) and when the differen-
tiated cell death rate, δD is slightly decreased from baseline (C). Model predictions
of the CSC percentage vs time for the control cases as well as for treatment with 1
or 5 mg/kg TCZ when the amplification factor, Ain, is slightly increased (B) and
when the differentiated cell death rate, δD is slightly decreased (D).
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Figure 3.17: Model Predictions of the Tumor Volume vs. Time for the Control Case
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14, 21 and 28 Days.
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3.4 Summary and Discussion
Tumors are often heterogeneous, being composed of multiple cell types with
different phenotypic and molecular properties. Numerous studies have demon-
strated that a small subset of cancer cells (cancer stem cells) is capable of tumor ini-
tiation. In order to improve patient outcomes for stem-cell driven cancers, substan-
tial research is being focused on understanding the molecular biology of cancer
stem cell (CSC) self-renewal in an attempt to selectively target pathways that give
them their tumorigenic potential. Studies of HNSCC have shown that these can-
cers express high levels of Interleukin-6 (IL-6), and both autocrine and paracrine
signaling have been hypothesized as mechanisms for their IL-6 mediated growth
dynamics Krishnamurthy et al. (2014); Neiva et al. (2014). IL-6 has also been found
to play an important role in the inducible formation of CSCs and their dynamic
equilibrium with non-stem cells Kim et al. (2013). Taken together, this data has
prompted investigations of the therapeutic inhibition of the IL-6 pathway by hu-
manized anti-IL-6 antibodies and IL-6 receptor antagonists Mochizuki et al. (2015).
Recent studies show that Il-6 ligand and receptor targeted therapies can inhibit the
survival of cancer stem cells, delay tumor initiation, prevent tumor recurence, and
enhance the anti-tumor effect of conventional chemotherapy Krishnamurthy et al.
(2014); Mochizuki et al. (2015).
In this chapter we developed an experimentally based mathematical model for
the growth dynamics of HNSCC tumor xenografts, which were generated by trans-
planting a small number of primary human cancer stem cells (ALDHHIGHCD44HIGH)
in IL-6+/+ immunodeficient mice. The model includes the effects of human tu-
mor cell-secreted IL-6 signaling on tumor cell survival and proliferation, and also
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captures the effect of IL-6 on the probability of self-renewal for cancer stem cells.
While numerous models of cancer stem cell driven tumor growth and related treat-
ments have been proposed (see Weekes et al. (2014) for a review), few work across
the scales proposed here, from signal initiation to tissue level cancer growth. This
model is the first of its kind in that it incorporates the molecular details of IL-6
binding to its natural receptor, IL-6R and allows for the quantification of the tem-
poral changes fractional occupancies of bound receptors and their impact on tu-
mor growth dynamics. The model predictions suggest that a fractional occupancy
of 12% on CSCs is sufficient to result in the experimentally observed tumor growth
rate for these primary tumor xenografts. In the experimental system that is mod-
eled here, the only source of human IL-6 is the cancer cells themselves, as murine
IL-6 does not bind to human IL-6R (refs) and cannot directly initiate signals on
human cells. We tested the situation where tumors cells were not able to produce
IL-6 and found the final tumor sizes to be approximately 45% smaller without di-
rect IL-6 signaling.
There is evidence that human endothelial cells, key players in tumor angiogen-
esis, can secrete even higher levels of IL-6 than tumor cells [26]. This implies that
the 12% fractional occupancies predicted by our model leaves room for increases in
proportion of bound IL-6R and more aggressive tumor growth when endothelial
cells add to the amount of IL-6 available in the tumor microenvironment. There
are several experimental models where human dermal microvascular endothe-
lial cells (HDMECs) are transplanted in mice along with human tumor cells us-
ing biodegradable, polymer scaffolds Krishnamurthy et al. (2014); Mochizuki et al.
(2015); Neiva et al. (2014); No¨r et al. (2014). In Chapter 3, we develop a mathe-
matical model of this experimental paradigm and our results show high fractional
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occupancies of IL-6R lead to even greater interdependencies among IL-6, tumor
growth dynamics and the tumorigenic potential of CSCs.
According to the cancer stem cell hypothesis, only a small minority of cells
within the tumor be should tumor-initiating cells. Our model is also able to accu-
rately capture the correct, experimentally observed tumor composition consisting
of a very small proportion of cancer stem cells. A simple and general model of the
cancer stem cell hypothesis was developed to track cell state transitions. Following
Ganguly and Puri (2006); Gentry and Jackson (2013), each non-cancer stem cell is
amplified by a factor, Ain upon entry into the progenitor cell pool. Interestingly, the
best fit to the experimental data was obtained with a value of Ain = 2, which im-
plies that each progenitor or transient amplifying cell (TAC) only undergoes a one
round of amplification before differentiating into a terminally differentiated cell
(see derivation in Section 2.1). The fact that our model predicts that little ampli-
fication occurs is not surprising because we are using data from human primary
tumor cell xenografts, as opposed to cancer cell lines. Also, in the experimen-
tal system modeled here that does not include microenvironmental production of
IL-6 by endothelial cells, tumors grow relatively slowly, which is consistent with
limited amplification. In Chapter 3’s extended version of this model that includes
human endothelial cells, we are able to show that increased amplification and long
with additional IL-6R engagement can predict the faster tumor growth dynamics
that are observed with this experimental approach.
It also important to note that although we model the traditional cancer stem
cell ideology (CSC −→ Progenitor cell −→ Terminal cell), which has been pub-
lished for several solid tumor types Ganguly and Puri (2006), transient amplify-
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ing cells are somewhat challenging to fit into the rubric of HNSCC cancer stem
cells due to limitations in the identification of markers for these cells. Here we
consider cancer stem cells to be ALDHHIGHCD44HIGH. Therefore, our three cellu-
lar compartment approach could be envisioned to consist of: CD44HIGH cells as
the population of stem cells, various combinations of ALDHHIGHCD44LOW and
ALDHLOWCD44HIGH cells as pool mixed cells, and finally ALDHLOWCD44LOW
cells. Our model predicts an amplification factor of 2 for the mixed cell pool. In
terms of previously mentioned markers for HNSCC, our modeling paradigm can
be thought of as each ALDHHIGHCD44HIGH cell (S) asymmetrically dividing (with
some probability) to become one ALDHHIGHCD44LOW or one ALDHLOWCD44HIGH
(P) cell. That newly generated cell then divides to give rise to 2 new mixed cells.
Those two mixed cells then eventually divide to give four terminally differentiated
ALDHLOWCD44LOW (D) cells. This limited amount of amplification predicted for
primary tumor cells leads to relatively slow tumor growth and a tumor composi-
tion that consists of mostly differentiated cells. Interestingly, preliminary simula-
tions of the experimental system that includes SCC cell lines and human endothe-
lial cells shows that increased amplification and IL-6R engagement can lead not
only lead to faster tumor growth, but can also change the tumor composition to be
dominated by progenitor cells. It is important to note that this is simply one way
to interpret the modeling results. Transitions between stem and non stem states
have not been established temporally or in response therapy. These are topics that
we will tackle in future modeling and experimental studies.
Uncertainty analysis offers a way to investigate the uncertainty in the model
output due to the uncertainty in parameter inputs and sensitivity analysis assesses
how variations in model outputs can be apportioned to different input sources.
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Uncertainty and sensitivity analyses determines an approach to establish what fac-
tors and how affect model outputs. Depending on the type of system under study,
different techniques should be performed Blower and Dowlatabadi (1994); Marino
et al. (2008). For nonlinear but monotonic relationships between outputs and in-
puts (such as our model), partial rank correlation coefficient (PRCC) works well
Marino et al. (2008). However, it is critical to mention that PRCC values are not ac-
curate when the relationships between inputs and output is non-monotonic. With
the sampling-based methods, such as PRCC, scatter plots enable us to graphically
examine the nonlinearities, non-monotonicities, and correlations between model
inputs and outputs Marino et al. (2008); Sanchez and Blower (1997). Therefore, we
used scatter plots to determine the monotonicity dependence of the model outputs
to its parameters (it is not shown) and then performed uncertainty and sensitivity
analysis. The PRCC values revealed that the “most influential” parameters on tu-
mor volume growth dynamics, percentage of cancer stem cells and fractional occu-
pancies of IL-6R may change as tumor volume increases. For instance, our analysis
showed that Ain is always one of the most influential parameters on tumor volume
whereas other parameters are only influential early or late in tumor growth. For
example, ρ has more impacts over the later stages rather than the early stage of
tumor growth.
We also used the model to predict tumor response to administration of the
humanized IL-6R monoclonal antibody, tocilizumab (TCZ), as monotherapy. Al-
though the significance of IL-6 as a conceptual target for cancer treatment is well
documented Krishnamurthy et al. (2014); Mochizuki et al. (2015), we still do not
fully understand how anti-IL6 therapies work in vivo. Our simulations predict
that as little as 1mg/kg of TCZ administered weekly for 7 weeks is sufficient to
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result in tumor reduction and a sustained tumor slowing of tumor growth. The
observed effect of TCZ is due to the fact that it competes with IL-6 for the signal-
ing receptor, IL-6R. The model also predicts that administration of doses as small
as 1mg/kg of TCZ is sufficient for saturating IL-6R with TCZ molecules. We expect
that larger doses of TCZ may be necessary to achieve this same type of interference
when xenografts include both human endothelial cells and human tumor cells, as
in this case the amount of competing IL-6 in the tumor microenvironment will sig-
nificantly increase.
We were interested to know if TCZ had greater impact on cell death or on can-
cer stem cell self-renewal, as changes in self-renewal and death rates of CSCs can
alter the final proportion of CSCs post-treatment. The model predicts that effect of
TCZ on cell death is more pronounced than its effect on CSC self-renewal, and this
leads to an increase in the percentage of CSCs after treatment with TCZ. Therefore,
for these primary tumor xenografts that do not include human endothelial cells,
TCZ results in overall tumor reduction, but a final tumor composition that has a
slightly larger proportion of CSCs. In [33], the effect of TCZ on Mucoepidermoid
carcinoma (MEC) cell lines is investigated in an experimental setting that included
human endothelial cells. In that study, they showed that TCZ has mixed effects on
the fraction of CSCs post therapy. Interestingly, our preliminary model simulations
of an experimental system that includes SCC cell lines and human endothelial cells
shows that TCZ leads to a decrease in the proportion of cancer stem cells.
It is clear that IL-6 plays a critical role in the pathobiology of cancer, due in part
to its impact on cancer stem cells. This has provided strong rationale for develop-
ing targeted inhibitors of IL-6. This modeling study not quantifies the influence on
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IL-6 on primary tumor xenografts; it also provides some explanations for the var-
ious effects of TCZ on tumor growth and CSC percentage. In the next chapter, we
will modify this model to describe xenografts that include human endothelial cells
that have been demonstrated to produce IL-6 in greater amounts than tumor cells.
We will also extend the model to include combination therapies with traditional
chemotherapeutic agents, like cisplatin. This extended model can be used to simu-
late different dose-scheduling regimens in order to investigate synergism between
the two therapies. Continued modeling efforts in this direction have the potential
to shed light conditions under which TCZ sensitizes cancer cells for treatment with
cisplatin and can be used to predict the optimal dose scheduling that will lead to
maximal tumor response.
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Chapter 4
MODELING IL-6 MEDIATED CROSS-TALK BETWEEN ENDOTHELIAL AND
TUMOR CELLS AND ITS IMPACT COMBINATION THERAPIES
In Chapter 2 we showed that even relatively small amounts of tumor cell-
secreted IL-6 can greatly enhance both tumor growth and the fraction of CSCs
within xenograft tumors. Interestingly, there is experimental evidence that en-
dothelial cells secrete significantly higher levels of IL-6 than HNSCC tumor cells
Krishnamurthy et al. (2014). Furthermore, it has been shown that HNSCC CSCs
reside in perivascular niches and depend on crosstalk with tumor associated en-
dothelial cells for their survival and growth Krishnamurthy et al. (2010, 2014).
Therefore, all of this motivates us to explore the effects of endothelial cell-secreted
IL-6 on the survival, self-renewal and tumorigenic potentials of CSCs within the
HNSCC tumor niche, and further leads us to investigate it as a potential thera-
peutic target against HNSCC tumors. In this chapter we extend the pre-treatment
model in the previous chapter to a multi-scale framework to investigate the role
of endothelial cell-secreted IL-6 on the bidirectional communication (i.e. crosstalk)
between endothelial cells and tumor cells that contributes to and enhances key
aspects of tumorigenesis. This model is used to describe tumor angiogenesis, vas-
cular tumor growth, and response to treatment based on a SCID Mouse Model of
Human Tumor Angiogenesis.
4.1 The Model for Cross-talk between Endothelial and Tumor Cells
In this section we follow the mathematical framework developed in Jain and
Jackson (2017); Jain et al. (2008, 2009) to develop a mathematical model to describe
92
the interaction (crosstalk) between endothelial cells (ECs) and tumor cells (TCs)
(Figure 4.1) in an in vivo setting, by tracking the cellular and molecular species
used in the experiments described in Kaneko et al. (2007); Krishnamurthy et al.
(2014); Neiva et al. (2009). The proposed pre-treatment EC-TC model operates at
the following levels: (1) Intracellular level: regulation of signaling pathways that
are critical to cell proliferation, apoptosis, and migration; (2) Cellular level: cell-
surface dynamics of receptor-ligand binding and receptor activation that lead to
intracellular signal transduction cascades; and (3) Tissue level: dynamics of sig-
naling chemicals and anti-cancer agents within the tissue, tumor growth dynam-
ics, and tumor and vascular response to treatment.
The pre-treatment model describes the temporal changes in cancer stem cell, pro-
genitor cell and differentiated cell density, free tumor and/or endothelial cell-
secreted IL-6 concentration, endothelial cell density, free VEGF concentration and
free Bcl-2 mRNA expressed by both tumor and endothelial cells. VEGF can bind
to its natural receptors, VEGFR1 and VEGFR2, on endothelial cells to form a signal
initiating complex, VEGF–VEGFR2, and a decoy complex, VEGF–VEGFR1 Mac Gab-
hann and Popel (2007a); Zhang et al. (2010). Although VEGF can bind to VEGFR1
expressed on the surface of all tumor cell types, we do not consider it in our model.
All of the IL-6 binding dynamics that were previously described in Chapter 2 carry
over to this model.
Figure 4.1 is a schematic drawing illustrating the proposed mechanism behind
the EC-TC crosstalk model. Under hypoxia tumor cells secrete VEGF. Tumor-cell
secreted VEGF binds to its receptors, VEGFR1 and VEGFR2 on endothelial cells
initiates a “paracrine” signaling cascade that results in phosphorylation of STAT3,
Akt, and ERK in tumor cells. These phosphorylation enhance the expression of
Bcl-2 and that Bcl-2 itself enhances the secretion of CXCL8 (IL-8) in both tumor and
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Figure 4.1: A Model for Crosstalk Between Endothelial and Tumor Cells: Tumor
cell-secreted VEGF binds to its receptors, VEGFR1 and VEGFR2, to induce Bcl-
2 expression. Bcl-2 signaling is sufficient to induce IL-6 secretion by endothelial
cells. Kaneko et al. (2007); Neiva et al. (2009).
endothelial cells. Up-regulation of Bcl-2 is enough to enhance survival, prolifera-
tion and migration of endothelial cells. Enhanced proliferation rate of endothelial
cells results in more secretion of IL-6 which itself leads to survival and prolifera-
tion of tumor cells, particularly CSCs. This bidirectional communication between
endothelial cells and tumor cells is centrally regulated by VEGF (Figure 4.2), which
would in turn maintain this feedback loop Kaneko et al. (2007); Neiva et al. (2009).
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Figure 4.2: Model for Cross-Talk Between Endothelial and Tumor Cells Kaneko
et al. (2007)
4.1.1 Equations related to the EC-TC model
We begin with a mathematical description of the interaction between endothe-
lial and tumor cells by tracking the temporal changes in the cellular and molecular
species listed in Table 3.1 below.
Human dermal microvascular endothelial cell response to VEGF
It has been reported that VEGF and its receptor VEGFR-1/2 are highly expressed
in HNSCC and that VEGF-mediated signaling is vital for free ECs’ proliferation,
survival and migration Jain and Jackson (2017); Kaneko et al. (2007); Neiva et al.
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Table 4.1: Description of Variables of EC-TC Cross-Talk Model
Variables Description Units
H Endothelial cell number #
S Cancer stem cell number #
E Progenitor cell number #
D Differentiated cell number #
A Amount of free VEGF fmol
RHA1 Number of free VEGFR1 on endothelial cells fmol
RHA2 Number of free VEGFR2 on endothelial cells fmol
RSA1 Number of free VEGFR1 on tumor stem cells fmol
REA1 Number of free VEGFR1 on tumor progenitor cells fmol
RDA1 Number of free VEGFR1 on tumor differentiated cells fmol
CHA1 VEGF-VEGFR1 complexes on endothelial cells fmol
CHA2 VEGF-VEGFR2 complexes on endothelial cells fmol
CSA1 VEGF-VEGFR1 complexes on stem cells fmol
CEA1 VEGF-VEGFR1 complexes on progenitor cells fmol
CDA1 VEGF-VEGFR1 complexes on differentiated cells fmol
L IL-6 secreted by endothelial & tumor (stem/non-stem)
cells
fmol
RS IL-6R on tumor stem cells fmol
RE IL-6R on tumor progenitor cells fmol
RD IL-6R on tumor differentiated cells fmol
CS IL-6–IL-6R complex on tumor stem cell fmol
CE IL-6–IL-6R complex on tumor progenitor cell fmol
CD IL-6–IL-6R complex on tumor differentiated cell fmol
BH Bcl-2 mRNA expression level per endothelial cell dimensionless
BT Total Bcl-2 mRNA expression level by tumor cells dimensionless
(2009); Tarquinio et al. (2012). The VEGF induces Bcl-2 expression in ECs and that
Bcl-2 expression level in tumor-associated endothelial cells play a direct role in tu-
mor angiogenesis and tumor growth Neiva et al. (2009). It is also known that Bcl-2
enhances HNSCC survival, invasiveness and local recurrence Neiva et al. (2009).
Therefore, the rate of change of the HDMEC population is chosen to be an increas-
ing function of the fractional occupancies of VEGFR2 per cell (φEA2 ). Also the rate
of endothelial cell death is assumed to be a decreasing function of intracellular
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Bcl-2 expression by ECs (BH). Thus, we have:
dH
dt︸︷︷︸
Endothelial cells
= αHφ
nH
HA2
H︸ ︷︷ ︸
Activated VEGFR2-mediated
proliferation
− δH
1+ βHBH
H︸ ︷︷ ︸
Bcl-2-mediated
apoptosis
, (4.1.1)
where, φHA2 =
CHA2
RtHA2
H .
Tumor cells (stem/bulk cells) response to IL-6 and Bcl-2
The equations for the growth dynamics of tumor cells (CSCs, PCs and DCs) are
the same as equations given in Chapter 2. However, we are now modeling EC-
TC scaffolds, which are initially hypoxic. Because we are now interested in the
impact of human ECs and, subsequent functional blood vessels on tumor growth,
we modify the cancer cell equations so that cellular proliferation and death are
dependent on oxygen concentration, N(t). The effects of oxygen pressure on tumor
cell proliferation and survival are denoted by H(N − Np) and 1 + H(Nd − N),
respectively, where H(.) is a Heaviside function. That is, when the oxygen level is
less than a critical threshold (N < Np), tumor cells stop proliferating and a further
decline in oxygen level (below Nd) results in a doubling of the death rate of the
tumor cells. Furthermore, the oxygen pressure level is assumed to be proportional
to the vascular proportion of the tumor cell numbers defined as the percentage
V = 100H/(H + S + E + D), that is, N(t) = σF(t)V where
σF(t) = σN
e(t−3)
1+ e(t−3)
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and σN denotes the proportionality constant relating the vessel fraction. The func-
tion σF gradually approaches to its maximum, σN. The rationale for choosing “3”
in σF function is that it takes almost five or six days for human ECs to generate
microvessel networks, connect to mouse vessels and begin blood flow. With “3”
chosen, σF is approximately 0.95 at t=6 and is 1 with at least 8 digits of accuracy at
t=13. It also takes three days for the function to reach half of its maximal. Thus,
an increase in the proportion of ECs compared to the number of TCs results in an
increase in the level of oxygenation within the tumor.
dS
dt︸︷︷︸
Tumor stem cells
= αSPS(S, φS)SH(N − Np)︸ ︷︷ ︸
Stem cell self-renewal
− δS
1+ γSφS
S[1+H(Nd − N)]︸ ︷︷ ︸
IL-6 & Bcl-2 mediated
apoptosis
,
(4.1.2)
where,
PS(S, φS) =
(PSmax − PSmin(φS))PnNs
PnNs + S
n + PSmin(φS),
PSmin(φS) = µS
(
PSmax − P∗Smin
)
φS + P∗Smin
dE
dt︸︷︷︸
Tumor
progenitor cells
= AinαS [1− PS(S, φS)] SH(N − Np)︸ ︷︷ ︸
Amplified
stem cell differentiation
− αEEH(N − Np)︸ ︷︷ ︸
Progenitor cell
differentiation
− δE
1+ γEφE
E[1+H(Nd − N)]︸ ︷︷ ︸
IL-6 & Bcl-2 mediated
apoptosis
(4.1.3)
dD
dt︸︷︷︸
Tumor
differentiated cells
= 2αEEH(N − Np)︸ ︷︷ ︸
progenitor cell
differentiation
− δD
1+ γDφD
D[1+H(Nd − N)]︸ ︷︷ ︸
IL-6 & Bcl-2 mediated
apoptosis
(4.1.4)
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IL-6 uptake and binding by tumor cells
Once bound to its receptors, VEGF enhances expression level of Bcl-2 on both
endothelial and tumor cells Kaneko et al. (2007); Neiva et al. (2009). That Bcl-2
signaling induces IL-6 expression in endothelial/tumor cells Neiva et al. (2009).
Therefore, the last two terms in Eq. 4.1.1 describe the secretion of IL-6 by both
endothelial and tumor cells, which are increasing functions of fraction of activated
VEGFR1 and VEGFR2 on the tumor and endothelial cells, respectively. All the
equations related to IL-6 binding dynamics are the same as previously described
in Chapter 2.
dL
dt︸︷︷︸
IL-6
= − k f LRS︸ ︷︷ ︸
IL-6 binding to
stem cells
+ krCS︸︷︷︸
IL6 dissociation
from stem cells
− k f LRE︸ ︷︷ ︸
IL-6 binding to
progenitor cells
+ krCE︸︷︷︸
IL-6 dissociation
from progenitor cells
− k f LRD︸ ︷︷ ︸
IL-6 binding to
differentiated cells
+ krCD︸ ︷︷ ︸
IL-6 dissociation
from differentiated cells
− λLL︸︷︷︸
IL-6 natural decay
+ ρT(S + E + D)︸ ︷︷ ︸
IL-6 Production
by tumor cells
+ ρHφ
nL
HA2
H︸ ︷︷ ︸
Bcl-2-mediated
IL-6 production
by ECs
(4.1.5)
(4.1.6)
Following Chapter 2, we define:
PS(S, φS) = αSPS(S, φS)SH(N − Np) (4.1.7)
PE(E, φS) = AinαS[1− PS(S, φS)]SH(N − Np) (4.1.8)
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PD(E) = 2αEEH(N − Np), (4.1.9)
and,
DS(φS, BS) =
δS
1+ γSφS
S[1+H(Nd − N)] (4.1.10)
DE(φE, BE) =
δE
1+ γEφE
E[1+H(Nd − N)] + αEEH(N − Np) (4.1.11)
DD(φD, BD) =
δD
1+ γDφD
D[1+H(Nd − N)] (4.1.12)
Then we have:
dRS
dt
= − k f LRS︸ ︷︷ ︸
IL-6 binding to
stem cells
+ krCS︸︷︷︸
IL-6 dissociation
from stem cells
+ kpCS︸︷︷︸
Recycling
+ RTSPS(S, φS)︸ ︷︷ ︸
Generation of new RS
via cell proliferation
− RS
RS + CS
RTSDS(φS, BS)︸ ︷︷ ︸
Loss of RS
via cell death
(4.1.13)
dRE
dt
= − k f LRE︸ ︷︷ ︸
IL-6 binding to
progenitor cells
+ krCE︸︷︷︸
IL-6 dissociation
from progenitor cells
+ kpCE︸ ︷︷ ︸
Recycling
+ RTEPE(E, φS)︸ ︷︷ ︸
Generation of new RE
via cell proliferation
− RE
RE + CE
RTEDE(φE, BE)︸ ︷︷ ︸
Loss of RE
via cell death
(4.1.14)
dRD
dt
= − k f LRD︸ ︷︷ ︸
IL-6 binding to
differentiated cells
+ krCD︸ ︷︷ ︸
IL-6 dissociation
from differentiated cells
+ kpCD︸ ︷︷ ︸
Recycling
+ RTDPD(E)︸ ︷︷ ︸
Generation of new RD
via cell proliferation
− RD
RD + CD
RTDDD(φS, BD)︸ ︷︷ ︸
Loss of RD
via cell death
(4.1.15)
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dCS
dt
= k f LRS︸ ︷︷ ︸
IL-6 binding to RS
− krCS︸︷︷︸
IL-6 dissociation
from RS
− kpCS︸︷︷︸
Internalization
− CS
RS + CS
RTSDS(φS, BS)︸ ︷︷ ︸
Loss of CS
via cell death
(4.1.16)
dCE
dt
= k f LRE︸ ︷︷ ︸
IL-6 binding to RE
− krCE︸︷︷︸
IL-6 dissociation
from RE
− kpCE︸ ︷︷ ︸
Internalization
− CE
RE + CE
RTEDE(φE, BE)︸ ︷︷ ︸
Loss of CE
via cell death
(4.1.17)
dCD
dt
= k f LRD︸ ︷︷ ︸
IL-6 binding to RD
− krCD︸ ︷︷ ︸
IL-6 dissociation
from RD
− kpCD︸ ︷︷ ︸
Internalization
− CD
RD + CD
RTDDD(φD, BD)︸ ︷︷ ︸
Loss of CD
via cell death
(4.1.18)
Tumor and/or endothelial cell-secreted VEGF
dA
dt︸︷︷︸
VEGF
= −k fH1RHA1 A + krH1CHA1 − k fH2RHA2 A + krH2CHA2︸ ︷︷ ︸
reaction with VEGFR1/2 on endothelial cells
− k fTRSA1 A + krTCSA1︸ ︷︷ ︸
reaction with VEGFR1
on stem cells
− k fTREA1 A + krTCEA1︸ ︷︷ ︸
reaction with VEGFR1
on progenitor cells
− k fTRDA1 A + krTCDA1︸ ︷︷ ︸
reaction with VEGFR1
on differentiated cells
− λA A︸︷︷︸
natural
decay
+ αA
BH
1+ βABH
H︸ ︷︷ ︸
Bcl-2-mediated production
by endothelial cells
+
νA
1+ e−κA(Nh−N)
(S + E + D)︸ ︷︷ ︸
hypoxia-mediated VEGF
production by stem/bulk cells
(4.1.19)
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VEGF uptake and binding by endothelial cells
The equations for VEGFR1 and VEGFR2 binding are given below and they are
derived analogously to the equations given for IL-6R binding.
dRHA1
dt︸ ︷︷ ︸
free-VEGFR1
receptors
on ECs
= −k fH1RHA1 A + krH1CHA1 + kpH1CHA1︸ ︷︷ ︸
reaction with VEGF
+ RtHA1αHφ
nH
HA2
H︸ ︷︷ ︸
production due to
endothelial cell proliferation
− RHA1
RHA1 + CHA1
RtHA1
δH
1+ βHBH
H︸ ︷︷ ︸
loss due to
endothelial cell apoptosis
(4.1.20)
dRHA2
dt︸ ︷︷ ︸
free-VEGFR2
receptors
on ECs
= −k fH2RHA2 A + krH2CHA2 + kpH2CHA2︸ ︷︷ ︸
reaction with VEGF
+ RtHA2αHφ
nH
HA2
H︸ ︷︷ ︸
production due to
endothelial cell proliferation
− RHA2
RHA2 + CHA2
RtHA2
δH
1+ βHBH
H︸ ︷︷ ︸
loss due to
endothelial cell apoptosis
, (4.1.21)
dCHA1
dt︸ ︷︷ ︸
VEGF-VEGFR1
complex
on ECs
= k fH1RHA1 A− krH1CHA1 − kpH1CHA1︸ ︷︷ ︸
VEGFR1 activation by VEGF
on endothelial cells
− CHA1
RHA1 + CHA1
RtHA1
δH
1+ βHBH
H︸ ︷︷ ︸
loss due to
endothelial cell apoptosis
(4.1.22)
dCHA2
dt︸ ︷︷ ︸
VEGF-VEGFR2
complex
on ECs
= k fH2RHA2 A− krH2CHA2 − kpH2CHA2︸ ︷︷ ︸
VEGFR2 activation by VEGF
on endothelial cells
− CHA2
RHA2 + CHA2
RtHA2
δH
1+ βHBH
H︸ ︷︷ ︸
loss due to
endothelial cell apoptosis
(4.1.23)
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The Bcl-Family of Proteins
Bcl-2 mRNA is constitutively expressed within ECs, and undergoes natural de-
cay. VEGF signals through VEGFR1 and VEGFR2 on ECs and induces expression
of Bcl-2 and the proangiogenic chemokines such as CXCL1 and CXCL8 in ECs.
Combining these processes we obtain the following equations for Bcl-2 mRNA ex-
pression in ECs.
dBH
dt︸︷︷︸
Bcl-2 produced
by ECs
= χH︸︷︷︸
Constitutive
expression
by ECs
+ ηH
φnBHA2
ωnBH + φ
nB
HA2︸ ︷︷ ︸
Activated VEGFR2-
mediated production
by ECs
− δBBH︸ ︷︷ ︸
natural
decay
(4.1.24)
4.1.2 Reduced form of EC-TC cross-talk model
EC-TC cross-talk model can be reduced to the following model with five less
equations by using the fact that,
RS = RTS S− CS (4.1.25)
RE = RTE E− CE (4.1.26)
RD = RTD D− CD (4.1.27)
RHA1 = R
t
HA1 H − CHA1 (4.1.28)
RHA2 = R
t
HA2 H − CHA2 (4.1.29)
Thus, we have:
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dH
dt
= αHφ
nH
HA2
H︸ ︷︷ ︸
Activated VEGFR2-mediated
proliferation
− δH
1+ βHBH
H︸ ︷︷ ︸
Bcl-2-mediated
apoptosis
(4.1.30)
dS
dt
= αSPS(S, φS)SH(N − Np)︸ ︷︷ ︸
Stem cell self-renewal
− δS
1+ γSφS
S[1+H(Nd − N)]︸ ︷︷ ︸
IL-6 & Bcl-2 mediated
apoptosis
(4.1.31)
dE
dt
= AinαS [1− PS(S, φS)] SH(N − Np)︸ ︷︷ ︸
Amplified
stem cell differentiation
− αEEH(N − Np)︸ ︷︷ ︸
Progenitor cell
differentiation
− δE
1+ γEφE
E[1+H(Nd − N)]︸ ︷︷ ︸
IL-6 & Bcl-2 mediated
apoptosis
(4.1.32)
dD
dt
= 2αEEH(N − Np)︸ ︷︷ ︸
progenitor cell
differentiation
− δD
1+ γDφD
D[1+H(Nd − N)]︸ ︷︷ ︸
IL-6 & Bcl-2 mediated
apoptosis
(4.1.33)
dL
dt︸︷︷︸
IL-6
= − k f LRS︸ ︷︷ ︸
IL-6 binding to
stem cells
+ krCS︸︷︷︸
IL6 dissociation
from stem cells
− k f LRE︸ ︷︷ ︸
IL-6 binding to
progenitor cells
+ krCE︸︷︷︸
IL-6 dissociation
from progenitor cells
− k f LRD︸ ︷︷ ︸
IL-6 binding to
differentiated cells
+ krCD︸ ︷︷ ︸
IL-6 dissociation
from differentiated cells
− λLL︸︷︷︸
IL-6 natural decay
+ρT(S + E + D)︸ ︷︷ ︸
IL-6 Production
by tumor cells
+ ρHφ
nL
HA2
H︸ ︷︷ ︸
Bcl-2-mediated
IL-6 production
by ECs
(4.1.34)
dCS
dt
= k f LRS︸ ︷︷ ︸
IL-6 binding to RS
− krCS︸︷︷︸
IL-6 dissociation
from RS
− kpCS︸︷︷︸
Internalization
−CSDS(φS, BS)︸ ︷︷ ︸
Loss of CS
via cell death
(4.1.35)
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dCE
dt
= k f LRE︸ ︷︷ ︸
IL-6 binding to RE
− krCE︸︷︷︸
IL-6 dissociation
from RE
− kpCE︸ ︷︷ ︸
Internalization
−CEDE(φE, BE)︸ ︷︷ ︸
Loss of CE
via cell death
(4.1.36)
dCD
dt
= k f LRD︸ ︷︷ ︸
IL-6 binding to RD
− krCD︸ ︷︷ ︸
IL-6 dissociation
from RD
− kpCD︸ ︷︷ ︸
Internalization
−CDDD(φD, BD)︸ ︷︷ ︸
Loss of CD
via cell death
(4.1.37)
dA
dt
= −k fH1RHA1 A + krH1CHA1 − k fH2RHA2 A + krH2CHA2︸ ︷︷ ︸
reaction with VEGFR1/2 on endothelial cells
− λA A︸︷︷︸
natural
decay
+ αA
BH
1+ βABH
H︸ ︷︷ ︸
Bcl-2-mediated production
by endothelial cells
+
νA
1+ e−κA(Nh−N)
(S + E + D)︸ ︷︷ ︸
hypoxia-mediated VEGF
production by stem/bulk cells
(4.1.38)
dCHA1
dt
= k fH1RHA1 A− krH1CHA1 − kpH1CHA1︸ ︷︷ ︸
VEGFR1 activation by VEGF
on endothelial cells
− CHA1
δH
1+ βHBH︸ ︷︷ ︸
loss due to
endothelial cell apoptosis
(4.1.39)
dCHA2
dt
= k fH2RHA2 A− krH2CHA2 − kpH2CHA2︸ ︷︷ ︸
VEGFR2 activation by VEGF
on endothelial cells
− CHA2
δH
1+ βHBH︸ ︷︷ ︸
loss due to
endothelial cell apoptosis
(4.1.40)
dBH
dt
= χH︸︷︷︸
Constitutive
expression
by ECs
+ ηH
φnBHA2
ωnBH + φ
nB
HA2︸ ︷︷ ︸
Activated VEGFR2-
mediated production
by ECs
− δBBH︸ ︷︷ ︸
natural
decay
(4.1.41)
Similar to model (1) in Chapter 2, the EC-TC crosstalk represents the tumor
growth dynamics in three levels: (1) intracellular; (2) cellular/molecular; and (3)
tissue level. The equations dHdt ,
dS
dt ,
dE
dt and
dD
dt in the model describe the tumor
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Figure 4.3: Representing the Different Scales Represented in the EC-TC Crosstalk
Model.
growth at the tissue level whereas the equations related to IL-6 and VEGF repre-
sent the cell surface dynamics of receptor-ligand bindings. Similarly, binding IL-6
to IL-6R on TCs and VEGF to its receptors on ECs activates the receptors on the
cells’ membrane which leads to intracellular signal transduction cascade which
by itself impacts the tumor growth dynamics. Tracking the temporal changes of
the number of IL-6-IL-6R and VEGF-VEGFR1/2 complex molecules at the intra-
cellular level allows us to quantify the impacts of IL-6 mediated pathways on CSC
self-renewal potentials and tumor cell death as well as the VEGF-mediated path-
ways on proliferation and death of the ECs. A schematic representation of the
incorporated scales in the EC-TC crosstalk model is given in Figure 4.3.
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4.2 Numerical Analysis of Pre-treatment Tumor Growth
In this section, we first introduce the parameter values that we can find from
the literature. For parameters which there is no information, we estimate them
by finding the best fit of the pre-treatment EC-TC model to experimental data.
Then we use the estimated parameter valued to numerically explore the impact of
EC-IL-6 on tumor growth and compare the results with experimental data. The
ultimate goal is to add treatment to the current model and study the responses of
TCs to combination therapies.
4.2.1 Experimental data
To begin to evaluate the role of endothelial cell-secreted IL-6 on the tumorigenic
potential and survival of primary human HNSCC CSCs, Krishnamurthy et al. Kr-
ishnamurthy et al. (2014) silenced the IL-6 secretion in endothelial cells and used
these cells to generate tumor xenografts with a humanized vasculature. Briefly, im-
mediately after surgical removal of the primary tumor from patients with HNSCC,
they sorted and seeded 1’000 HNSCC CSCs (ALDHHIGHCD44HIGH cells) into IL-6
+/+ immunodeficient mice along with 5× 105 either IL-6-silenced endothelial cells
(HDMEC-shRNA-IL-6) or endothelial cells transduced with empty lentiviral vec-
tors (HDMEC-shRNA-C) in poly(L-lactic) acid biodegradable scaffolds. Bilateral
scaffolds were implanted subcutaneously in the dorsum of each mouse. Tumor
volumes were calculated and recorded over 81 days after implantation. Figure 4.4
shows the relevant data directly taken from Krishnamurthy et al. (2014). Red data
points in Figure 4.4-C show the volume of xenograft tumors vascularized with IL-
6-silenced ECs (HDMEC-shRNA-IL-6) and the blue data points show the volume
of the xenograft tumors vascularized with control ECs (HDMEC-shRNA-C) over
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days after implantation. When 1’000 ALDHHIGHCD44HIGH cells were transplanted
with HDMEC-shRNA-IL-6 cells into the IL-6 +/+ mice, the average tumor volume
was smaller as compared to the transplantation of 1’000 (ALDHHIGHCD44HIGH)
with HDMEC-shRNA-C cells, demonstrating that endothelial cell-secreted IL-6 en-
hances the tumorigenic potential of CSCs (in vivo). Moreover, they evaluated the
percentage of CSCs in those xenograft tumors and observed that ablation of EC-
IL-6 within the tumor microenvironment reduced the fraction of CSCs in tumor
(Figure 4.4-D).
4.2.2 Estimating baseline parameter values
A list of parameter values found from the literature are tabulated in Table 4.2.
The baseline values for the remaining parameters are estimated by fitting the pre-
treatment EC-TC model to the control ECs. Similar to the procedure applied in
Chapter 2, we use Monte Carlo parameter sweep method Cowan (1998) to minimize
the Pearson χ2 statistic by comparing the average tumor volume extracted from
the data and the tumor volume predicted by the pre-treatment EC-TC model, over
days after implantation. The estimated parameter values are listed in Table 4.3.
Figure 4.5-A depicts the best fit of the model to the data related to the ECs in
control case . The blue dots represent the individual tumor volumes over time
(for 13 mice), red dots represent the average tumor volume at each time point
and the black solid line shows the tumor volumes predicted by the pre-treatment
EC-TC model. In addition, we also used the estimated baseline parameter val-
ues to predict the percentage of CSC% at day 30 after implantation and com-
pared it with the CSC% given by Figure 4.4-C. Figure 4.5-B illustrates the percent-
age of (ALDHHIGHCD44HIGH) cells in primary human HNSCC. Blue bar shows
the CSC% in xenograft tumor vascularized with HDMEC-shRNA-C, and red bar
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Figure 4.4: Endothelial Cell-Secreted IL-6 Enhances the Tumorigenic Potential of
CSCs in HNSCC: (A) Schematic representation of the approach used for testing
the role of endothelial cell-secreted IL-6 on the tumorigenic potential of primary
human ALDHHIGHCD44HIGH cells. ALDHHIGHCD44HIGH cells were sorted from
primary HNSCC and implanted in immunodeficient mice to generate xenograft tu-
mors vascularized with HDMEC-shRNA-IL-6 or control HDMEC-shRNA-C (Fig-
ure 2-A in Krishnamurthy et al. (2014)). (B) Graph showing individual tumor
volume over time. Photomicrographs (×200) of HE-stained tissue sections of
scaffolds 30 days after implantation. Few (if any) tumor cells are visible in the
implants vascularized with HDMEC-shRNA-IL-6, while the entire microscopy
field is populated with tumor cells in the implants vascularized with HDMEC-
shRNA-C (Figure 2-C in Krishnamurthy et al. (2014)); (C) the percentage of
(ALDHHIGHCD44HIGH) cells: the orange bar shows the CSC% in primary human
HNSCC; blue bar shows the CSC% in xenograft tumor vascularized with HDMEC-
shRNA-C; and gray bar shows the CSC% in xenograft tumor vascularized with
HDMEC-shRNA-IL-6 at day 30 after implantation (Figure 3-1 in Krishnamurthy
et al. (2014) ).
shows the CSC% predicted by the pre-treatment EC-TC model in the xenograft tu-
mor vascularized with HDMEC-shRNA-C at day 30 after implantation.
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Figure 4.5: The Best-Fit of the Pre-Treatment EC-TC Model to EC-Control Data: (A)
1’000 primary human ALDHHIGHCD44HIGH cells along with HDMEC-shRNA-C
cells were seeded in 13 mice; blue dots represent the individual tumor volumes
over time, red dots represent the average tumor volume at each time point and the
black solid line shows the tumor volumes predicted by the pre-treatment EC-TC
model. (B) The percentage of (ALDHHIGHCD44HIGH) cells; the orange bar shows
the CSC% in primary human HNSCC; the blue bar shows the CSC% in xenograft
tumor vascularized with HDMEC-shRNA-C; and the red bar shows the CSC%
predicted by the pre-treatment EC-TC model in the xenograft tumor vascularized
with HDMEC-shRNA-C at day 30 after implantation.
Endothelial cell-secreted IL-6 enhances primary HNSCC tumor growth
To evaluate the impact of endothelial cell-secreted IL-6 on tumorigenic poten-
tial of CSCs, the IL-6 expression in primary human dermal microvascular endothe-
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lial cells was silenced (Figure 4.6). Red data points in Figure 4.6-A show the vol-
ume of xenograft tumors vascularized with IL-6-silenced ECs (HDMEC-shRNA-
IL-6) and the blue data points show the average volume of the xenograft tumors at
each day after implantation.
In order to find the best-fit to HDMEC-shRNA-IL-6, we decreased the secretion
rate ofIL-6 by ECs to a very low level (8.9e-07) and then predicted the tumor vol-
ume at each time point. The numerical simulations (data is not shown) suggest
that some of the parameters that are influenced by IL-6 should be also altered. As
we discussed in Chapter 2, disturbance of IL-6 secretion can potentially change
Ain, PNS and n values. Therefore, in order to estimate the new altered values of n,
Ain and PNs , we fit the pre-treatment model to HDMEC-shRNA-IL-6 when ρH is
much smaller as compared to HDMEC-shRNA-C data (Figure 4.5).
Model predictions for both HDMEC-shRNA-IL-6 and HDMEC-shRNA-C data
indicates that the proposed model is capable of making relatively reliable pre-
dictions of tumor growth. In the next sections we will use and extend this pre-
treatment model in order to study the tumor cell responses to treatment.
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Figure 4.6: The best-Fit of the Pre-Treatment EC-TC Model to EC-IL-6-Silent Data:
(A) 1’000 primary human ALDHHIGHCD44HIGH cells along with HDMEC-shRNA-
IL-6 cells were seeded in 13 mice; red dots represent the individual tumor vol-
umes over time, blue dots represent the average tumor volume at each time point
and the black solid line shows the tumor volumes predicted by the pre-treatment
EC-TC model. (B) The percentage of (ALDHHIGHCD44HIGH) cells; the orange bar
shows the CSC% in primary human HNSCC; red bar shows the CSC% in xenograft
tumor vascularized with HDMEC-shRNA-C; and the black bar shows the CSC%
predicted by the pre-treatment EC-TC model in the xenograft tumor vascularized
with HDMEC-shRNA-Il-6 at day 30 after implantation
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Table 4.2: Parameter Values Taken from the Literature and Their Sources.
∗ VolT is the volume of the tumor in µl and is equal to (volume of 1 million ECs)×
H+ (volume of 1 million TCs)× (S+E+D), where, the volume of 1 EC is 2.2× 10−6µl
King et al. (2004) and 1 TC is 1× 10−6µl Cunningham et al. (1999).
Parameter Value Units Source
αS 0.6 day
−1 Driessens et al. (2012); Gao
et al. (2013)
αE
log(2)
1.04 day
−1 Driessens et al. (2012); Gao
et al. (2013)
P∗Smin 0.014 dimensionless Weekes et al. (2014)
PSmax 0.90 dimensionless Weekes et al. (2014)
k f 2.35 fmol
−1day−1 O¨zbek et al. (1998)
kr 2.24 day−1 Hirabayashi and Lemmey
(2012); O¨zbek et al. (1998)
λL 0.4152 day
−1 Lindmark et al. (2001)
ρT 7× 10−7 fmol−1day−1per cell Bran et al. (2011); Nilsson
et al. (2005); PRIES et al.
(2006)
RTS 1.66× 10−6 fmol−1per cell Boayue et al. (1998); Shkeir
et al. (2013); Snyers and
De Wit (1990); Takizawa
et al. (1993)
RTE
1
8 RTS fmol
−1per cell Krishnamurthy et al. (2014)
RTD
1
8 RTS fmol
−1per cell Krishnamurthy et al. (2014)
k fH1 11.4048/Vol
∗
T fmol
−1 day−1 Mac Gabhann et al. (2005);
von Tiedemann and
Bilitewski (2002)
krH1 86.4 day
−1 Mac Gabhann and Popel
(2007b)
kpH1 24.1920 day
−1 Mac Gabhann and Popel
(2007b)
k fH2 10.0757/Vol
∗
T fmol
−1 day−1 Cunningham et al. (1999);
Mac Gabhann et al. (2005)
krH2 86.4 day
−1 Mac Gabhann and Popel
(2007b)
kpH2 24.1920 day
−1 Mac Gabhann and Popel
(2007b)
RtHA1 6.63e-5 fmol per cell Wang et al. (2002)
RtHA2 1.92e-4 fmol per cell Wang et al. (2002)
λA 16.6355 day
−1 Yen et al. (2011)
δB 6.6542 day
−1 Yang et al. (2003)113
Table 4.3: Estimated Parameter Values
Parameter Estimated Value Units Source
αH 1.019 per day Estimated
nH 0.85 dimensionless Estimated
δH 0.09 per day Jain and Jackson (2017)
βH 600 dimensionless Estimated
Np 5.5 mmHg Jain and Jackson (2017)
δS 0.0126 day−1 Ch 2
Nd 1 mmHg Jain and Jackson (2017)
γS 2.38 dimensionless Ch 2
δE 0.0612 day−1 Ch 2
γE 2.38 dimensionless Ch 2
δD 0.0612 day−1 Ch 2
µS 0.018 dimensionless Ch 2
γD 2.38 dimensionless Ch 2
nL 2.18 dimensionless Estimated
Ain 4 dimensionless Ch 2
n 12.66 dimensionless Ch 2
ρH 0.0002 fmol
−1day−1cell−1 Estimated
kp 24.95 day−1 Ch 2
PNs 755500 dimensionless Ch 2
αA 1.54× 10−6 fmol cell−1 day−1 Jain and Jackson (2017)
βA 0.65 dimensionless Estimated
νA 5e-4 fmol cell−1 day−1 Jain and Jackson (2017)
κA 2 dimensionless Jain and Jackson (2017)
Nh 10 mmHg Jain and Jackson (2017)
χH 6.6542 per day Jain and Jackson (2017)
ηH 1063 per day Jain and Jackson (2017)
ωH 0.3341 dimensionless Jain and Jackson (2017)
nB 5 dimensionless Jain and Jackson (2017)
σN 1.087 mmHg Jain and Jackson (2017)
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4.3 Treatment of HNSCC Tumor With Tocilizumab and Cisplatin
Based on the stage, location, and histological features, conventional therapies
for HNSCC can be surgical resction, radiation therapy, chemotherapy, or a combi-
nation of these. Cisplatin is the most common chemotherapeutic drug for the treat-
ment of HNSCC. Although Cisplatin is relatively successful in de-bulking the tu-
mor, it is proposed that CSCs evade therapies with Cisplatin, and, with the passage
of time, these cells are activated and regenerate tumors locally or at distant sites
Krishnamurthy and No¨r (2012); No¨r et al. (2014) (Figure 4.7-Conventional Ther-
apy).
In the previous sections, we saw that endothelial cell-secreted IL-6 can signifi-
cantly enhance the survival of CSCs and promote tumor growth. We also observed
that the fraction of CSCs was significantly reduced when xenografts were vascular-
ized with IL-6 silenced human endothelial cells. Thus, the significant physiological
role of IL-6 provided the rationale for the therapeutic targeting of the IL-6 signal-
ing pathway in HNSCC (Figure 4.7-Perivascular niche-targeted Therapy).
To understand the therapeutic potential of targeting IL-6 signaling in HNSCC, our
collaborators in the University of Michigan used UM-SCC-1 and UM-SCC-22B cell
lines to conduct a series of treatment experiments with TCZ. The data suggested
that inhibition of IL-6 signaling reduced the survival and/or the self-renewal of
HNSCC stem cells. Furthermore, they performed a series of individual treatment
experiments with only Cisplatin and the combination of Cisplatin with TCZ. Col-
lectively, it was observed that combination therapy with Cisplatin and TCZ has
better outcomes than treatment with only Cisplatin or TCZ. All together, these
facts motivate us to add treatment with TCZ and Cisplatin to our current model
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Figure 4.7: Possible Implications of the CSC Hypothesis for Therapy. Conventional
chemotherapy targets primarily the bulk of the tumor cells (non-CSCs). As a re-
sult, under suitable tumor microenvironment, the CSCs proliferate which leads
to tumor recurrence. Perivascular niche-targeted therapy or indirect targeting of
CSCs via disruption of their perivascular niche can potentially eliminate them. Ab-
lation of the CSCs may inhibit the regeneration of the tumor and ultimately result
in tumor regression. The figure is taken from Krishnamurthy and No¨r (2012).
and to explore the ability of our model in predicting the growth rate of tumors
generated in mice.
Recall that in the experiment described in Figure 4.4, ALDHHIGHCD44HIGH cells
were sorted from “primary” human HNSCC tumor and implanted in mice along
with endothelial cells to study the impacts of EC-IL-6 on tumor initiation and tu-
morigenic properties of CSCs. Primary cells are isolated directly from human or
animal tissue and are immediately placed in an artificial environment whereas cell
lines have been continually passaged over a long period of time and have acquired
homogenous genotypic and phenotypic characteristics. Immortalized or continu-
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ous cell lines have acquired the ability to proliferate indefinitely. Moreover, despite
the fact that cell lines have lost the true characteristics of the original tissue from
which isolated, they are widely used in lab experiments as they are easy to handle.
In contrast, primary cells usually are believed to be more biologically relevant tools
than cell lines but they have a limited lifespan, slow proliferation and are not well
characterized making them hard to maintain. Therefore, since primary cells and
cell lines show different behavior, we, firstly, need to find the baseline parameter
values for each aforementioned cell lines. Secondly, we add equations related to
treatment to the current model and use those obtained baseline parameter values
to predict the rate of tumor growth post treatment with TCZ and/or Cisplatin and
with the combination therapy of TCZ and Cisplatin. Finally, we use our model to
make suggestions/predictions for the most optimized dosing/scheduling combi-
nation of Cisplatin and TCZ.
4.3.1 Experimental data
In two separate set of experiments designed specifically for this modeling study,
100,000 unsorted University of Michigan Squamous Cell Carcinoma 1 (UM-SCC-1)
and 100,000 University of Michigan Squamous Cell Carcinoma 22B (UM-SCC-22B)
cell lines along with 900,000 ECs were implanted bilaterally in mice. When tumors
reached approximately 250 mm3, the mice were assigned into 4 groups and re-
ceived: (1) 5mg/kg Cisplatin combined with 5mg/kg TCZ; (2) 5mg/kg Cisplatin;
(3) 5mg/kg TCZ and (4) control via i.p. injections. Cisplatin was administered
weekly for three weeks and the tocilizumab was administered weekly for 9 weeks.
Treatment started on day 23 for the UM-SCC-1 cohort and on day 36 for the UM-
SCC-22B cohort based on the tumor sizes at those starting day numbers. The tu-
mor sizes were calculated as mm3 from length and width measurements via (long
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Figure 4.8: Effects of Tocilizumab and/or Cisplatin in the In Vivo Model of HNSCC
Described in Subsection 4.3.1. The graphs depict tumor volume over time until the
last day of study.
axis×short axis2)/2. Figure 4.8 shows the data obtained from the experiments.
Figure 4.8-A suggests that treating the UM-SCC-1 cohort with single agent TCZ
have a better therapeutical effects on tumor growth than treatment with only Cis-
platin. Notably, the combination of TCZ with Cisplatin increases the overall effect
of therapy leading to a decrease in the tumor volume when compared to the control
group. On the contrary, treating UM-SCC-22B cells with only TCZ inhibits tumor
growth to the same extent as combination of TCZ and Cisplatin. Treatment with
Cisplatin does not show any beneficial therapeutical effects and, interestingly, even
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promotes the tumor growth in some of the mice. Collectively, the overall trends
suggest that TCZ in combination with Cisplatin group has the most considerable
effect on tumor volume compared with control group, and single agent TCZ or
Cisplatin.
4.3.2 Estimating baseline parameter values
In order to estimate the baseline parameter values, the pre-treatment EC-TC
model is separately fitted to the control treatment data related to UM-SCC-1 and
UM-SCC-22 cell line cohorts. Figures 4.9 and 4.10 depict the best fit of the model to
the control data for the UM-SCC-1 and UM-SCC-22B cohort, respectively. The blue
points depict the tumor volume generate in six mice over time and the red points
depict the average tumor volume at each time point. Over the first two or three
weeks after treatment starts, our model predicts a slower rate for tumor growth
than control data, while for the later weeks the model can fairly predict the tumor
growth generated in mice. In the next steps we will first add the equations related
to treatment to the current model and then use the estimated parameter values to
test the ability of the treatment model to predict the response of cell lines to treat-
ment.
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Table 4.4 tabulates all the estimated baseline parameter values.
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Figure 4.9: The Best Fit of the Pre-Treatment EC-TC Model to the Control Tumor
Volume for UM-SCC-1 Group. The blue points depict the tumor volume generate
in mice (n=6) over time and the red points depict the average tumor volume at
each time point. The black line shows the pre-treatment model predictions.
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Figure 4.10: The Best Fit of the Pre-Treatment EC-TC Model to the Control Tumor
Volume for UM-SCC-22B Group. The blue points depict the tumor volume gener-
ate in mice (n=6) over time and the red points depict the average tumor volume at
each time point. The black line shows the pre-treatment model predictions.
Table 4.4: Baseline Parameter Values for the Pre-Treatment EC-TC Model Using
UM-SCC-1 and UM-SCC-22B Cohort Data
Parameter Estimated Value Estimated Value Units
nH 0.5 0.5 dimensionless
βH 1078.7 1457.3 dimensionless
αH 1.09 1.08 day−1
δS 0.0126 0.0126 day−1
δE 0.012 0.012 day−1
δD 0.5 0.5 day−1
µS 0.075 0.035 dimensionless
Ain 3 3 dimensionless
n 13.00 17.00 dimensionless
ρH 0.0622 0.0622 fmol
−1day−1cell−1
PNs 1.5034e+06 1.4242e+06 dimensionless
βA 0.59 0.59 dimensionless
nL 0.80 0.86 dimensionless
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4.4 Treatment I: Chemotherapy with Cisplatin
4.4.1 Introduction
The published clinical results suggest that some tumor cells can evade chemother-
apy with Cisplatin and have the capability to migrate and initiate a new tumor
locally or in distance No¨r et al. (2014). No¨r et al. No¨r et al. (2014) performed a thor-
ough lab experiment to study the effects of Cisplatin therapy on HNSCC tumor
lines. Briefly, 100,000 UM-SCC-22B cells were seeded along with 900,000 HDMEC
in poly-(L-lactic) acid biodegradable scaffolds in severe combined immunodefi-
cient mice. Bilateral scaffolds were implanted subcutaneously in the dorsum of
each mouse (n=12). Mice were treated weekly with 5 mg/kg Cisplatin started
when the average volume of the rumors reached 200 mm3 (Figure CisTherapy-A).
In summary, they observed that treatment with Cisplatin enhanced the fraction
of CSCs in HNSCC and hypothesized that the combination of Cisplatin with the
high expression of IL-6 in tumor niche leads to a dramatic increase in the fraction
of CSCs (Figure CisTherapy-B). Furthermore, they reported that Cisplatin has roles
in activation of key signaling pathways involved in the regulation of stemness of
CSCs (Figure 4.11-C). Finally, to investigate the effect of Cisplatin on stemness in
HNSCC, they generated cisplatin-resistant cell lines (UM-SCC-22Cis1, UM-SCC-
22Cis6 and UM-SCC-22Cis12) in vitro and saw that these cells are endowed with
cancer stemlike features (Figure 4.11-D). Collectively, they observed that IL-6 con-
tributes to Cisplatin-induced stemness, suggesting that a combination therapy in-
volving a platinum-based drug and IL-6R inhibitor might be beneficial for improv-
ing more effective treatment and/or cure for HNSCC tumors.
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Figure 4.11: Cisplatin Therapy of HNSCC. (A) schematic drawing depicts the ex-
perimental design (Figure 1-A in No¨r et al. (2014)); (B) the percentage of CSCs
(ALDHHIGHCD44HIGH cells) in xenograft tumors treated with Cisplatin or vehicle
control (n=11) (Figure 1-C in No¨r et al. (2014)). (C) Western plot for phosphorylated
and total key signaling pathways involved in the regulation of stemness includ-
ing STAT3, ERK, and AKT in UM-SCC-22B (Figure 3-B in No¨r et al. (2014)); and
(D) number of orospheres generated with parental UM-SCC-22B cells or cisplatin-
resistant cells (UM-SCC-22BCis12) treated with cisplatin (0 or 2 µM) and/or rhIL-6
(0 or 20 ng/ml) for 10 days in ultralow attachment plates (Figure 4-B in No¨r et al.
(2014)).
In this section, we use the above features to extend the pre-treatment EC-TC
model to include Cisplatin therapy of HNSCC tumors. We further use the exper-
imental data described in Subsection 4.3.1 to validate the predictions of the pro-
posed model. Once validated, this model will be used and extended to study the
tumor cell responses to combination therapy with TCZ and Cisplatin. Before pro-
ceeding to model development, we first estimate the pharmacokinetic parameters
of Cisplatin.
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4.4.2 Pharmacokinetics of Cisplatin
To estimate the pharmacokinetic parameters of Cisplatin we use the analytic
solution of PK-model with i.p. injection given by Eq. 3.3.3 in Chapter 2 with the
new variables and parameters:
Xs(t) = Xp(t0)
(
Ape−α(t−t0) + Bpe−β(t−t0)
)
, t ≥ t0 (4.4.1)
where,
α =
(kC12 + k
C
21 + k
C
el) +
√
(kC12 + k
C
21 + k
C
el)
2 − 4kC21kCel
2
β =
(kC12 + k
C
21 + k
C
el)−
√
(kC12 + k
C
21 + k
C
el)
2 − 4kC21kCel
2
Ap =
kC21
β− α
Bp =
kC21
α− β
where kC12 and k
C
21 are the distribution rate constants between the systemic central
compartment (Xs) and peripheral compartment (Xp). Moreover, kCel is the elimina-
tion rate from central compartment.
In order to estimate the pharmacokinetic parameters, we used the data given
in Ling et al. (2015). Figure 4.12 shows the best-fit of the pharmacokinetic model to
the data and the estimated parameter values are listed in Table 4.5.
4.4.3 Equations for Cisplatin-therapy
In this section we modify the pre-treatment EC-TC model to include the equa-
tions related to Cisplatin therapy.
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Figure 4.12: Time Profiles of Plasma Cisplatin Concentration Given in Ling et al.
(2015). The gray points depict Pt concentration in the plasma versus time after a
single intravenous injection of cisplatin in rats. Data are presented as mean ± SD
(n = 12) and the solid red line shows the model prediction of Cisplatin elimination
from plasma.
Table 4.5: Estimated Pharmacokinetic Parameters of Cisplatin
Parameters Values Units Reference
kC12 84 day
−1 Estimated
kC21 7 day
−1 Estimated
kCel 20 day
−1 Estimated
Cisplatin-induces death of tumor cells
In order to include the Cisplatin-induced death of the tumor cells we use a stan-
dard Michaelis-Menten equation as a function of the concentration of Cisplatin
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within tumor, X(t), and denoted by:
MS(X) = δS(1− e)
(
1
1+ γSφS
+
ΠSX
KSM + X
)
S, e 6= 1
ME(X) = δE(1− e)
(
1
1+ γEφE
+
ΠEX
KEM + X
)
E, e 6= 1
MD(X) = δD(1− e)
(
1
1+ γDφD
+
ΠDX
KDM + X
)
D, e 6= 1
KiM, for i = S, E and D, are representing the half maximal inhibitory of Cisplatin
concentration and Πi, denotes the amount by which Cisplatin can increase the
maximum natural death rate of CSCs, PCs and DCs, respectively. The parameter e
determines the type of interaction between the two ligands (Cisplatin and IL-6). If
e < 1 then there are enhanced effects and if e > 1 then there are synergistic effects
?. For simplicity we assume that e = 0.
Cisplatin enhances the self-renewal capacity of normal and cancer stem cells
As mentioned above, Cisplatin can enhance the stemness of CSCs. In fact, Cis-
platin can increase the expression of Bmi-1, a member of the poly comb group
family of transcriptional regulators that plays an essential role in stem cell fate
decisions and regulates the self-renewal capacity of normal and CSCs No¨r et al.
(2014). Therefore, in order to integrate this feature of Cisplatin, we add a posi-
tive feedback function of X (Cisplatin concentration in tumor) to the self-renewal
probability function of CSCs (PS) as following:
PS(S, φS) =
(PSmax − PSmin(φS))PnNs
PnNs + S
n + PSmin(φS),
PSmin(φS) = µS
(
PSmax − P∗Smin
)(
φS +
X
KS + X
)
+ P∗Smin
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Thus, adding the above changes to the pre-treatment EC-TC model gives us the
following set of ODEs.
Variables related to pharmacokinetic of Cisplatin are tabulated in Table 4.6.
Table 4.6: Variables Related to Cisplatin-Therapy Model
Variable Description Units
X Free Cisplatin in tumor fmol
Xs Free Cisplatin in systemic circulation fmol
Xp Free Cisplatin in peripheral compartment fmol
dS
dt
= αSPS(S, φS)S︸ ︷︷ ︸
Stem cell self-renewal
− δS
(
1
1+ γSφS
+
ΠSX
KSM + X
)
S︸ ︷︷ ︸
Stem cell death
dE
dt
= AinαS(1− PS(S, φS))S︸ ︷︷ ︸
Amplified
stem cell differentiation
− αEE︸︷︷︸
Progenitor cell
differentiation
− δE
(
1
1+ γEφE
+
ΠEX
KEM + X
)
E︸ ︷︷ ︸
progenitor cell death
dD
dt
= 2αEE︸ ︷︷ ︸
progenitor cell
differentiation
− δD
(
1
1+ γDφD
+
ΠDX
KDM + X
)
D︸ ︷︷ ︸
differentiated cell death
dL
dt
= − k f LRS︸ ︷︷ ︸
IL6 binding to
stem cells
+ krCS︸︷︷︸
IL6 dissociation
from stem cells
− k f LRE︸ ︷︷ ︸
IL6 binding to
progenitor cells
+ krCE︸︷︷︸
IL6 dissociation
from progenitor cells
− k f LRD︸ ︷︷ ︸
IL6 binding to
differentiated cells
+ krCD︸ ︷︷ ︸
IL6 dissociation
from differentiated cells
− λLL︸︷︷︸
IL6 natural decay
+ ρT(S + E + D)︸ ︷︷ ︸
IL-6 Production
by tumor cells
dRS
dt
= − k f LRS︸ ︷︷ ︸
IL-6 binding to
stem cells
+ krCS︸︷︷︸
IL-6 dissociation
from stem cells
+ kpCS︸︷︷︸
Recycling
+ RTSPS (S, φS)︸ ︷︷ ︸
Generation of new RS
via cell proliferation
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− RS
RS + CS
RTSDS (S, φS)︸ ︷︷ ︸
Loss of RS
via cell death
dCS
dt
= + k f LRS︸ ︷︷ ︸
IL6 binding to RS
− krCS︸︷︷︸
IL6 dissociation
from RS
− kpCS︸︷︷︸
Internalization
− CS
RS + CS
RTSDS (S, φS)︸ ︷︷ ︸
Loss of CS
via cell death
dRE
dt
= − k f LRE︸ ︷︷ ︸
IL-6 binding to
progenitor cells
+ krCE︸︷︷︸
IL-6 dissociation
from progenitor cells
+ kpCE︸ ︷︷ ︸
Recycling
+ RTEPE (E, φE)︸ ︷︷ ︸
Generation of new RE
via cell proliferation
− RE
RE + CE
RTEDE (E, φE)︸ ︷︷ ︸
Loss of RE
via cell death
dCE
dt
= + k f LRE︸ ︷︷ ︸
IL6 binding to RE
− krCE︸︷︷︸
IL6 dissociation
from RE
− kpCE︸ ︷︷ ︸
Internalization
− CE
RE + CE
RTEDE (E, φE)︸ ︷︷ ︸
Loss of CE
via cell death
dRD
dt
= − k f LRD︸ ︷︷ ︸
IL-6 binding to
differentiated cells
+ krCD︸ ︷︷ ︸
IL-6 dissociation
from differentiated cells
+ kpCD︸ ︷︷ ︸
Recycling
+ RTDPD (E, φD)︸ ︷︷ ︸
Generation of new RD
via cell proliferation
− RD
RD + CD
RTDDD (E, φD)︸ ︷︷ ︸
Loss of RD
via cell death
dCD
dt
= + k f LRD︸ ︷︷ ︸
IL6 binding to RD
− krCD︸ ︷︷ ︸
IL6 dissociation
from RD
− kpCD︸ ︷︷ ︸
Internalization
− CD
RD + CD
RTDDD (D, φD)︸ ︷︷ ︸
Loss of CD
via cell death
dX
dt
= + kC12Xs − kC21X︸ ︷︷ ︸
Pharmacokinetics
Next, we use the baseline parameter values for UM-SCC-1 and UM-SCC-22B co-
horts and predict try to test the capability of our proposed model in capturing the
tumor growth dynamics after chemotherapy with Cisplatin.
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4.4.4 Cisplatin-therapy does not cause a significant decrease in tumor volume
We already have introduced the treatment data in Subsection 4.3.1. Figure 4.13
compares the average volume of tumors only in Cisplatin group (n=6) with the
average volume of tumors in control group (n=6). The blue dots in Figure 4.13 de-
picts the average volume of xenograft tumors initiated from UM-SCC-1 (UM-SS-
22B) cell lines and treated with 5mg/kg Cisplatin for three weeks starting at day
23 (36) after implantation. The red dots represent the average volume of tumors
generated by implanting UM-SCC-1 (UM-SCC-22B) with control vehicle. As it is
shown in Figure 4.13, this treatment regimen does not cause a significant decrease
(if any) in tumor volume post-treatment in both UM-SCC-1 and Um-SCC-22B co-
horts. Notably, UM-SCC-22B cell lines show even higher rate of tumor growth
when compared with control group. These results motivate us to use our Cisplatin
model to possibly provide some insight into the underlying mechanisms involved
in chemotherapeutic effects of Cisplatin.
We use the baseline parameter values obtained from fitting pre-treatment EC-TC
model to control data (Figures 4.9 and estimate the parameters related to Cisplatin-
therapy (Πi and KS). Figures 4.14-A and 4.15-A plot the best fit of the Cisplatin-
therapy model to treatment data given in Figure 4.13. The orange line represents
the tumor volumes predicted by the Cisplatin-therapy model and the black line
represents the tumor volumes for control group predicted by the pre-treatment
EC-TC model. The estimated parameter values are given in Table 4.7. Interest-
ingly, the Cisplatin-therapy model suggests that for larger values of KS, we see the
better pro-therapeutic effects of Cisplatin suggesting that when Cisplatin
Finally, we observed that the percentage of CSCs post-treatment is higher for
UM-SCC-22B than the post-treatment CSC percentage in UM-SCC-1 group (Fig-
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Figure 4.13: Cisplatin-Therapy in Compare to Control
ures 4.14-B and 4.15-B). Collectively, these results suggest that the there is a nega-
tive correlation between percentage of CSCs post-treatment and the pro-therapeutic
role of Cisplatin.
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Table 4.7: Estimated Parameter Values for the Cisplatin-Therapy Model Using data
related to Cisplatin Therapy for UM-SCC-1 and UM-SCC-22B Cohorts.
Parameter UM-SCC-1 UM-SCC-22B Units Source
ΠS 7.7e-04 3.8e-04 dimensionless Estimated
ΠE 0.7026 0.080143 dimensionless Estimated
ΠD 0.0014 0.0027026 dimensionless Estimated
KS 5.8277e+19 8.7289e+05 fmol Estimated
KSM 850000 850000 fmol No¨r et al. (2014)
KEM 850000 850000 fmol No¨r et al. (2014)
KDM 850000 850000 fmol No¨r et al. (2014)
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Figure 4.14: At day 23 after tumor implantation, Cisplatin-therapy model is used
to predict the tumor volume growth dynamics and the results are compared with
the treatment data related to UM-SCC-1 cohort. Model predictions plotted along
with experimental data for UM-SCC-1 tumor growth in the control case, without
treatment (black line and red dots), and for Cisplatin therapy (orange line and blue
dots)
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Figure 4.15: At day 36 after tumor implantation, Cisplatin-therapy model is used
to predict the tumor volume growth dynamics and the results are compared with
the treatment data related to UM-SCC-22B cohort. Model predictions plotted along
with experimental data for UM-SCC-22B tumor growth in the control case, without
treatment (black line and red dots), and for Cisplatin therapy (orange line and blue
dots)
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4.5 Treatment II: Treatment of HNSCC Cell Lines With Tocilizumab
4.5.1 Introduction
We have already shown, in the pre-treatment section, that silencing the secre-
tion of IL-6 in endothelial cells (the primary source of IL-6 secretion) leads to a
significant reduction in the tumor growth rate and the final percentage of CSCs.
Recall that the effects of IL-6 are modeled thorough the fraction of occupied IL-6R
on tumor cells. All together, these facts motivate us to add treatment with TCZ
(anti-IL-6R antibody), to the pre-treatment EC-TC model and explore its effects on
the growth rate of xenograft tumors. Next, we use this model to predict and com-
pare the behavior of tumor growth dynamics with the data related to TCZ-therapy
and described in Subsection 4.3.1. Once, we assure that our proposed model can
fairly capture the tumor growth dynamics over time then we combine it with the
Cisplatin-therapy model developed in the previous section in order to design a
model for combination therapy with TCZ and Cisplatin.
4.5.2 Model equations related to TCZ-therapy
In this section we modify the pre-treatment EC-TC model with the equations
necessary to describe treatment with TCZ. The treatment model is developed using
the same approach used for TCZ-therapy EC-TC model in Chapter 2. However, in
this chapter we have additional equations related to endothelial cells and hypoxia.
Briefly, TCZ as an anti-IL-6R antibody binds to IL-6R on tumor cells and inhibits
formation of IL-6–IL-6R complex molecules. Soon after drug administration, TCZ
reaches the tumor environment and binds to IL-6R on tumor cells at a rate kIf , and
dissociates at a rate kIr. Similarly, the complex of TCZ and IL-6R on stem, progen-
itor and differentiated cells are denoted by CIS, C
I
E and C
I
D, respectively. Equation
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dI
dt describes the association and dissociation of TCZ in the tumor, I(t), to IL-6 cell-
bound receptors on tumor cells. Underlying assumptions for this equations are the
same as Chapter 2. Thus, the full model after adding treatment with TCZ can be
given by:
dH
dt
= αHφ
nH
HA2
H︸ ︷︷ ︸
Activated VEGFR2-mediated
proliferation
− δH
1+ βHBH
H︸ ︷︷ ︸
Bcl-2-mediated
apoptosis
dS
dt
= αSPS(S, φS)SH(N − Np)︸ ︷︷ ︸
Stem cell self-renewal
− δS
1+ γSφS
S[1+H(Nd − N)]︸ ︷︷ ︸
IL-6 & Bcl-2 mediated
apoptosis
dE
dt
= AinαS [1− PS(S, φS)] SH(N − Np)︸ ︷︷ ︸
Amplified
stem cell differentiation
− αEEH(N − Np)︸ ︷︷ ︸
Progenitor cell
differentiation
− δE
1+ γEφE
E[1+H(Nd − N)]︸ ︷︷ ︸
IL-6 & Bcl-2 mediated
apoptosis
dD
dt
= 2αEEH(N − Np)︸ ︷︷ ︸
progenitor cell
differentiation
− δD
1+ γDφD
D[1+H(Nd − N)]︸ ︷︷ ︸
IL-6 & Bcl-2 mediated
apoptosis
dL
dt
= − k f LRS︸ ︷︷ ︸
IL-6 binding to
stem cells
+ krCS︸︷︷︸
IL6 dissociation
from stem cells
− k f LRE︸ ︷︷ ︸
IL-6 binding to
progenitor cells
+ krCE︸︷︷︸
IL-6 dissociation
from progenitor cells
− k f LRD︸ ︷︷ ︸
IL-6 binding to
differentiated cells
+ krCD︸ ︷︷ ︸
IL-6 dissociation
from differentiated cells
− λLL︸︷︷︸
IL-6 natural decay
+ρT(S + E + D)︸ ︷︷ ︸
IL-6 Production
by tumor cells
+ ρHφ
nL
HA2
H︸ ︷︷ ︸
Bcl-2-mediated
IL-6 production
by ECs
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dI
dt
= − kIf IRS︸ ︷︷ ︸
Anti-IL6R binding to
stem cells
+ kIrC
I
S︸︷︷︸
Ani-IL6R dissociation
from stem cells
− kIf IRE︸ ︷︷ ︸
Anti-IL6R binding to
progenitor cells
+ kIrC
I
E︸︷︷︸
Anti-IL6R dissociation
from progenitor cells
− kIf IRD︸ ︷︷ ︸
Anti-IL6R binding to
differentiated cells
+ kIrC
I
D︸ ︷︷ ︸
IL6 dissociation
from differentiated cells
+ k12 Is − k21 I︸ ︷︷ ︸
Pharmacokinetics
dRS
dt
= − k f LRS︸ ︷︷ ︸
IL-6 binding to
stem cells
+ krCS︸︷︷︸
IL-6 dissociation
from stem cells
+ kpCS︸︷︷︸
Recycling
− kIf IRS︸ ︷︷ ︸
Anti-IL6R binding to
IL-6R
+ kIrC
I
S︸︷︷︸
Anti-IL-6R dissociation
from stem cells
+ RTSPS (S, φS)︸ ︷︷ ︸
Generation of new RS
via cell proliferation
− RS
RS + CS + CIS
RTSDS (S, φS)︸ ︷︷ ︸
Loss of RS
via cell death
dCIS
dt
= + kIf IRS︸ ︷︷ ︸
Anti-IL6R binding to
IL-6R
− kIrCIS︸︷︷︸
Ani-IL6R dissociation
from stem cells
− C
I
S
RS + CS + CIS
RTSDS (S, φS)︸ ︷︷ ︸
Loss of CIS
via cell death
dCS
dt
= + k f LRS︸ ︷︷ ︸
IL6 binding to RS
− krCS︸︷︷︸
IL6 dissociation
from RS
− kpCS︸︷︷︸
Internalization
− CS
RS + CS + CIS
RTSDS (S, φS)︸ ︷︷ ︸
Loss of CS
via cell death
dRE
dt
= − k f LRE︸ ︷︷ ︸
IL-6 binding to
progenitor cells
+ krCE︸︷︷︸
IL-6 dissociation
from progenitor cells
+ kpCE︸ ︷︷ ︸
Recycling
− kIf IRE︸ ︷︷ ︸
Anti-IL6R binding to
IL-6R
+ kIrC
I
E︸︷︷︸
Anti-IL-6R dissociation
from progenitor cells
+ RTEPE (E, φE)︸ ︷︷ ︸
Generation of new RE
via cell proliferation
− RE
RE + CE + CIE
RTEDE (E, φE)︸ ︷︷ ︸
Loss of RE
via cell death
dCIE
dt
= + kIf IRE︸ ︷︷ ︸
Anti-IL6R binding to
IL-6R
− kIrCIE︸︷︷︸
Ani-IL6R dissociation
from progenitor cells
− C
I
E
RE + CE + CIE
RTEDE (E, φE)︸ ︷︷ ︸
Loss of CIE
via cell death
dCE
dt
= + k f LRE︸ ︷︷ ︸
IL6 binding to RE
− krCE︸︷︷︸
IL6 dissociation
from RE
− kpCE︸ ︷︷ ︸
Internalization
− CE
RE + CE + CIE
RTEDE (E, φE)︸ ︷︷ ︸
Loss of CE
via cell death
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dRD
dt
= − k f LRD︸ ︷︷ ︸
IL-6 binding to
differentiated cells
+ krCD︸ ︷︷ ︸
IL-6 dissociation
from differentiated cells
+ kpCD︸ ︷︷ ︸
Recycling
− kIf IRD︸ ︷︷ ︸
Anti-IL6R binding to
IL-6R
+ kIrC
I
D︸ ︷︷ ︸
Anti-IL-6R dissociation
from differentiated cells
+ RTDPD (E, φD)︸ ︷︷ ︸
Generation of new RD
via cell proliferation
− RD
RD + CD + CID
RTDDD (E, φD)︸ ︷︷ ︸
Loss of RD
via cell death
dCID
dt
= + kIf IRD︸ ︷︷ ︸
Anti- nding to
IL-6R
− kIrCID︸ ︷︷ ︸
Ani-IL6R dissociation
from differentiated cells
− C
I
D
RD + CD + CID
RTDDD (D, φD)︸ ︷︷ ︸
Loss of CID
via cell death
dCD
dt
= + k f LRD︸ ︷︷ ︸
IL6 binding to RD
− krCD︸ ︷︷ ︸
IL6 dissociation
from RD
− kpCD︸ ︷︷ ︸
Internalization
− CD
RD + CD + CID
RTDDD (D, φD)︸ ︷︷ ︸
Loss of CD
via cell death
dA
dt
= −k fH1RHA1 A + krH1CHA1 − k fH2RHA2 A + krH2CHA2︸ ︷︷ ︸
reaction with VEGFR1/2 on endothelial cells
− λA A︸︷︷︸
natural
decay
+ αA
BH
1+ βABH
H︸ ︷︷ ︸
Bcl-2-mediated production
by endothelial cells
+
νA
1+ e−κA(Nh−N)
(S + E + D)︸ ︷︷ ︸
hypoxia-mediated VEGF
production by stem/bulk cells
dCHA1
dt
= k fH1RHA1 A− krH1CHA1 − kpH1CHA1︸ ︷︷ ︸
VEGFR1 activation by VEGF
on endothelial cells
− CHA1
δH
1+ βHBH︸ ︷︷ ︸
loss due to
endothelial cell apoptosis
dCHA2
dt
= k fH2RHA2 A− krH2CHA2 − kpH2CHA2︸ ︷︷ ︸
VEGFR2 activation by VEGF
on endothelial cells
− CHA2
δH
1+ βHBH︸ ︷︷ ︸
loss due to
endothelial cell apoptosis
dBH
dt
= χH︸︷︷︸
Constitutive
expression
by ECs
+ ηH
φnBHA2
ωnBH + φ
nB
HA2︸ ︷︷ ︸
Activated VEGFR2-
mediated production
by ECs
− δBBH︸ ︷︷ ︸
natural
decay
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dBT
dt
= χT︸︷︷︸
Constitutive
expression
by TCs
− δBBT︸ ︷︷ ︸
natural
decay
Similar to the calculation for TCZ-therapy model in Chapter 2, the following
equations for treatment model satisfy:
RS = RTS S− CS − CIS
RE = RTE E− CE − CIE
RD = RTD D− CD − CID
Variables and parameter values related to anti-IL-6R treatment are the same as
ones tabulated in Tables 3.7 and 3.8 in Chapter 2, respectively.
4.5.3 Predicting the effects of TCZ-therapy on HNSCC tumor growth
We use the model to predict tumor response to administration of TCZ as a sin-
gle agent therapy in order to understand the mechanism behind the IL-6 role on
tumor growth behavior. Furthermore, by directly comparing (i.e. no additional pa-
rameter fitting) the model predictions and the TCZ-therapy data we can validate
the proposed model. To do so, we use the best fit parameter values obtained from
fitting the EC-TC model to the control data for both UM-SCC-1 and UM-SCC-22B
cell lines, and predict the tumor growth dynamics post TCZ- therapy.
Figures 4.16 and 4.16 depict model predictions along with experimental data
for UM-SCC-1 and UM-SCC-22B cohorts, respectively. The orange dots represent
the average volume of UM-SCC-1 (or UM-SCC-22B) tumors post TCZ-therapy and
the red plots show the average volume of tumors in control case, without treat-
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ment. Comparing the orange and red dots, data suggests that TCZ can cause a
considerable decrease in the tumor growth rate in UM-SCC-1 cohort while, treat-
ing UM-SCC-22B cell lines does not show a significant decrease in tumor volume
when compared to the control case. At day 23 (36) after tumor implantation, TCZ-
therapy model is used to predict the tumor volume growth dynamics. Comparing
the model outcomes with experimental data for UM SCC-1 (UM-SCC-22B) tumor
growth in the control case (purple line and red dots), and in the TCZ therapy case
(green line and orange dots) show that our model has fairly reliable predictions in
both cases.
Furthermore, the TCZ-therapy model suggests that nine weeks of therapy with
5mg/kg TCZ causes 15 %, and 10% decrease in tumors generated from UM-SCC-1
and UM-SCC-22B cohorts, respectively, as compared to the corresponding control
cases. Interestingly, we see where TCZ-therapy causes more reduction in the CSC
percentage (i.e. in UM-SCC-1 group), the treatment has a better tumor growth in-
hibition effects (i.e. more effectively decreases the rate of tumor growth).
In the previous section, we hypothesized that the anti-therapeutic effects of
Cisplatin might be because of the observed increased percentage of the CSCs after
chemotherapy. Furthermore, the TCZ-therapy model suggested that treating the
cell lines with anti-IL-6R antibody could reduce the percentage of CSCs as com-
pared with control case. Together, these findings provide a rationale for trying to
treat the tumor cells with a combination of TCZ and Cisplatin. In the next section
we use both TCZ-therapy and Cisplatin-therapy model to include the effects of
combination therapy with both of the drugs.
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Figure 4.16: At day 23 after tumor implantation, TCZ-therapy model is used to
predict the tumor volume growth dynamics and the results are compared with
the treatment data related to UM-SCC-1 cohort. Model predictions plotted along
with experimental data for UM SCC-1 tumor growth in the control case, without
treatment (purple line and red dots), and for combination TCZ therapy (green line
and orange dots)
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Figure 4.17: At day 36 after tumor implantation, TCZ-therapy model is used to
predict the tumor volume growth dynamics and the results are compared with
the treatment data related to UM-SCC-22 cohort. Model predictions plotted along
with experimental data for UM SCC-22 tumor growth in the control case, without
treatment (purple line and red circles), and for TCZ therapy (green line and orange
circles)
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4.6 Treatment III- Combination Therapy of TCZ and Cisplatin
Nor et al. reported that the combination of Cisplatin treatment with the high
expression of IL-6, which is typically observed in HNSCC, leads to a dramatic
increase in the fraction of CSCs post treatment No¨r et al. (2014). They observed
that IL-6 enhances the stemness of HNSCC cells and that Cisplatin cannot over-
come IL-6-IL-6R induced signaling pathways that are involved in the acquisition
of a stemlike phenotype in the cell lines. This result suggest that a combination
therapy involving Cisplatin and IL-6R inhibitor (TCZ) might overcome the anti-
therapeutic effect of Cisplatin.
In this section, we combine the TCZ- and Cisplatin-therapy models and use it
to predict the tumor volumes after combination therapy with TCZ and Cisplatin.
Figures 4.18 and 4.19 depict the model predictions and results of the in vivo exper-
iment (described in Subsection 4.3.1) in which UM-SCC-1 and UM-SCC-22B cell
lines were treated with a combination of TCZ and Cisplatin. The purple dots rep-
resent tumor volume in control case (without treatment) and the orange dots rep-
resents tumor volumes for combination therapy. Comparing the tumor volumes
before and after combination treatment suggest that UM-SCC-1 cell lines positively
responded to treatment and had a slower growth after treatment (Figure 4.19)
while the UM-SCC-22B cell lines showed even faster growing rate as compared to
tumor volumes in control group (Figure 4.19). We used our TCZ-Cisplatin-therapy
model to predict the percentage of CSCs after treatment. Interestingly, our model
predicted that in the first 7 weeks after treatment, the CSC percentage in UM-SCC-
1 tumors could be decreased to a lower level than the CSC percentage in the control
group but started growing faster and getting a higher value than the control group
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over the remaining time. In contrast, the combination treatment of UM-SCC-22B
cell lines dramatically increased the CSC percentage in tumor suggesting that TCZ
could not decrease the Cisplatin-IL-6-mediated growth (as reported in No¨r et al.
(2014)) in UM-SCC-22B cell lines.
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Figure 4.18: Model predictions plotted along with experimental data for UM SCC-
1 tumor growth in the control case, without treatment (blue line and purple dots),
and for combination TCZ + Cisplatin therapy (green line and orange dots).
Collectively, the partial successes of treating xenograft tumors with combina-
tion of TCZ and Cisplatin provide enough rationale for running more simulations
in order to find the most effective combinations of these two drugs. In the next
section we use the baseline parameter values for UM-SCC-1 cohort and try to sug-
gest/find a dose-scheduling regimen with the most optimal outcome.
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Figure 4.19: Model Predictions Plotted Along the Experimental Data for UM SCC-
22B Tumor Growth in the Control Case, Without Treatment (blue line and purple
dots), and for Combination TCZ + Cisplatin Therapy (green line and orange dots).
4.7 Treatment Optimization
In order to determine the most favorable combinations and investigate po-
tential synergism between TCZ and Cisplatin, we simulated a number of dose-
scheduling regimens (Table 4.8). The ultimate goal is to determine the optimal
dosing strategy that minimizes tumor growth, while also minimizing the amount
of drug administered. In these simulations, TCZ is administered weekly for nine,
six or three weeks starting at day 0 of week 0. The tumor is pre-, co-, or post-treated
with 1, 5 or 15 mg/kg Cisplatin weekly for one or three weeks. For each treatment
strategy we compute the IC30 value, which corresponds to the amount of TCZ re-
quired for 30% reduction (compared to control) in tumor volume at day 63 after
treatment. Using the IC30, we define a metric that we refer to as the dose Schedul-
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ing Index (S.I.) to indicate the level of synergism between the two drugs. S.I. is
defined as a ratio of the predicted IC30 for each dose scheduling strategy with the
IC30 for the baseline case, wherein the tumor is co-treated with Cisplatin and TCZ
weekly for three weeks followed by treatment with only TCZ for the remainder
of the therapeutic window (rows 4, 13, 20, 29, 36 and 42). The S.I. values (the last
column of Table 4.8) help us to quantify the therapeutic efficacy of the different
dose scheduling strategies. An S.I. value greater than one represents sub-optimal
dosing; whereas, a value less than one indicates some level of synergism between
the two drugs Cook et al. (2015); Jain and Meyer-Hermann (2010).
Therefore, to find an optimal schedule, we need to minimize the amount of TCZ
required for a fixed amount of the total Cisplatin (3, 15, or 45 mg/kg) administered
by changing the timing/ordering of administering the two drugs with respect to
each other. As can be seen in Table 4.8 (rows 10-12, 16, 26-28 and 32), model simu-
lations predict that in general pre-treatment with Cisplatin followed by immediate
treatment with TCZ is preferred over post-treatment and co-treatment with Cis-
platin. Specially, pre-treatment with 3 mg/kg of Cisplatin, followed by weekly
administration of 5mg/kg TCZ for six weeks (rows 28 and 32), totaling 30 mg/kg
of TCZ seems to be one of the best options. Strategies that work equally well
are the pre-treatment with 1mg/kg (2mg/kg) Cisplatin followed by co-treatment
with TCZ for two weeks (one week) and ending with TCZ alone for an additional
four (five) weeks (rows 26 and 27). However, if treatment with high doses of 15
mg/kg of Cisplatin for each single injection are allowed, then the TCZ administra-
tion schedule can be shortened to a total of 18 mg/kg TCZ over three weeks (rows
34 and 35). Interestingly, post-treatment with Cisplatin in all the cases (for instance,
rows 5, 22, and 44) seems to do poorly when compared with pre- or co-treatment
and results in some level of antagonism between the two drugs. Finally, the model
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Table 4.8: Optimizing Combination Therapy: TCZ is administrated weekly for 9,
6, or 3 weeks (gray cells). Based on the number of weeks that TCZ is adminis-
tered and the total doses of Cisplatin, treatment strategies are divided into sub-
categories that are separated by horizontal solid lines in the table. Cisplatin is
administered weekly for one or three weeks in doses of 1, 5, and 15 mg/kg. CIS
stands for 1mg/kg Cisplatin and W stands for week. Gray cells show the weeks
at which TCZ is administered. The pink cells indicate the baseline IC30 for each
sub-strategy
W-3 W -2 W -1 W 0 W 1 W 2 W 3 W 4 W 5 · · · W 8 IC30* S.I.
1 — 5 CIS 5 CIS 5 CIS · · · 45 1
2 5 CIS 5 CIS 5 CIS · · · 45 1
3 5 CIS 5 CIS 5 CIS · · · 45 1
4 — — 5 CIS 5 CIS 5 CIS · · · 45 1
5 — — 5 CIS 5 CIS 5 CIS · · · 54 1.2
6 — — 5 CIS 5 CIS · · · 54 1.2
7 15 CIS · · · 45 1
8 15 CIS · · · 45 1
9 15 CIS · · · 45 1
10 — CIS CIS CIS · · · 45 0.91
11 CIS CIS CIS · · · 45 0.91
12 CIS CIS CIS · · · 45 0.91
13 — — CIS CIS CIS · · · 49.5 1
14 — — CIS CIS CIS · · · 54 1.09
15 — — CIS CIS · · · 54 1.09
16 3 CIS · · · 45 0.91
17 — 5 CIS 5 CIS 5 CIS · · · 30 1
18 5 CIS 5 CIS 5 CIS · · · 30 1
19 5 CIS 5 CIS 5 CIS · · · 30 1
20 — — 5 CIS 5 CIS 5 CIS · · · 30 1
21 — — 5 CIS 5 CIS 5 CIS · · · 36 1.2
22 — — 5 CIS 5 CIS 5 CIS · · · 36 1.2
23 — 15 CIS · · · 30 1
24 15 CIS · · · 30 1
25 — — 15 CIS · · · 30 1
26 — CIS CIS CIS · · · 30 0.91
27 CIS CIS CIS · · · 30 0.91
28 CIS CIS CIS · · · 30 0.91
29 — — CIS CIS CIS · · · 33 1
30 — — CIS CIS CIS · · · 36 1.1
31 — — CIS CIS CIS · · · 36 1.1
32 — 3 CIS · · · 30 0.91
33 — — 3 CIS · · · 33 1
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Table 4.8 Continued: Optimal treatment strategies.
W-3 W -2 W -1 W 0 W 1 W 2 W 3 W 4 W 5 · · · W 8 IC30* S.I.
34 — 15 CIS 15 CIS 15 CIS · · · 16.5 0.92
35 15 CIS 15 CIS 15 CIS · · · 16.5 0.92
36 — — 15 CIS 15 CIS 15 CIS · · · 18 1
37 — — 15 CIS 15 CIS 15 CIS · · · 19.5 1.08
38 — — 15 CIS 15 CIS 15 CIS · · · 21 1.16
39 — 15 CIS 15 CIS 15 CIS · · · 22.5 1.25
40 — 5 CIS 5 CIS 5 CIS · · · 18 1
41 5 CIS 5 CIS 5 CIS · · · 16.5 0.92
42 — — 5 CIS 5 CIS 5 CIS · · · 18 1
43 — — 5 CIS 5 CIS 5 CIS · · · 19.5 1.08
44 — — 5 CIS 5 CIS 5 CIS · · · 21 1.16
45 — 15 CIS · · · 16.5 0.92
46 15 CIS · · · 16.5 0.92
47 — — 15 CIS · · · 18 1
48 — 5 CIS 5 CIS 5 CIS · · · 22.5 1.25
49 5 CIS 5 CIS 5 CIS · · · 25.5 1.41
50 — 5 CIS 5 CIS 5 CIS · · · 24 1.33
predicts that alternating between Cisplatin and TCZ results in the worse possible
treatment outcomes compared to any other dose scheduling strategy (rows 39 and
48-50). Thus, in all cases, pre-treatment with Cisplatin is predicted to optimize the
synergism between Cisplatin and TCZ.
4.8 Summary and Conclusions
Cancer stem cells are highly tumorigenic cells within tumors that exhibit self-
renewal and the capacity to differentiate and recapitulate a heterogeneous organ
from a single progenitor cell Hermann et al. (2010); Krishnamurthy et al. (2014);
Pearson et al. (2016); Prince et al. (2007). It also has been hypothesized that these
CSCs are responsible for chemotherapy and/or radiotherapy resistance, tumor
metastasis and tumor recurrence. All these facts suggest that ablation of CSCs
is essential to improve the treatment outcomes for stem-cell driven cancers. How-
ever, since CSCs and normal stem cells share similar properties, direct targeting of
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CSCs may lead to harming or killing the normal cells. It has been demonstrated
that CSCs live in perivascular niches and are highly dependent on crosstalk with
those associated endothelial cells for their survival and division. These findings
raised the idea of the therapeutic blockade of the crosstalk between endothelial
cells and CSCs within the perivascular niche.
Studies of HNSCC have revealed the existences of CSCs and that those tumor-
associated endothelial cells express high levels of IL-6. It has also been shown that
IL-6 play a major role in enhancing the growth rate of HNSCC Krishnamurthy
et al. (2014); Neiva et al. (2014). Notably, IL-6 binds to its receptor on tumor cells
and activates the key pathways involving in regulation of self-renewal, differenti-
ation and survival of CSCs. All together, these discoveries suggest that therapeutic
inhibition of the IL-6-mediated pathways by targeting that IL-6 ligand and recep-
tor might be beneficial for patients with head and neck cancer.
In this chapter we developed a mathematical modeling framework for investi-
gating IL-6 mediated, cancer stem cell driven tumor growth and targeted treatment
with TCZ alone and/or in combination with Cisplatin. The model is based on a
experimental setup in which human tumor cells were seeded along with endothe-
lial cells in poly(L-lactic) acid biodegradable scaffolds, and transplanted into SCID
mice. Our model includes the effects of both human tumor and endothelial cell-
secreted IL-6 signaling on tumor cell survival and proliferation, and also captures
the effects of IL-6 on the probability of self-renewal for cancer stem cells. Specif-
ically, it describes the interaction (crosstalk) between endothelial cells (ECs) and
tumor cells (TCs), by tracking the cellular and molecular species used in the exper-
iments described in Figure 4.4. The proposed pre-treatment EC-TC model tracks
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the temporal changes in cancer stem cell, progenitor cell and differentiated cell
density, free tumor and/or endothelial cell-secreted IL-6 concentration, endothe-
lial cell density, free VEGF concentration and free Bcl-2 mRNA expressed by both
tumor and endothelial cells. VEGF can bind to its natural receptors, VEGFR1 and
VEGFR2, on endothelial cells to form a signal initiating complex, VEGF–VEGFR2,
and a decoy complex, VEGF–VEGFR1 Mac Gabhann and Popel (2007a); Zhang
et al. (2010). Furthermore, VEGF can also bind to VEGFR1 expressed on the sur-
face of all tumor cell types (cancer stem cells (CSCs), progenitor cells (PCs) and
differentiated cells (DCs)) and form the signaling complex for tumor cells, VEGF-
VEGFR1 Mac Gabhann and Popel (2007a); Zhang et al. (2010). All of the IL-6 bind-
ing dynamics that were previously described in Chapter 2 carry over to this model.
To evaluate the impact of endothelial cell-secreted IL-6 on tumorigenic poten-
tials of CSCs, Krishnamurthy et al. Krishnamurthy et al. (2014) used a scaffold
model and seeded 1’000 HNSCC CSCs in mice along with 500’000 either IL-6-
silenced ECs (HDMEC-shRNA-IL-6) or control ECs (HDMEC-shRNA-C) the IL-6
expression in primary human dermal microvascular endothelial cells was silenced.
They observed that silencing IL-6 could significantly decrease the tumor growth
rate and the percentage of CSCs in primary tumor. In order to calibrate and test
the abilities of the proposed pre-treatment model, we first fit it to the control data
related to HDMEC-shRNA-C (Figure 4.4) and estimated the unknown parameter
values. Then we decreased the secretion rate of IL-6 secretion by ECs and pre-
dicted the tumor volumes over time (data is not shown). Comparing the EC-TC
model predictions with the HDMEC-shRNA-IL-6 data suggested that in order to
get more accurate predictions, some of the parameters which can be influenced by
IL-6 should be also altered. As we discussed in Chapter 2, disturbance of the IL-
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6 secretion can potentially change the Ain, PNS and n values. Overall, the model
predictions were reliably matching the experimental data in both cases where ECs
could secrete IL-6 and when the secretion of IL-6 was silenced in ECs. In addition,
the model could predict the percentage of CSC observed in the experiment. This
allowed us to use and extend the pre-treatment EC-TC model to run a range of
simulations for TCZ- and Cisplatin- therapy and for synergistic combinations of
TCZ and Cisplatin.
Cisplatin is the most common conventional chemotherapeutic agent used to
improve the poor outcomes of standard of care for HNSCC including surgery and
radiation. However, it could not significantly change the survival rate of patients
due to drug-resistance and metastasis. Attempts to understand the mechanism
behind the anti-therapeutic effects of Cisplatin revealed that Cisplatin can not de-
crease the tumor volume rate as compared to control case without treatment. It
also enhances the percentage of CSCs in HNSCC and that percentage is amplified
when Cisplatin is combined with IL-6. It was also hypothesized that these CSCs
are responsible for drug-resistance and metastasis. In this chapter we extended the
pre-treatment model to include the effects of Cisplatin on tumor growth dynamics.
The proposed model not only covered the biological characteristics of Cisplatin
but it was also developed based on a experimental data in which two cell lines
UM-SCC-1 and UM-SCC-22B were seeded in mice along with ECs. When tumors
reached approximately 250 mm3, the mice were assigned into 4 groups and re-
ceived: (1) 5mg/kg Cisplatin combined with 5mg/kg TCZ; (2) 5mg/kg Cisplatin;
(3) 5mg/kg TCZ and (4) control via i.p. injections. Cisplatin was administered
weekly for three weeks and the tocilizumab was administered weekly for 9 weeks
(Subsection 4.3.1). We calibrated our model by fitting it to the control data for both
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UM-SCC-1 and UM-SCC-22B cohort and estimated the baseline parameter values
(Figures 4.10 and 4.10). Then we used those estimated baseline parameter values
to predict the effects of Cisplatin on tumorigenic potential of HNSCC. The model
could reliably predict the tumor growth rate after Cisplatin-therapy. Interestingly,
we used the Cisplatin-therapy model to predict the percentage of CSCs in tumor
xenografts. Our model suggested that the anti-therapeutic effects of Cisplatin on
tumor growth is in a direct positive correlation with the percentage of CSCs after
treatment. This result is in line with the experimental results observed by No¨r et
al. in No¨r et al. (2014).
It has been demonstrated that growth and survival of CSCs are highly influ-
enced by tumor micro-environmental factors and molecular signaling, including
IL-6 Krishnamurthy et al. (2014). More interestingly, it has been revealed that HN-
SCC CSCs reside in perivascular niches and that IL-6 secreted by endothelial cells
(ECs) in the tumor niche enhances the survival, self-renewal and tumor initiation
potentials of CSCs in primary head and neck tumor Krishnamurthy et al. (2014).
Therefore, targeting the IL-6-induced signaling pathways may inhibit the survival
and self-renewal potential of CSCs. Thus, TCZ as a potential alternative treatment
has being used to improve patients outcomes for HNSCC. Therefore, in order to
study and make the predictions of tumor cells’ responses to TCZ-therapy we ex-
tended the pre-treatment model to include the effects of TCZ in our model. Then
we used the estimated baseline parameter values and predicted the tumor vol-
umes at each time point in TCZ-therapy data. The prediction results was reliably
matched with the TCZ-therapy data for UM-SCC-1 cell lines. However, our model
is not capable of capturing the increase observed in tumor volumes after treatment
for UM-SCC-22B cell lines.
150
Furthermore, we combined the TCZ-therapy and Cisplatin-therapy model to
study the CSC responses to the combination therapy with TCZ and Cisplatin. Our
model predictions matched with the tumor growth dynamics reported in the ex-
perimental data (Figures 4.18 and 4.19). In addition, our model predicts that high
levels of CSCs after treatment is strongly correlated with the poor therapeutic ef-
fects of Cisplatin. It has been observed that combined use of Cisplatin and IL-
6 further enhances the stemness of CSCs. Also recall that in this model the the
molecular effects of IL-6 binding to its receptor, IL-6R is incorporated via tracking
the temporal changes of fractional occupancies of bound receptors on tumor cells.
All these facts together, motivated us to look at the dynamics of the fractional oc-
cupancies of IL-6R on both UM-SCC-1 and UM-SCC-22B cells lines when treated
with a combination of TCZ and Cisplatin (see Figure 4.20).
Surprisingly, we see that the overall fraction of occupied IL-6R is smaller on UM-
SCC-22B (4.20-B) cell lines than UM-SCC-1 cell lines (4.20-A). The smaller the frac-
tion of occupied IL-6R by IL-6 means the higher fraction of occupied IL-6R by
TCZ. Therefore, we would expect better results for combination therapy for UM-
SCC-22B cohort. However, we see that the combination therapy with Cisplatin
and TCZ increases the tumor growth rate. One possible explanation might be due
to the more available IL-6 in the tumor niche after treating with TCZ. We do not
model the other microenvironmental factors and there might be a chance that those
free IL-6 indirectly facilitates the tumor growth via binding to its receptor on en-
dothelial cells which results in faster proliferation of them Neiva et al. (2009). The
other possible read of this result is that TCZ has almost the same impact on tumor
volume reduction for both UM-SCC-1 and UM-SCC-22 cell line and since the com-
bination therapy has opposite impacts on tumor growth for the two cell lines we
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Figure 4.20: Fractional Occupancies of IL-6R on CSCs on UM-SCC-1 (left panel)
and UM-SCC-22B (right panel) Cell Lines. The black line is the model prediction
for control case without treatment and the orange line is the model prediction after
treatment with Cisplatin.
can conclude that Cisplatin might be responsible for the faster growth observed
in the data for UM-SCC-22B cell lines. However, the fact that combination ther-
apy of UM-SCC-1 cell line with Cisplatin could successfully decrease the tumor
growth in compared with control group along with the contradictory responses
of these two cell lines to treatment raise the idea that there might be some levels
of antagonism between the two drugs. Therefore, we ran simulations for various
dose/scheduling regimens of Cisplatin and TCZ in order to investigate potential
synergism between TCZ and Cisplatin. Our simulations suggests that low lev-
els of Cisplatin is enough to be effective and also we concluded that in all cases,
pre-treatment with Cisplatin followed by TCZ optimizes the synergism between
Cisplatin and TCZ.
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Chapter 5
SUMMARY AND CONCLUSIONS
Cancer is a genetic disease caused by the accumulation of mutations in somatic
cells Altrock et al. (2015). During the multiple steps of evolution from normal to
cancerous, altered somatic cells acquire the capabilities of sustaining proliferative
signaling, evading growth suppressors, resisting cell apoptosis, enabling replica-
tive immortality, inducing angiogenesis, and activating invasion and metastasis
Altrock et al. (2015); Hanahan and Weinberg (2011b); Hermann et al. (2010). In
particular, these mutated cells, so called cancer stem cells (CSCs), do not obey
the highly regulated processes of normal cell division and death, which can re-
sult in tumor initiation Jackson et al. (2014). There are many theories trying to
explain the malignancy potential of these mutated tumor cells. Among those, can-
cer stem cell hypothesis has gained credibility within the cancer research community
Molina-Pen˜a and A´lvarez (2012). According to that, tumors found in adult tissues
arise from CSCs that exhibit the ability to self-renew and give rise to differentiated
tissue cells Krishnamurthy et al. (2014); No¨r et al. (2014); Zhu et al. (2014). Ad-
ditionally, it states that CSCs make up an often-argued minor subpopulation of
cells and the bulk of the tumor tissue is composed of rapidly proliferating cells
that lack longevity and have only limited proliferative potential, so called transit-
amplifying cells and post-mitotic differentiated cells. These cells do not contribute
to tumor initiation. They are derived from the CSCs by differentiation, but are
not capable of tumor initiation by themselves Prince and Ailles (2008); Reya et al.
(2001); Weekes et al. (2014). Heterogeneous populations of cancer cells composed
of both CSCs and non-CSCs have been identified in a variety of malignancies, in-
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cluding tumors of the blood, breast, colon, prostate, brain, and head and neck
Al-Hajj et al. (2003); Gentry and Jackson (2013); Krishnamurthy et al. (2014); Singh
et al. (2003).
Despite the fact that CSC biology has been extensively studied in the last few
years, unfortunately, it is not fully understood yet due to the lack of efficient exper-
imental methods Frank et al. (2010); Nguyen et al. (2012); Pardal et al. (2003); Weekes
et al. (2014). However, mathematical and computational modeling approaches
provide a useful framework to study cancer progression since they can integrate
biological parameters and make predictions across different time and/or spatial
scales. Moreover, mathematical models provide a powerful tool to facilitate drug
development and pre-clinical evaluation of efficacy, which cannot be easily un-
derstood by using conventional wet-lab experiments alone Olsen and Siegelmann
(2013); Tang et al. (2014); Wang et al. (2015). Therefore, the contribution of mathe-
matical modeling in cancer biology can be useful in order to restrict the number of
lab experiments needed for testing hypotheses and for generating new conjectures.
Several mathematical, physical, computational, stochastic and engineering tech-
niques have been applied to the complex biological system that arises from stem
cells and non-stem cell dynamics Dingli et al. (2007); Foo et al. (2009); Fornari et al.
(2014); Kapitanov (2012); Kim et al. (2008); Komarova and Wodarz (2007); Michor
et al. (2005); Sottoriva et al. (2010); Tomasetti and Levy (2010); Turner et al. (2009);
Youssefpour et al. (2012). In particular, there are several mathematical models of
stem cell-driven tumors designed to investigate the mechanism behind the tumor
growth dynamics and also the proportion of CSCs that can initiate, propagate and
re-initiate tumors. While most of them either neglect asymmetric division, or pro-
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genitor cells, or have made assumptions on a fixed symmetric/asymmetric divi-
sion probability Boman et al. (2007); Deleyrolle et al. (2011); Gupta et al. (2011);
Mackillop et al. (1983); Molina-Pen˜a and A´lvarez (2012); Morton et al. (2011); Rodriguez-
Brenes et al. (2011); Sehl et al. (2009), in Chapter 1 we designed a model based on
the CSC hypothesis which includes progenitor cells and a negative feedback on the
self-renewal probability of CSCs. This assumption is consistent with several exper-
imental reports in which these three main cell subtypes are identified in cancer Ba-
pat et al. (2005); Dylla et al. (2008). This model is a simplified version of the model
developed by Ganguly and Puri (2006), as we described in Section ??, but instead
of adding sub-compartments of progenitor cells, it is assumed that each differen-
tiated stem cell is amplified on upon entry into the progenitor. That is, the efflux
from the stem compartment is amplified by a factor Ain as soon as the cells enter
the progenitor pool. The progenitor cells transition to fully differentiated cells via
TA cell division. It is also assumed that differentiated cells do not differentiate
any more. Moreover, we used a Hill function to reflect autocrine effects on CSC
self-renewal by assuming that if the number of CSCs approaches zero, the prob-
ability of CSC self-renewal (based on chemical signaling in the niche) approaches
the maximum value. With the inclusion of feedback mechanisms like these that
govern stem cell division, cancer cells do not necessarily grow exponentially and
tend to reach an equilibrium level Gentry and Jackson (2013). In fact, the results of
mathematical analysis of our model, suggested that the qualitative behavior of the
model depends on the balance between the net growth rate of CSCs, αSPS, and the
death rate of CSCs, δS. For the values of δS between the maximum and the mini-
mum net growth rate of CSCs, αSPSmin < δS < αSPSmax , tumor growth is bounded
and reaches to a steady population whereas δS < αSPSmin causes an exponential
growth of CSCs which can results in unbounded exponential growth of tumor.
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It was also shown that once the non-trivial exists and is positive, then it is always
locally asymptotically stable. That is, once the tumor emerges it reaches to an equi-
librium level and relatively small perturbations in parameter values do not change
the behavior of the tumor growth dynamics. Furthermore, it was shown that if the
death rate of CSCs is below a critical threshold, tumor grows exponentially. Very
large division rates of CSCs also lead to a exponential growth of tumor. Consistent
with our modeling approach, Liu et al. (2013) developed a set of mathematical
models for studying the dynamic interaction between CSCs and non-CSCs both in
vitro and in vivo. However, they defined feedback loops from terminally differ-
entiated cells to both division rate of CSCs (PCs) and to self-renewal probabilities
of CSCs (PCs) and concluded that the appropriate model needs both of the neg-
ative feedbacks in order to obtain the experimentally observed balance between
CSCs and non-CSCs. Rodriguez et al. (2013) also described a new model with two
negative feedback mechanisms on the symmetric division probability and differ-
entiation probability and their model predictions could show an excellent agree-
ment with the observed experimentally data on the growth curve. Furthermore,
Monlina-Pen˜a and A´lvarez presented a simple model, with an analytical solution,
that also includes the three cell subpopulations (CSCs, progenitors, and terminally
differentiated cells) but assumes that each event related to cell division or death
of each one of these subpopulations happen at a constant rate. They used their
model to fit to experimental data sets from three different tumor growth scenarios
and showed that in order to sustain exponential tumor growth with a less than
1% CSCs within the tumor, symmetric and asymmetric CSC division rates must
be of the same order of magnitude, and non-stem cancer cells must divide more
frequently and have significantly higher cell death rates.
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An initially assumed minor subpopulation of CSCs has been challenged with
recent data suggesting widely different proportions of CSCs in tumor cells John-
ston et al. (2010); Liu et al. (2013). Therefore, we used our model to predict the
asymptotic behavior /proportion of CSCs at equilibrium level and over the tu-
mor’s exponential growth phase. Interestingly, our model suggests that depend-
ing on the parameter values the percentage of CSCs can vary between 0 and 100.
Johnson et al. (2010) also developed an ODE model of stem, progenitor and fully
differentiated cell populations and studied constant fractions of CSCs in tumors
and reported the same result about the percentage of the CSCs. They showed that
depending on the tumor growth and differentiation rates balance, CSCs can com-
prise any proportion of the tumor, and that higher stem cell proportions likely
yield more aggressive tumors.
There is increasing evidence to support the theory that growth and survival of
CSCs are highly influenced by tumor micro-environmental factors and molecular
signaling, initiated by cytokines and growth factors Li (2002); Morrison and Kim-
ble (2006); Morrison et al. (1997); Simons and Cleavers (2011). Interleukin-6 (IL-6)
is a pleiotropic cytokine, secreted by a variety of cell types, that is key player in
number of cellular processes including proliferation, survival, differentiation, mi-
gration and invasion Choudhary et al. (2016). IL-6 binds to its natural receptor,
IL-6R, on the surface of tumor cells. Once bound to IL-6, the IL-6R-gp130 com-
plex results in the activation of signaling pathways which enhance the CSCs’ self-
renewal and survival Krishnamurthy et al. (2014); Neiva et al. (2009). Therefore,
in order to quantify the impacts of IL-6 on tumor growth and CSC self-renewal,
in Chapter 2 we expanded the model developed in Chapter 1 to incorporate the
molecular level details of tumor cell-secreted IL-6 signaling. This model follows
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the modeling techniques pioneered by Jackson and Jain Jain et al. (2008, 2009).
They developed a multi-scale model that operates at three levels: (1) Intracellular
level: regulation of signaling pathways that are critical to cell proliferation, apop-
tosis, and migration; (2) Cellular level: cell-surface dynamics of receptor-ligand
binding and receptor activation that lead to intracellular signal transduction cas-
cades; and (3) Tissue level: dynamics of signaling chemicals and anti-cancer agents
within the tissue, tumor growth dynamics, and tumor and vascular response to
treatment. Their model was used to describe tumor angiogenesis, vascular tumor
growth, and response to treatment based on the SCID Mouse Model of Human Tu-
mor Angiogenesis Jain and Jackson (2017); Jain et al. (2008, 2009). However, it does
not include the heterogenous populations of tumor cells. It is necessary to model
CSCs as a distinct subpopulation from other tumor cells since they are identified
as “drivers” of the tumorigenic process in cancer. Furthermore, tissue hierarchy
must be considered because stem, progenitor, and differentiated cells have very
different properties. Our model (and its expansions) is unique in a way that not
only it includes assumptions of the CSC hypothesis, but it also includes the molec-
ular level details of IL-6-mediated signaling initiation and its effect on tumor cell
survival and CSC self-renewal. To author’s knowledge, this is the first model of
cancer stem cell driven tumor growth that operates across the scales of receptor-
ligand binding and tissue level cancer growth. Tracking the temporal changes in
fractional occupancies of IL-6 receptors on tumor cells allows us to quantify the
impacts of IL-6 on tumor growth dynamics and also connects the scales.
Another worth mentioning feature of our model is that it is developed based
on lab experimental studies of human head and neck primary tumors xenografts
generated from a small population of CSCs in mice (described in Krishnamurthy
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et al. (2014)). Our model could successfully capture the experimentally observed
growth dynamics for these primary tumor xenografts. In addition, it suggested
that only a fractional occupancy of 12% on CSCs is sufficient to capture the tumor
growth dynamics observed in data. Moreover, our model predicted that each PC
undergoes only one round of amplification before differentiating into two termi-
nally differentiated cells leading to a tumor composition that consists of mostly
differentiated cells. This is consistent with the relatively slowly growth rate of tu-
mor cells observed in the experimental data.
Although the importance of the role of IL-6 on tumor progression and survival
is well documented but the mechanism behind anti-IL-6R therapies is not fully
understood yet. Therefore, we modified the model in Chapter 2 to include the
therapeutic administration of an anti-IL-6R antibody, Tocilizumab (TCZ), to study
the response of tumor cells to this targeted treatment. This model not only quan-
tifies the influence of IL-6 on primary tumor xenografts but also provides some
explanations for the various effects of TCZ on tumor growth and CSC percentage.
Our TCZ-therapy model tracks the IL-6-TCZ binding dynamics on the tumor cells.
We defined a TCZ dosing schedule based on the experiments described in
Mochizuki et al. (2015). The simulations predicted that small amounts of TCZ is
sufficient to result in tumor reduction and a sustained tumor slowing of tumor
growth. Also, for primary tumor xenografts (grown in the absence of human ECs),
our model predicts that effect of TCZ on the death rate of the tumor cells is more
pronounced than its effect on CSC self-renewal, and this leads to a small increase
in the percentage of CSCs after treatment with TCZ. This result is comparable with
the results reported in Mochizuki et al. (2015). In that study, in an experimental
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setting that included human endothelial cells (ECs), the effect of TCZ on Mucoepi-
dermoid carcinoma (MEC) cell lines is investigated and it is shown that TCZ has
mixed effects on the fraction of CSCs post therapy. Finally, it was shown that the
frequency of dosing does not significantly impact tumor response to TCZ.
In the experimental settings used in Chapter 2, that does not include microen-
vironmental production of IL-6 by endothelial cells. There is evidence that human
endothelial cells associated to HNSCC niche can secrete significantly higher lev-
els of IL-6 than tumor cells Krishnamurthy et al. (2014). We already showed that
even relatively small amounts of tumor cell-secreted IL-6 can greatly enhance both
tumor growth and the fraction of CSCs within xenograft tumors. Interestingly, it
has been shown that HNSCC CSCs reside in perivascular niches and depend on
that crosstalk with tumor associated endothelial cells for their survival and growth
Krishnamurthy et al. (2010, 2014). All together, these facts motivated us to extend
the model developed in Chapter 2 to include human endothelial cells and further
to explore the effects of EC-secreted IL-6 on the survival, self-renewal and tumori-
genic potentials of CSCs within the HNSCC tumor niche. As mentioned earlier,
this model follows the models introduced in Jain and Jackson (2017); Jain et al.
(2008, 2009). Among those, Jain and Jackson (2017) developed a model to explore
the role of VEGF-mediated cross-talk between endothelial and tumor cells on both
cell types’ survival and proliferation in both in vitro and in vivo settings. The
model in Chapter 3 closely follows their model structure but at the same time it is
an extension of the model developed in Chapter 2. To authors’ knowledge, this EC-
TC cross-talk model is the first model of its kind that goes across the scales from in-
tracellular signaling level to tissue level incorporating the CSC hypothesis and the
impacts of microenvironmental molecular factors (IL-6, Bcl-2, VEGF and oxygen)
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on CSC-mediated tumor growth dynamics. This is a fully multi-scale approach
where the fractional occupancies of IL-6R, VEGF receptors, VEGFR1 and VEGFR2,
connect the cellular level (receptor-ligand binding) to both the tissue level (TC and
EC growth) and the intracellular level (pro-survival protein, Bcl-2 upregulation).
After discussing the results of mono-therapy, the relevant question is whether
combination therapy (always) achieve better results than a single drug therapy. If
the population size of CSCs can indeed negatively affect the self-renewal probabil-
ity of CSCs, removal of them by CSC targeting therapies (such as TCZ) can remove
the negative feedback regulation, leading to enhancement of self-renewal of CSCs.
In order to address this question for HNSCC tumors, we modified the EC-TC cross-
talk model to include the response of tumor cell types, specially CSCs, to combi-
nation therapy with TCZ and Cisplatin, the most common chemotherapeutic drug
being used in HNSCC treatment No¨r et al. (2014). Our model is also based on an
experimental setup in which human tumor cell (UM-SCC-1 and UM-SCC-22B cell
lines) are seeded along with human dermal microvascular endothelial cells (HD-
MECs) in poly(L-lactic) acid biodegradable scaffolds, and transplanted into SCID
mice. The model is calibrated using control data for both UM-SCC-1 and UM-SCC-
22B cancer cell lines, and is validated by directly comparing (i.e. no additional pa-
rameter fitting) the experimental data and the model predictions for combination
treatment of TCZ and Cisplatin. Although there are several mathematical models
for describing targeted therapies (see Gallasch et al. (2013); Swierniak et al. (2009)
and Michor and Beal (2015) for reviews), if not any, only in few of them model
predictions for treatment might directly be compared to the experimental data.
Our model could fairly predict the responses of tumor cells to both mono- and
combination therapies. Furthermore, simulations of Cisplatin-therapy suggested
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that the anti-therapeutic effects of Cisplatin on tumor growth are directly corre-
lated with the percentage of CSCs after treatment. In addition, the TCZ-therapy
reliably predicts the tumor volume growth dynamics observed in tumor volumes
after treatment for UM-SCC-1 cell lines. However, our model is not capable of
capturing the increase observed in tumor volumes after treatment for some of the
UM-SCC-22B cell line data. The combination-therapy model also predicted that
high levels of CSCs after treatment is strongly correlated with the poor therapeutic
effects of Cisplatin. Finally, our simulations suggested that low levels of Cisplatin
is enough to be effective and pre-treatment with Cisplatin followed by TCZ opti-
mizes the synergism between Cisplatin and TCZ.
In summary, our full model has a sufficient resolution to evaluate the molec-
ular details (i.e. cytokine-mediated signal initiation resulting from receptor lig-
and binding) of phenotype switching among cells, which is the level of detail re-
quired to make informed predictions when cells express the same receptors but
ultimately integrate signals differently to elicit diverse responses. The model pre-
dictions have been validated using experimental data specifically designed for the
modeling study. Most models stop at verification ensuring that the model behaves
as expected and matches existing experimental data. Here we validated important
features of our model by directly comparing the data sets with modeling output
(not parameter fitting). Lastly, the model considers the connections between in-
tracellular (up-regulation of survival proteins), cellular (receptor-ligand binding
necessary for signal initiation) and tissue level events (Figure 5.1). While some
models exist that include one of two the above, few if any, incorporate all three.
This type of integration of multilevel descriptions in a single model is novel for
computational cancer research.
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Figure 5.1: Model for Cross-Talk Between Endothelial and Tumor Cells Neiva et al.
(2009)
The next step is extending these ideas into a spatio-temporal modeling frame-
work. Such a model could be used to investigate the differential motility of cancer
stem cells and the subsequent invasion of tumors with multiple cellular pheno-
types. The ultimate goal would be to determine the effect of IL-6 signaling on
the acquisition of an invasive phenotype by head and neck cancer stem cells. The
inherent tumor heterogeneity, manifested by phenotype-dependent proliferation
and motility, could lead to the sorting of cells into localized microenvironment
(vascular niches) within a solid tumor and enhance invasive and metastatic poten-
tial. With a spatiotemporal computational approach, the underlying mechanisms
for local tumor invasion can be isolated and studied in detail.
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APPENDIX A
LATIN HYPERCUBE SAMPLING AND PARTIAL RANK CORRELATION
COEFFICIENTS
175
The sensitivity of each of the parameters of the model to a specified response/output
function can be accounted for using Partial Rank Correlation coefficients (PRCC)
along with using an appropriate sampling technique, such as Latin Hyperbolic
Sampling (LHS) Blower and Dowlatabadi (1994); Marino et al. (2008); Sanchez and
Blower (1997). The method is briefly described below.
Let X1, . . . , Xd be input parameter values that are randomly chosen from a spec-
ified sample space (i.e., they are random variables). Furthermore, appropriate
probability distribution functions (PDFs) Blower and Dowlatabadi (1994); McKay
et al. (2000); Sanchez and Blower (1997) for each of the these parameters are cho-
sen (based on the biology cancer being modeled). Any specified PDF describes the
range of possible values and the probability of occurrence of any specific value.
Definition A.0.1 McKay et al. (2000). Latin Hypercube Sampling (LHS) is a stratified
sampling method for sampling the input parameter values. Using stratified sampling, the
sample space S (possible range of each parameter) of Xi are partitioned into N disjoint
strata of equal marginal probability 1/N. LHS ensures us that all portions of sample space
are sampled, and each of the input variables has all portions of its distribution represented
by input parameter values.
Definition A.0.2 Blower and Dowlatabadi (1994); Sanchez and Blower (1997). Sen-
sitivity analysis follows uncertainty analysis to identify critical inputs (parameters and
initial conditions) of a model and quantify how input uncertainty impacts model out-
come(s).
Definition A.0.3 Blower and Dowlatabadi (1994). Partial Rank Correlation Coeffi-
cient (PRCC) can be used to evaluate the statistical relationships between each input pa-
rameter and each outcome variable, while keeping all of the other input parameters constant
at their expected value.
PRCC can only be used to assess the sensitivity of outcome variables that are
monotonically related to the input parameters Blower and Dowlatabadi (1994).
A PRCC between an input parameter Xj, and an output variable Y, can be
calculated using formula given by Blower and Dowlatabadi (1994):
rXjY =
Cov(Xj, Y)√
Var(Xj)Var(Y)
=
∑Ni=1(Xij − X¯)(Yi − Y¯)√
∑Ni=1(Xij − X¯)2∑Ni=1(Yi − Y¯)2
:= PRCC(Y, Xj)
(A.0.1)
where, Cov(Xj, Y) represents the covariance between Xj and Y, while Var(Xj) and
Var(Y) are the variance of Xj and Y, respectively (the quantities X¯ and Y¯ are the
respective sample means).
It is worth mentioning that PRCC always varies between −1 and +1. The sign
of PRCC indicates the specific qualitative relationship between input and output
variables. Furthermore, the magnitude of the PRCC indicates the importance of
the uncertainty in estimating the value of the input variable due to the imprecision
in predicting the value of the outcome variable Blower and Dowlatabadi (1994);
Sanchez and Blower (1997). The relative importance of the input variables can be
directly evaluated by comparing the PRCC values Blower and Dowlatabadi (1994);
Sanchez and Blower (1997).
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APPENDIX B
TWO-COMPARTMENT PHARMACOKINETIC MODELS
177
Analytic solution of singe-dose PK-model with i.v. injection given by Eq. 3.3.1
Without loss of generality we assume that t0 = 0. Using matrix notation, the
pharmacokinetic equations can be given by:(
dIs
dt
dIp
dt
)
︸ ︷︷ ︸
x′(t)
=
(−k12 − kel k21
k12 −k21
)
︸ ︷︷ ︸
=:A
(
Is
Ip
)
︸ ︷︷ ︸
x(t)
(B.0.1)
Applying the Laplace transformation to Eq. B.0.1 we have:
L{
(
dIs
dt
dIp
dt
)
} = L{A
(
Is
Ip
)
} ⇐⇒ L{x′(t)} = L{Ax(t)}
⇐⇒ sX(s)− x(0) = AX(s)
⇐⇒ (sI − A)X(s) = x(0)
⇐⇒
(
s + k12 + kel −k21−k12 s + k21
)
︸ ︷︷ ︸
=:L(s)
(
X1(s)
X2(s)
)
︸ ︷︷ ︸
=:X(s)
=
(
Is(0)
Ip(0)
)
︸ ︷︷ ︸
=:b
Solving L(s)X(s) = b =
(
Is(0)
0
)
for X1(s) and X2(s) gives:
X1(s) =
(s + k21)Is(0)
(s + k12 + kel)(s + k21)− k12k21
X2(s) =
k12
s + k21
X1(s)
The denominator in the equation of X1(s) can be re-written as (s + α)(s + β) such
that
α & β =
(k12 + k21 + kel)±
√
(k12 + k21 + kel)2 − 4k21kel
2
· (B.0.2)
In other word,
α+ β = k12 + k21 + kel
αβ = kelk21
Therefore,
X1(s) = Is(0)
(s + k21)
(s + α)(s + β)
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The original differential equation B.0.1 then can be solved by applying the inverse
Laplace transform.
L−1 {X1(s)} = L−1
{
Is(0)
(s + k21)
(s + α)(s + β)
}
= Is(0)L−1
{
s
(s + α)(s + β)
}
+ Is(0) k21L−1
{
1
(s + α)(s + β)
}
= Is(0)
[−αe−αt
β− α +
−βe−βt
α− β + k21
(
e−αt
β− α +
e−βt
α− β
)]
= Is(0)
[
k21 − α
β− α e
−αt + k21 − β
α− β e
−βt
]
Thus,
Is(t) = Is(0)
[
k21 − α
β− α e
−αt + k21 − β
α− β e
−βt
]
,
Let define
A =
k21 − α
β− α (B.0.3)
B =
k21 − β
α− β (B.0.4)
Then Is(t) for a single dose injection can be rewritten as following:
Is(t) = Is(0)
(
Ae−αt + Be−βt
)
.
This completes the proof.
Multiple-dosing PK-model with i.v. injection
Using the definition of I js given by Eq. 3.3.4, we have
I1s (t) = d
[
Ae−α(t−τ1) + Be−β(t−τ1)
]
, t ∈ [τ1, τ2)
I2s (t) = d
[
Ae−α(t−τ1) + Be−β(t−τ1)
+ Ae−α(t−τ2) + Be−β(t−τ2)
]
, t ∈ [τ2, τ3]
...
Ims (t) = d
[
Ae−α(t−τ1) + Be−β(t−τ1)
+ Ae−α(t−τ2) + Be−β(t−τ2)
179
...
+ Ae−α(t−τm) + Be−β(t−τm)
]
, t ≥ τm
Therefore, for t ∈ [τj, τj+1], and 1 ≤ j ≤ m− 1 we have:
I js(t) =
j
∑
i=1
d
[
Ae−α(t−τi) + Be−β(t−τi)
]
= d
[
e−α(t−τj) A
j
∑
i=1
e
−α(t−τi)
−α(t−τj) + e−β(t−τj) B
j
∑
i=1
e
−β(t−τi)
−β(t−τj)
]
= d
[
e−α(t−τj) A
j
∑
i=1
e−α(τj−τi) + e−β(t−τj) B
j
∑
i=1
e−β(τj−τi)
]
= d
[
e−α(t−τj) A
j−1
∑
k=0
e−kpiα + e−β(t−τj) B
j−1
∑
k=0
e−kpiβ
]
= d
[
e−α(t−τj) A1− e
−jpiα
1− e−piα + e
−β(t−τj) B1− e
−jpiβ
1− e−piβ
]
That is,
I js(t) = d
[
Ae−α(t−τj) 1− e
−jpiα
1− e−piα + Be
−β(t−τj) 1− e−jpiβ
1− e−piβ
]
, τj ≤ t < τj+1 & 1 ≤ j ≤ m− 1
The same approach can be used to show that the above formula also satisfies for
j = m. This completes the proof.
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